<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Diverda Sans Com Light";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Minion Pro";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Calibri Light",sans-serif;
	color:#2E74B5;
	font-weight:normal;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
	{color:#0563C1;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;}
span.apple-converted-space
	{mso-style-name:apple-converted-space;}
span.screen-reader-text
	{mso-style-name:screen-reader-text;}
span.z-TopofFormChar
	{mso-style-name:"z-Top of Form Char";
	mso-style-link:"z-Top of Form";
	font-family:"Arial",sans-serif;
	display:none;}
span.z-BottomofFormChar
	{mso-style-name:"z-Bottom of Form Char";
	mso-style-link:"z-Bottom of Form";
	font-family:"Arial",sans-serif;
	display:none;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	margin-bottom:.0001pt;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Diverda Sans Com Light",sans-serif;
	color:black;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Calibri Light",sans-serif;
	color:#2E74B5;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-family:"Calibri",sans-serif;}
.MsoPapDefault
	{margin-bottom:8.0pt;
	line-height:107%;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-IN link="#0563C1" vlink="#954F72">

<div class=WordSection1>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Infusion Drug
Delivery Devices Market US$ 10.5 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>infusion drug delivery
devices </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>market
to attain US$ 10.5 Billion by 2023, growing at a CAGR of 5.7% over the forecast
period.</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt'>Visit the global infusion drug
delivery devices market segmented by product (ambulatory pumps, disposable
pumps, enteral nutrition pumps, implantable pumps, insulin pumps, syringe
pumps, volumetric pumps); </span><span lang=EN-US style='font-size:10.0pt'>by
geography and forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/infusion-drug-delivery-devices-market/">https://www.ihealthcareanalyst.com/report/infusion-drug-delivery-devices-market/</a>
</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>The global infusion drug delivery devices market
report provides market size (Revenue USD Million 2015 to 2023), market share,
trends and forecasts growth trends (CAGR%, 2018 to 2023). The global infusion
drug delivery devices market research report is further segmented by geography
into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain,
Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America
(Brazil, Mexico, Rest of LA), and Rest of the World. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>The global infusion drug delivery devices market
report also provides the detailed market landscape (market drivers, restraints,
and opportunities), market attractiveness analysis and tracks the major
competitors operating in the market by company overview, financial snapshot,
key products, technologies and services offered, market share analysis and
recent trends in the global market. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>Major players operating in the global infusion
drug delivery devices market and profiled in this report include B. Braun
Melsungen AG, Baxter Healthcare, Becton Dickinson and Company, Cardinal Health,
Inc., Cellnovo SA, CME America LLC, CR Bard, Inc., Epic Medical PTE LTD, F.
Hoffman-La Roche AG, Fresenius Kabi, Halyard Health, Inc., ICU Medical, Inc.,
Insulet Corporation, Johnson &amp; Johnson, Medline Industries, Inc., Medtronic
PLC, Moog, Inc., Nestle SA, PFM Medical, Inc., RMS Medical Products, Inc.,
Smiths Medical, Inc., Stryker Corporation, Tandem Diabetes Care, Inc., Terumo
Medical Corporation, Valeritas, Inc., Vygon SA, and WalkMed Infusion LLC.</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>1.             Product</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>1.1.         Ambulatory Pumps</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>1.2.         Disposable Pumps</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>1.3.         Enteral Nutrition Pumps </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>1.4.         Implantable Pumps</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>1.5.         Insulin Pumps</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>1.6.         Syringe Pumps</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>1.7.         Volumetric Pumps</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>2.             Geography (Region, Country)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>2.1.         North America (U.S., Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>2.2.         Europe (U.K., Germany, France,
Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>2.3.         Latin America (Brazil, Mexico,
Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>2.4.         Asia Pacific (Japan, China,
India, Rest of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>2.5.         Rest of the World (Middle East
&amp; Africa)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.             Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.1.         B. Braun Melsungen AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.2.         Baxter Healthcare</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.3.         Becton Dickinson and Company</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.4.         Cardinal Health, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.5.         Cellnovo SA</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.6.         CME America LLC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.7.         CR Bard, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.8.         Epic Medical PTE LTD</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.9.         F. Hoffman-La Roche AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.10.       Fresenius Kabi</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.11.       Halyard Health, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.12.       ICU Medical, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.13.       Insulet Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.14.       Johnson &amp; Johnson</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.15.       Medline Industries, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.16.       Medtronic PLC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.17.       Moog, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.18.       Nestle SA</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.19.       PFM Medical, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.20.       RMS Medical Products, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.21.       Smiths Medical, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.22.       Stryker Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.23.       Tandem Diabetes Care, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.24.       Terumo Medical Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.25.       Valeritas, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.26.       Vygon SA</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>3.27.       WalkMed Infusion LLC </span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>&#8195;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/infusion-drug-delivery-devices-market/">https://www.ihealthcareanalyst.com/report/infusion-drug-delivery-devices-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Respiratory
Therapeutics Market US$ 40 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>respiratory therapeutics </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>market to attain US$ 40
Billion by 2023, declining at a CAGR of 0.4% over the forecast period.</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt'>Visit the global respiratory
therapeutics market by drug class [asthma and COPD - LABA/ICS combination products,
leukotriene antagonists, inhaled corticosteroids (ICS), anticholinergics, short
acting beta-agonists (SABA), anticholinergics / beta agonists, long acting
beta-agonists (LABA), other drug classes]; allergic rhinitis (systemic
antihistamines, nasal preparations); </span><span lang=EN-US style='font-size:
10.0pt'>by geography and forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/respiratory-therapeutics-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/respiratory-therapeutics-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>The global respiratory therapeutics market
report provides market size (Revenue USD Million 2015 to 2023), market share,
trends and forecasts growth trends (CAGR%, 2018 to 2023). The global
respiratory therapeutics market research report is further segmented by
geography into North America (U.S., Canada), Europe (U.K., Germany, France,
Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC),
Latin America (Brazil, Mexico, Rest of LA), and Rest of the World. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>The global respiratory therapeutics market
report also provides the detailed market landscape (market drivers, restraints,
and opportunities), market attractiveness analysis and tracks the major
competitors operating in the market by company overview, financial snapshot,
key products, technologies and services offered, market share analysis and
recent trends in the global market. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>Major players operating in the global
respiratory therapeutics market and profiled in this report include Adams
Respiratory Therapeutics, Inc., Allergan plc, AstraZeneca, Boehringer Ingelheim,
F. Hoffmann-La Roche, GlaxoSmithKline, Merck &amp; Co., Novartis, Respiratory
Therapeutics Group, LLC, and Takeda Pharmaceutical.</span></p>

<p class=MsoListParagraphCxSpMiddle><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.             Drug Class</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.1.         Asthma and COPD</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.1.1.      LABA/ICS combination products</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.1.2.      Leukotriene antagonists</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.1.3.      Inhaled corticosteroids (ICS)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.1.4.      Anticholinergics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.1.5.      Short acting beta-agonists (SABA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.1.6.      Anticholinergics / beta agonists</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.1.7.      Long acting beta-agonists (LABA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.1.8.      Other drug classes</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.2.         Allergic Rhinitis</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.2.1.      Systemic antihistamines</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.2.2.      Nasal preparations</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.             Geography (Region, Country)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.1.         North America (U.S., Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.2.         Europe (U.K., Germany, France, Italy,
Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.3.         Latin America (Brazil, Mexico, Rest of
LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.4.         Asia Pacific (Japan, China, India, Rest
of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.5.         Rest of the World (Middle East &amp;
Africa)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.             Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.1.         Adams Respiratory Therapeutics, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.2.         Allergan plc</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.3.         AstraZeneca</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.4.         Boehringer Ingelheim</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.5.         F. Hoffmann-La Roche</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.6.         GlaxoSmithKline</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.7.         Merck &amp; Co.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.8.         Novartis</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.9.         Respiratory Therapeutics Group, LLC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.10.       Takeda Pharmaceutical</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>&#8195;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/respiratory-therapeutics-market/">https://www.ihealthcareanalyst.com/report/respiratory-therapeutics-market/</a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global Spinal
Cord Stimulation Devices Market US$ 5.3 Billion by 2023 </span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global spinal cord stimulation devices market
expected to reach US$ 5.3 billion by 2023, growing at CAGR 13.3% over the
forecast period, </span><span lang=EN-US style='font-size:10.0pt'>due to fast
advancing applications and technologies, allowing more effective and
individualized treatment for patients</span><span lang=EN-US style='font-size:
10.0pt'>.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>spinal cord stimulation
devices </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>market
research report provides market size (Revenue USD Million 2015 to 2023), market
share analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>spinal cord stimulation
devices </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>market
research report is further segmented by geography into North America (U.S.,
Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany,
France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of
APAC), and Rest of the World. In addition, the global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>spinal cord stimulation devices </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>market report provides the
detailed market landscape (market drivers, restraints, opportunities), market
attractiveness analysis, and market profitability analysis by key products and
regions or countries.  The report also tracks the major competitors operating
in the global market by company overview, financial snapshot, major products,
technologies, services offered and recent developments.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Visit </span><span
lang=EN-US style='font-size:10.0pt'>Spinal Cord Stimulation Devices Market by
Product/Device Type (Rechargeable, Non-rechargeable); Application (Degenerative
Disk Disease, Failed Back Syndrome, Multiple Back Operations, Unsuccessful Disk
Surgery, Complex Regional Pain Syndrome, Arachnoiditis or Lumbar Adhesive
Arachnoiditis); End User (Hospitals, Ambulatory Surgery Centers) and Forecast
2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/spinal-cord-stimulation-devices-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/spinal-cord-stimulation-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Major players
operating in the global spinal cord stimulation devices market and profiled in
this report include Abbott Laboratories, Inc. (St. Jude Medical, Inc.), Boston
Scientific Corp., Medtronic PLC, Nevro Corp., Saluda Medical, and Stimwave
Technologies. Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Product/Device Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rechargeable </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Non-rechargeable</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Application </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Degenerative Disk
Disease (DDD) </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Failed Back Syndrome
(FBS)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Multiple Back
Operations </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Unsuccessful Disk
Surgery </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Complex Regional Pain
Syndrome (CRPS)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Arachnoiditis or Lumbar
Adhesive Arachnoiditis</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>End User</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Hospitals </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Ambulatory Surgery
Centers (ASCs)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Abbott Laboratories,
Inc. (St. Jude Medical, Inc.)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boston Scientific Corp.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Medtronic PLC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Nevro Corp.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Saluda Medical</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Stimwave Technologies.
Inc.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US style='font-size:10.0pt;
line-height:107%;color:black'>To request Table of Contents and Sample Pages of
this report visit:</span><span lang=EN-US style='font-size:10.0pt;line-height:
107%'> </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/spinal-cord-stimulation-devices-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/spinal-cord-stimulation-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>iHealthcareAnalyst,
Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Hemophilia
Treatment Market US$ 17 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>hemophilia treatment </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>market to attain US$ 17
Billion by 2023, growing at a CAGR of 5.5% over the forecast period.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>While less
than 1 million people suffer from hemophilia A or B globally, they are among
some of the most costly patients to treat because of frequent transfusions,
costly medicines and often have a poor health prognosis, particularly in the
absence of treatment. There are ~39,000 patients with haemophilia A and ~10,000
patients with haemophilia B across the EU5 countries (France, Germany, Italy,
Spain and the United Kingdom) plus the United States.</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt'>Visit the global hemophilia
treatment market by indication (hemophilia A, hemophilia B, hemophilia with inhibitors,
von Willebrand disease); by product class [recombinant coagulation factor
(factor VIII, factor IX, hemophilia with inhibitors, von Willebrand disease),
plasma-derived coagulation factor (factor VIII factor IX, hemophilia with
inhibitors, von Willebrand disease)]; by treatment regime [prophylaxis (factor
VIII, factor IX, inhibitors, von Willebrand disease), on-demand (factor VIII,
factor IX, inhibitors, von Willebrand disease)]; by patient [adult  hemophilia
a, hemophilia b, hemophilia with inhibitors, von Willebrand disease), pediatric
(hemophilia A, hemophilia B, hemophilia with inhibitors, von Willebrand
disease)]; and by distribution channel (e-commerce, hospital pharmacies, retail
pharmacies); </span><span lang=EN-US style='font-size:10.0pt'>by geography and
forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/hemophilia-treatment-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/hemophilia-treatment-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>The global hemophilia treatment market
report provides market size (Revenue USD Million 2015 to 2023), market share,
trends and forecasts growth trends (CAGR%, 2018 to 2023). The global hemophilia
treatment market research report is further segmented by geography into North
America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe
(U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China,
India, Rest of APAC), and Rest of the World. The global hemophilia drugs market
report also provides the detailed market landscape (market drivers, restraints,
and opportunities), market attractiveness analysis and tracks the major
competitors operating in the market by company overview, financial snapshot,
key products, technologies and services offered, market share analysis and
recent trends in the global market. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>Major players operating in the global
hemophilia treatment market and included in this report are Bayer AG, Biogen
Idec, Biomarin, Biotest AG, CSL Behring, F. Hoffmann-La Roche Ltd., Grifols,
Kedrion, Novo Nordisk A/S, Octapharma AG, Pfizer, Inc., and Shire Plc
(Baxter/Baxalta).</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.             Indication</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.1.         Hemophilia A </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.2.         Hemophilia B </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.3.         Hemophilia with Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>1.4.         von Willebrand disease</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.             Product Class</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.1.         Recombinant Coagulation Factor</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.1.1.      Factor VIII</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.1.2.      Factor IX</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.1.3.      Hemophilia with Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.1.4.      von Willebrand disease</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.2.         Plasma Derived Coagulation Factor</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.2.1.      Factor VIII</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.2.2.      Factor IX</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.2.3.      Hemophilia with Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>2.2.4.      von Willebrand disease</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.             Treatment Regime</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.1.         Prophylaxis</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.1.1.      Factor VIII</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.1.2.      Factor IX</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.1.3.      Hemophilia with Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.1.4.      von Willebrand disease</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.2.         On-Demand </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.2.1.      Factor VIII</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.2.2.      Factor IX</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.2.3.      Hemophilia with Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>3.2.4.      von Willebrand disease</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>4.             Patient</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>4.1.         Adult </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>4.1.1.      Hemophilia A </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>4.1.2.      Hemophilia B </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>4.1.3.      Hemophilia with Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>4.1.4.      von Willebrand disease</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>4.2.         Pediatric</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>4.2.1.      Hemophilia A </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>4.2.2.      Hemophilia B </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>4.2.3.      Hemophilia with Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>4.2.4.      von Willebrand disease</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>5.             Distribution Channel </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>5.1.         E-commerce</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>5.2.         Hospital Pharmacies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>5.3.         Retail Pharmacies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>6.             Geography (Region, Country)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>6.1.         North America (U.S., Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>6.2.         Europe (U.K., Germany, France, Italy,
Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>6.3.         Latin America (Brazil, Mexico, Rest of
LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>6.4.         Asia Pacific (Japan, China, India, Rest
of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>6.5.         Rest of the World (Middle East &amp; Africa)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>7.             Company Profiles </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>7.1.         Bayer AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>7.2.         Biogen Idec</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>7.3.         Biomarin</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>7.4.         Biotest AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>7.5.         CSL Behring</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>7.6.         F. Hoffmann-La Roche Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>7.7.         Grifols</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>7.8.         Kedrion</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>7.9.         Novo Nordisk A/S</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>7.10.       Octapharma AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>7.11.       Pfizer, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:0in'><span lang=EN-US
style='font-size:10.0pt'>7.12.       Shire Plc (Baxter/Baxalta)</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/hemophilia-treatment-market/">https://www.ihealthcareanalyst.com/report/hemophilia-treatment-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct proprietary
single-client assignments targeted at client’s specific business objectives,
information needs, time frame and budget. Please contact us to receive a
proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey Hill
Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Robotic-Assisted
Surgical (RAS) Devices Market US$ 5.7 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>robotic-assisted surgical
(RAS) devices </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>market
to attain US$ 5.7 Billion by 2023, growing at a CAGR of 8.6% over the forecast
period.</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt'>Visit the global robotic-assisted
surgical (RAS) devices market by device (robotic-assisted systems, instruments
and accessories, services); by clinical application (general surgery, urology,
orthopedic, neurosurgery, cardiovascular, gynecology, radiology, transplant,
gastrointestinal, other); </span><span lang=EN-US style='font-size:10.0pt'>by
geography and forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/robotic-assisted-surgical-devices-market/">https://www.ihealthcareanalyst.com/report/robotic-assisted-surgical-devices-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt'>The global robotic-assisted
surgical (RAS) devices market report provides market size (Revenue US$ Million
2015 to 2023), market share, trends and forecasts growth trends (CAGR%, 2018 to
2023). The global robotic-assisted surgical (RAS) devices market research
report is further segmented by geography into North America (U.S., Canada),
Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan,
China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and
Rest of the World. The global robotic-assisted surgical (RAS) devices market
report also provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis and also tracks the major
competitors operating in the market by company overview, financial snapshot,
key products, technologies and services offered, market share analysis and
recent trends in the global market.</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt'>Major players operating in the
global robotic-assisted surgical (RAS) devices market and profiled in this
report include Accuray, Inc., AKTORmed , FlexDex Surgical , Hansen Medical/Auris
Surgical Robotics Inc., Intuitive Surgical, Inc., Mazor Robotics, Medrobotics
Corporation, Renishaw plc, Smith &amp; Nephew (Blue Belt Technologies),
Stereotaxis, Inc., Stryker Corporation (MAKO), Titan Medical, Inc.,
TransEnterix, Inc., and Zimmer Biomet Holdings, Inc. (Medtech SA).</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1. Device Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.1.        Robotic-Assisted Systems (RAS)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.2.        Instruments and Accessories</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.3.        Services</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2. Application</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.1.        General surgery</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.2.        Urology</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.3.        Orthopedic</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.4.        Neurosurgery</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.5.        Cardiovascular</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.6.        Gynecology</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.7.        Radiology</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.8.        Transplant</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.9.        Gastrointestinal</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.10.     Other</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3. Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.1.        North America (U.S., Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.2.        Latin America (Brazil, Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.3.        Europe (U.K., Germany, France, Italy,
Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.4.        Asia Pacific (Japan, China, India, Rest of
APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.5.        Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4. Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.1.        Accuray, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.2.        AKTORmed</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.3.        FlexDex Surgical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.4.        Hansen Medical/Auris Surgical Robotics
Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.5.        Intuitive Surgical, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.6.        Mazor Robotics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.7.        Medrobotics Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.8.        Renishaw plc</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.9.        Smith &amp; Nephew (Blue Belt
Technologies)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.10.     Stereotaxis, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.11.     Stryker Corporation (MAKO)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.12.     Titan Medical, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.13.     TransEnterix, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.14.     Zimmer Biomet Holdings, Inc. (Medtech SA)</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/robotic-assisted-surgical-devices-market/">https://www.ihealthcareanalyst.com/report/robotic-assisted-surgical-devices-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct proprietary
single-client assignments targeted at client’s specific business objectives,
information needs, time frame and budget. Please contact us to receive a
proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Transdermal Drug
Delivery Devices Market US$ 8.7 Billion by 2023, Trends and Forecast</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>transdermal drug delivery
devices </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>market
to attain US$ 8.7 Billion by 2023, growing at a CAGR of 3.3% over the forecast
period.</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt'>Visit the global transdermal
drug delivery devices market segmentation is based on technology (passive
transdermal transport systems, active transdermal transport systems); clinical
application [cardiovascular disease management (CVD), neurological disorder
management, hormone replacement therapy (HRT), pain management, genitourinary disorder
management]; patch-based pharmaceutical products [clonidine and nitroglycerin
products (CVD), neurological disorder treatment products, estrogen replacement
products (HRT), pain management products, urologic treatment products]; </span><span
lang=EN-US style='font-size:10.0pt'>by geography and forecast 2015-2023 at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/transdermal-drug-delivery-devices-market/">https://www.ihealthcareanalyst.com/report/transdermal-drug-delivery-devices-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt'>The global transdermal drug
delivery devices market report provides market size (Revenue US$ Million 2015
to 2023), market share, trends and forecasts growth trends (CAGR%, 2018 to
2023). The global transdermal drug delivery devices market research report is
further segmented by geography into North America (U.S., Canada), Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India,
Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the
World. The global transdermal drug delivery devices market report also provides
the detailed market landscape (market drivers, restraints, opportunities),
market attractiveness analysis and also tracks the major competitors operating
in the market by company overview, financial snapshot, key products,
technologies and services offered, market share analysis and recent trends in
the global market.</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt'>Major players operating in the
global transdermal drug delivery devices market and profiled in this report
include 3M Drug Delivery Systems, Allergan, Inc., Mylan Technologies, Inc./Mylan,
Noven Therapeutics, Hisamitsu Pharmaceutical Co., Inc., Novartis AG, Johnson
&amp; Johnson, Mylan N.V., Boehringer Ingelheim GmbH, Bayer AG, Bristol-Myers
Squibb Company, GlaxoSmithKline plc, Acrux Limited, Echo Therapeutics, Inc.,
and Endo Pharmaceuticals Inc.</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1. Technology</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.1.        Passive Transdermal Transport Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.2.        Active Transdermal Transport Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2. Clinical Application</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.1.        Cardiovascular Disease Management (CVD)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.2.        Neurological Disorder Management</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.3.        Hormone Replacement Therapy (HRT)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.4.        Pain Management</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.5.        Genitourinary Disorder Management</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3. Patch-Based Pharmaceutical Products</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.1.        Clonidine and Nitroglycerin Products (CVD)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.2.        Neurological Disorder Treatment Products</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.3.        Estrogen Replacement Products (HRT)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.4.        Pain Management Products</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.5.        Urologic Treatment Products</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4. Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.1.        North America (U.S., Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.2.        Latin America (Brazil, Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.3.        Europe (U.K., Germany, France, Italy,
Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.4.        Asia Pacific (Japan, China, India, Rest of
APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.5.        Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>5. Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>5.1. 3M Drug Delivery Systems,</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>5.2.        Acrux Limited</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>5.3.        Allergan, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>5.4.        Bayer AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>5.5.        Boehringer Ingelheim GmbH</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>5.6.        Bristol-Myers Squibb Company</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>5.7.        Echo Therapeutics, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>5.8.        Endo Pharmaceuticals Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>5.9.        GlaxoSmithKline plc</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>5.10.     Hisamitsu Pharmaceutical Co., Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>5.11.     Johnson &amp; Johnson</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>5.12.     Mylan Technologies, Inc./Mylan N.V.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>5.13.     Novartis AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>5.14.     Noven Therapeutics</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/transdermal-drug-delivery-devices-market/">https://www.ihealthcareanalyst.com/report/transdermal-drug-delivery-devices-market/</a>
 </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email: sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Injection Drug
Delivery Devices Market US$ 8 Billion by 2023, Trends and Forecast</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>injection drug delivery
devices </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>market
to attain US$ 8 Billion by 2023, growing at a CAGR of 5.6% over the forecast
period.</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt'>Visit the global injection
drug delivery devices market by product type [syringe/needles products
(standard syringes/needles, safety syringes/needles); and vascular access
devices (short peripheral catheters, midline catheters, peripherally inserted
central catheters, central venous catheters, implantable ports)]; </span><span
lang=EN-US style='font-size:10.0pt'>by geography and forecast 2015-2023 at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/injection-drug-delivery-devices-market/">https://www.ihealthcareanalyst.com/report/injection-drug-delivery-devices-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt'>The global injection drug
delivery devices market report provides market size (Revenue US$ Million 2015
to 2023), market share, trends and forecasts growth trends (CAGR%, 2018 to
2023). The global injection drug delivery devices market research report is
further segmented by geography into North America (U.S., Canada), Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India,
Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the
World. The global injection drug delivery devices market report also provides
the detailed market landscape (market drivers, restraints, opportunities), market
attractiveness analysis and also tracks the major competitors operating in the
market by company overview, financial snapshot, key products, technologies and
services offered, market share analysis and recent trends in the global market.</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt'>Major players operating in the
global injection drug delivery devices market and profiled in this report
include Air-Tite Products Co., Inc., AngioDynamics, Inc., B. Braun Melsungen
AG, Becton Dickinson and Company, Cook Medical/Cook Group, CR Bard, Inc.,
Health Line International Corporation, Medical Components (dba Medcomp),
Medtronic Minimally Invasive Therapies/Medtronic PLC, Navilyst Medical, Inc.,
Nipro Medical Corporation, Perouse Medical SAS/Vygon, Inc., Retractable
Technologies, Inc., Smiths Medical/Smiths Group PLC, Sol-Millennium Medical,
Inc., Teleflex Medical/Teleflex, Inc., Terumo Medical/Terumo Corporation, and
US Medical Instruments, Inc.</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1. Product Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.1.        Syringe/Needles Products</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.1.1.    Standard Syringes/Needles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.1.2.    Safety Syringes/Needles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.2.        Vascular Access Devices (VADs)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.2.1.    Short Peripheral Catheters (SPCs)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.2.2.    Midline Catheters</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.2.3.    Peripherally Inserted Central Catheters
(PICCs)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.2.4.    Central Venous Catheters (CVCs)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.2.5.    Implantable Ports</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2. Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.1.        North America (U.S., Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.2.        Latin America (Brazil, Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.3.        Europe (U.K., Germany, France, Italy,
Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.4.        Asia Pacific (Japan, China, India, Rest of
APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.5.        Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3. Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.1.        Air-Tite Products Co., Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.2.        AngioDynamics, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.3.        B. Braun Melsungen AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.4.        Becton Dickinson and Company</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.5.        Cook Medical/Cook Group</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.6.        CR Bard, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.7.        Health Line International Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.8.        Medical Components (dba Medcomp)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.9.        Medtronic Minimally Invasive Therapies/Medtronic
PLC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.10.     Navilyst Medical, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.11.     Nipro Medical Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.12.     Perouse Medical SAS/Vygon, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.13.     Retractable Technologies, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.14.     Smiths Medical/Smiths Group PLC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.15.     Sol-Millennium Medical, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.16.     Teleflex Medical/Teleflex, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.17.     Terumo Medical/Terumo Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.18.     US Medical Instruments, Inc.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/injection-drug-delivery-devices-market/">https://www.ihealthcareanalyst.com/report/injection-drug-delivery-devices-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Ophthalmic Drugs
Market US$ 10 Billion by 2023, Trends and Forecast</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>ophthalmic drugs </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>market to attain US$ 10
Billion by 2023, growing at a CAGR of 4.8% over the forecast period.</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt'>Visit the global ophthalmic
drugs market by disease type (allergy, dry eye disorder, glaucoma, retinal
disorder), and dispense type (over-the-counter, prescription); </span><span
lang=EN-US style='font-size:10.0pt'>by geography and forecast 2015-2023 at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/ophthalmic-drugs-market/">https://www.ihealthcareanalyst.com/report/ophthalmic-drugs-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt'>The global ophthalmic drugs
market report provides market size (Revenue US$ Million 2015 to 2023), market
share, trends and forecasts growth trends (CAGR%, 2018 to 2023). The global
ophthalmic drugs market research report is further segmented by geography into
North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America
(Brazil, Mexico, Rest of LA), and Rest of the World. The global ophthalmic
drugs market report also provides the detailed market landscape (market
drivers, restraints, opportunities), market attractiveness analysis and also
tracks the major competitors operating in the market by company overview,
financial snapshot, key products, technologies and services offered, market
share analysis and recent trends in the global market.</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt'>Major players operating in the
global ophthalmic drugs market and profiled in this report include Abbott
Healthcare, Allergan Plc, Bayer, Johnson &amp; Johnson, Merck &amp; Co.,
Novartis AG, Pfizer, Inc., Renegeron, Santen Pharmaceuticals Company Ltd., and
Valeant Pharmaceuticals, Inc.</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1. Disease Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.1.        Allergy</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.2.        Dry Eye Disorder</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.3.        Glaucoma</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.4.        Retinal Disorder</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2. Dispense Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.1.        Over-the-Counter</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.2.        Prescription</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3. Geography (Region, Country)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.1.        North America (U.S., Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.2.        Europe (U.K., Germany, France, Italy,
Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.3.        Latin America (Brazil, Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.4.        Asia Pacific (Japan, China, India, Rest of
APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.5.        Rest of the World (Middle East &amp;
Africa)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4. Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.1.        Abbott Healthcare</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.2.        Allergan Plc</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.3.        Bayer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.4.        Johnson &amp; Johnson</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.5.        Merck &amp; Co.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.6.        Novartis AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.7.        Pfizer, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.8.        Renegeron</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.9.        Santen Pharmaceuticals Company Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>4.10.     Valeant Pharmaceuticals, Inc.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/ophthalmic-drugs-market/">https://www.ihealthcareanalyst.com/report/ophthalmic-drugs-market/</a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Spinal Implants Market
US$ 6.6 Billion by 2023, Trends and Forecast</span></b><span lang=EN-US
style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>spinal implants </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>market to attain US$ 6.6
Billion by 2023, growing at a CAGR of 4.3% over the forecast period.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Visit spinal implants market by product [spinal fusion
instrumentation (anterior cervical plates, interbody fusion devices and pedicle
screws), dynamic stabilization devices (interspinous process spacers and
pedicle screw-based dynamic stabilization devices), vertebral compression
fracture treatments (balloon kyphoplasty/percutaneous vertebral augmentation
systems and vertebroplasty products), artificial cervical and lumbar discs,
other motion preserving devices (annulus repair); </span><span lang=EN-US
style='font-size:10.0pt'>by geography and forecast 2015-2023 at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/spinal-implants-market/">https://www.ihealthcareanalyst.com/report/spinal-implants-market/</a>
</span><span lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>The global spinal
implants market research report provides market size (Revenue USD Million 2015
to 2023), market share analysis, growth trends and forecast (CAGR%, 2018 to
2023). The global spinal implants market research report is further segmented
by geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global spinal implants market report provides the detailed market
landscape (market drivers, restraints, opportunities), market attractiveness
analysis, and market profitability analysis by key products and regions or
countries.  The report also tracks the major competitors operating in the
global market by company overview, financial snapshot, major products,
technologies, services offered and recent developments.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Major players
operating in the global spinal implants market include Alphatec Spine, Amedica,
Atlas Spine, AxioMed Spine, B. Braun Melsungen AG, Benvenue Medical, Biotechni,
Carefusion, Crosstrees Medical, DiscGenics, Depuy Synthes/Johnson &amp;
Johnson, DFINE, Exactech, Globus Medical, Heraeus Medical, Integra LifeSciences
Corp., Intrinsic Therapeutics, ISTO Technologies, K2M, Life Spine, LDR,
Medicrea, Medtronic plc, Mekanika, Mesoblast, Ltd., NuVasive, Inc., Ortho
Development, Orthofix, Orthopaedic &amp; Spine Development, Osseon, LLC,
Paradigm Spine, PINA Medizintechnik Vertriebs AG, Pioneer Surgical, Premia
Spine, Signus Medical, Simpirica Spine, Sintea Plustek, Spinal Elements, Spinal
Kinetics, Inc., SpineVision, SpineWave, Stryker, Synimed, Teknimed, Ulrich
Medical USA, VertiFlex, and Zimmer Biomet.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1. Product</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.1.        Spinal Fusion Instrumentation (Anterior
Cervical Plates, Interbody Fusion Devices and Pedicle Screws)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.2.        Dynamic Stabilization Devices
(Interspinous Process Spacers and Pedicle Screw-Based Dynamic Stabilization
Devices)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.3.        Vertebral Compression Fracture Treatments
(Balloon Kyphoplasty/Percutaneous Vertebral Augmentation Systems and
Vertebroplasty Products)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.4.        Artificial Cervical and Lumbar Discs</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>1.5.        Other Motion Preserving Devices (Annulus
Repair)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2. Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.1.        North America (U.S., Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.2.        Latin America (Brazil, Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.3.        Europe (U.K., Germany, France, Italy,
Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.4.        Asia Pacific (Japan, China, India, Rest of
APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>2.5.        Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3. Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.1.        Alphatec Spine</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.2.        Amedica</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.3.        Atlas Spine</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.4.        AxioMed Spine</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.5.        B. Braun Melsungen AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.6.        Benvenue Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.7.        Biotechni</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.8.        Carefusion</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.9.        Crosstrees Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.10.     DiscGenics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.11.     Depuy Synthes (Johnson &amp; Johnson)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.12.     DFINE</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.13.     Exactech</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.14.     Globus Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.15.     Heraeus Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.16.     Integra LifeSciences Corp.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.17.     Intrinsic Therapeutics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.18.     ISTO Technologies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.19.     K2M</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.20.     Life Spine</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.21.     LDR</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.22.     Medicrea</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.23.     Medtronic plc</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.24.     Mekanika</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.25.     Mesoblast, Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.26.     NuVasive, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.27.     Ortho Development</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.28.     Orthofix</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.29.     Orthopaedic &amp; Spine Development</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.30.     Osseon, LLC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.31.     Paradigm Spine</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.32.     PINA Medizintechnik Vertriebs AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.33.     Pioneer Surgical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.34.     Premia Spine</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.35.     Signus Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.36.     Simpirica Spine</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.37.     Sintea Plustek</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.38.     Spinal Elements</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.39.     Spinal Kinetics, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.40.     SpineVision</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.41.     SpineWave</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.42.     Stryker</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.43.     Synimed</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.44.     Teknimed</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.45.     Ulrich Medical USA</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.46.     VertiFlex</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>3.47.     Zimmer Biomet</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/spinal-implants-market/">https://www.ihealthcareanalyst.com/report/spinal-implants-market/</a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Gastroesophageal
Cancer Drugs Market US$ 10.9 Billion by 2023, Trends and Forecast</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global gastroesophageal
cancer drugs market to attain US$ 10.9 Billion by 2023, growing at a CAGR of 18.1%
over the forecast period.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The most common types of esophageal cancer are
squamous cell carcinoma and adenocarcinoma. Smoking and heavy alcohol use
increase the risk of esophageal squamous cell carcinoma. Gastroesophageal
reflux disease and Barrett esophagus may increase the risk of esophageal
adenocarcinoma. Esophageal cancer is often diagnosed at an advanced stage
because there are no early signs or symptoms.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Visit </span><span lang=EN-US style='font-size:10.0pt'>gastroesophageal
cancer drugs </span><span lang=EN-US style='font-size:10.0pt'>market by drug class
(angiogenesis inhibitors, CTLA4 inhibitors, cytotoxic agents, HER2 inhibitors,
MMP9 inhibitors, PD1 inhibitors, PDL1 inhibitors); </span><span lang=EN-US
style='font-size:10.0pt'>by geography and forecast 2015-2023 at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/gastroesophageal-cancer-drugs-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/gastroesophageal-cancer-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>gastroesophageal cancer drugs
</span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>market
research report provides market size (Revenue US$ Million 2015 to 2023), market
share analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>gastroesophageal cancer </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>market research report is
further segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. In addition, the global </span><span lang=EN-US style='font-size:10.0pt;
line-height:107%'>gastroesophageal cancer </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>market report provides the detailed
market landscape (market drivers, restraints, opportunities), market
attractiveness analysis, and market profitability analysis by key products and
regions or countries. The report also tracks the major competitors operating in
the global market by company overview, financial snapshot, major products, technologies,
services offered and recent developments.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Major players operating in the global gastroesophageal
cancer market and profiled in this report include Astellas Pharma, Bayer
HealthCare, BeiGene, Boston Biomedical, Bristol-Myers Squibb, Celgene, Daiichi
Sankyo, Gilead Sciences, LSK BioPharma, Merck KGaA, Merck Serono, Ono
Pharmaceutical, Pfizer, Servier Laboratories, Shionogi, Sumitomo Dainippon
Pharma, and Taiho Oncology.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Drug Class</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Angiogenesis inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>CTLA4 inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cytotoxic agents</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>HER2 inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>MMP9 inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>PD1 inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>PDL1 inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography (Region,
Country)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Astellas Pharma</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bayer HealthCare</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>BeiGene</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boston Biomedical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bristol-Myers Squibb</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Celgene</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Daiichi Sankyo</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Gilead Sciences</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>LSK BioPharma</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Merck KGaA</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Merck Serono</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Ono Pharmaceutical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Pfizer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Servier</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Shionogi</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Sumitomo Dainippon
Pharma</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.17.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Taiho Oncology</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/gastroesophageal-cancer-drugs-market/">https://www.ihealthcareanalyst.com/report/gastroesophageal-cancer-drugs-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Joint Arthroplasty Devices
Market US$ 18.5 Billion by 2023, Trends and Forecast</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global joint arthroscopy
devices market to attain US$ 18.5 Billion by 2023, growing at a CAGR of 4.6%
over the forecast period.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>Visit joint arthroscopy
devices market by procedure type (value &amp; volume) – ankle arthroplasty;
elbow arthroplasty (total elbow replacement, hemiarthroplasty); hip
arthroplasty (total hip arthroplasty – cemented hip arthroplasty, cementless
hip arthroplasty, hybrid hip replacement, partial hip arthroplasty, hip
resurfacing, revision hip surgeries); knee arthroplasty (total knee
arthroplasty, unicondylar knee arthroplasty, revision knee arthroplasty);
shoulder arthroplasty (total shoulder arthroplasty, reverse total shoulder
arthroplasty, shoulder hemiarthroplasty, shoulder resurfacing, revision
shoulder arthroplasty); by geography and forecast 2015-2023 at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/joint-arthroplasty-devices-market/">https://www.ihealthcareanalyst.com/report/joint-arthroplasty-devices-market/</a>
</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global joint arthroplasty devices market research
report provides market size (Revenue US$ Million 2015 to 2023), market share
analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global market
research report is further segmented by geography into North America (U.S.,
Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany,
France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of
APAC), and Rest of the World. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Major players operating in the market include Adler
Ortho, Arthrex, B. Braun Melsungen, BioPro, Corin, DePuy Synthes (Johnson &amp;
Johnson), DJO Global, Evolutis, Exactech, FH Orthopedics, Implantcast, Implants
International, Integra LifeSciences, JRI Orthopedics, Lima Corporate, Mathys,
MatOrtho, Medacta International, MicroPort Scientific, Smith &amp; Nephew,
Stryker, Tornier, Waldemar Link, Wright Medical Group, and Zimmer Biomet.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.             Procedure
Type (Value &amp; Volume)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.         Ankle
Arthroplasty</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.2.         Elbow
Arthroplasty</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.2.1.      Total
Elbow Replacement</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.2.2.      Hemiarthroplasty</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.3.         Hip
Arthroplasty</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.3.1.      Total
Hip Arthroplasty (THA)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.3.2.      Cemented
Hip Arthroplasty</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.3.3.      Cementless
Hip Arthroplasty</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.3.4.      Hybrid
Hip Replacement</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.3.5.      Partial
Hip Arthroplasty</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.3.6.      Hip
Resurfacing</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.3.7.      Revision
Hip Surgeries</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.4.         Knee
Arthroplasty</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.4.1.      Total
Knee Arthroplasty (TKA)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.4.2.      Unicondylar
Knee Arthroplasty</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.4.3.      Revision
Knee Arthroplasty</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.5.         Shoulder
Arthroplasty</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.5.1.      Total
Shoulder Arthroplasty (TSA)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.5.2.      Reverse
Total Shoulder Arthroplasty (RTSA)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.5.3.      Shoulder
Hemiarthroplasty</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.5.4.      Shoulder
Resurfacing</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.5.5.      Revision
Shoulder Arthroplasty</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.             Geography</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.1.         North
America (U.S., Canada)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.2.         Latin
America (Brazil, Mexico, Rest of LA)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.3.         Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.4.         Asia
Pacific (Japan, China, India, Rest of APAC</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.5.         Rest
of the World</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.             Company
Profiles</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.1.         Adler
Ortho</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.2.         Arthrex</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.3.         B.
Braun Melsungen</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.4.         BioPro</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.5.         Corin</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.6.         DePuy
Synthes (Johnson &amp; Johnson)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.7.         DJO
Global</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.8.         Evolutis</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.9.         Exactech</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.10.       FH
Orthopedics</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.11.       Implantcast</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.12.       Implants
International</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.13.       Integra
LifeSciences</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.14.       JRI
Orthopedics</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.15.       Lima
Corporate</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.16.       Mathys</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.17.       MatOrtho</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.18.       Medacta
International</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.19.       MicroPort
Scientific</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.20.       Smith
&amp; Nephew</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.21.       Stryker</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.22.       Tornier</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.23.       Waldemar
Link</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.24.       Wright
Medical Group</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.25.       Zimmer
Biomet</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/joint-arthroplasty-devices-market/">https://www.ihealthcareanalyst.com/report/joint-arthroplasty-devices-market/</a> 
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Arthroscopy and
Sport Medicine Devices Market US$ 7.0 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global arthroscopy and
sport medicine devices market to attain US$ 7.0 Billion by 2023, growing at a
CAGR of 4% over the forecast period.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Visit arthroscopy and
sport medicine devices market by  product – arthroscopy products (arthroscopic
visualization products, fluid management products, manual arthroscopy
instruments, powered arthroscopy instruments), and soft tissue fixation devices
(cruciate ligament fixation devices, hip fixation devices, meniscal fixation
devices, shoulder fixation devices); by geography and forecast 2015-2023 at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/arthroscopy-sport-medicine-devices-market/">https://www.ihealthcareanalyst.com/report/arthroscopy-sport-medicine-devices-market/</a>
</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>The global
arthroscopy and sport medicine devices market research report provides market
size (Revenue US$ Million 2015 to 2023), market share analysis, growth trends
and forecast (CAGR%, 2018 to 2023). The global market research report is
further segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Major players
operating in the market include Athos, Arthrex, Inc., ConMed Corp., DePuy Mitek
Inc. (Johnson &amp; Johnson), DJO Global, GE Healthcare, Medtronic, Smith &amp;
Nephew PLC, Stryker Corp., Tornier, Inc., Zimmer Biomet Holdings, Inc., Karl
Storz Endoscopy-America, and Richard Wolf Medical Instruments Corp.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.             Product/Device
Type</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.         Arthroscopy
Products</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.1.      Arthroscopic
Visualization Products</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.2.      Fluid
Management Products</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.3.      Manual
Arthroscopy Instruments</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.4.      Powered
Arthroscopy Instruments</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.2.         Soft
Tissue Fixation Devices</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.2.1.      Cruciate
Ligament Fixation Devices</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.2.2.      Hip
Fixation Devices</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.2.3.      Meniscal
Fixation Devices</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.2.4.      Shoulder
Fixation Devices</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.             Geography</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.1.         North
America (U.S., Canada)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.2.         Latin
America (Brazil, Mexico, Rest of LA)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.3.         Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.4.         Asia
Pacific (Japan, China, India, Rest of APAC</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.5.         Rest
of the World</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.             Company
Profiles</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.1.         Athos</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.2.         Arthrex,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.3.         ConMed
Corp.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.4.         DePuy
Mitek Inc. (Johnson &amp; Johnson)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.5.         DJO
Global</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.6.         GE
Healthcare</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.7.         Medtronic</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.8.         Smith
&amp; Nephew PLC</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.9.         Stryker
Corp.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.10.       Tornier,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.11.       Zimmer
Biomet Holdings, Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.12.       Karl
Storz Endoscopy-America</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.13.       Richard
Wolf Medical Instruments Corp.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/arthroscopy-sport-medicine-devices-market/">https://www.ihealthcareanalyst.com/report/arthroscopy-sport-medicine-devices-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Alzheimer’s Disease
Treatment Market US$ 13.2 Billion by 2023, Trends and Forecast</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global Alzheimer’s
disease treatment market to attain US$ 13.2 Billion by 2023, growing at a CAGR
of 19.7% over the forecast period.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Visit Alzheimer’s disease
treatment market by drug class (API) – acetylcholinesterase inhibitors
(donepezil, galantamine, rivastigmine), immunoglobulin (gammagard liquid),
N-methyl-daspartate (NMDA) receptor antagonist (memantine); by geography and
forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/alzheimers-disease-treatment-market/">https://www.ihealthcareanalyst.com/report/alzheimers-disease-treatment-market/</a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global Alzheimer’s
disease treatment market report provides market size (Revenue US$ Million 2015
to 2023), market share and forecasts growth trends (CAGR%, 2018 to 2023). The
global Alzheimer’s disease market report also provides the detailed market
landscape (market drivers, restraints, opportunities), market attractiveness
analysis and profiles of major competitors in the global market including
company overview, financial snapshot, key products, technologies and services
offered, and recent developments. The research report is divided by geography
into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA),
Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan,
China, India, Rest of APAC), and Rest of the World.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Major players
operating in the global Alzheimer’s market include Abbott Laboratories, AC
Immune, Affiris, AstraZeneca, Baxter International, Biogen Inc., Bristol-Myers
Squibb, Eisai, Eli Lilly, Janssen Pharmaceuticals (Johnson &amp; Johnson),
Lundbeck, Merck &amp; Co., Neurim Pharmaceuticals, Novartis, Pfizer, Roche
(Genentech), TauRx Therapeutics, vTv Therapeutics, and Warner-Lambert.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.             Drug
Class (API)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.         Acetylcholinesterase
(AChE) Inhibitors</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.1.      Donepezil</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.2.      Galantamine</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.3.      Rivastigmine</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.2.         Immunoglobulin</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.2.1.      Gammagard
Liquid</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.3.         N-Methyl-Daspartate
(NMDA) Receptor Antagonist</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.3.1.      Memantine</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.             Geography</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.1.         North
America (U.S., Canada)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.2.         Latin
America (Brazil, Mexico, Rest of LA)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.3.         Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.4.         Asia
Pacific (Japan, China, India, Rest of APAC)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.5.         Rest
of the World</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.             Company
Profiles</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.1.         Abbott
Laboratories</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.2.         AC
Immune</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.3.         Affiris</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.4.         AstraZeneca</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.5.         Baxter
International</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.6.         Biogen
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.7.         Bristol-Myers
Squibb</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.8.         Eisai</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.9.         Eli
Lilly</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.10.       Janssen
Pharmaceuticals (Johnson &amp; Johnson)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.11.       Lundbeck</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.12.       Merck
&amp; Co.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.13.       Neurim
Pharmaceuticals</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.14.       Novartis</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.15.       Pfizer</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.16.       Roche
(Genentech)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.17.       TauRx
Therapeutics</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.18.       vTv
Therapeutics</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.19.       Warner-Lambert</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/alzheimers-disease-treatment-market/">https://www.ihealthcareanalyst.com/report/alzheimers-disease-treatment-market/</a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Ostomy Drainage
Bags Market US$ 3.1 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global ostomy drainage
bags market to attain US$ 3.1 Billion by 2023, growing at a CAGR of 4.3% over
the forecast period.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Visit ostomy drainage bags
market by product (colostomy bags, ileostomy bags, urostomy bags, continent
ileostomy bags, continent urostomy bags); by usage (single-use ostomy drainage
bags, multi-use drainage bags); by clinical application (colorectal cancer,
bladder cancer, colonic diverticulitis, inflammatory bowel disease, other
diseases as crohn’s disease, ulcerative colitis); by sales channel (hospitals,
community) and forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/ostomy-drainage-bags-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/ostomy-drainage-bags-market/</span></a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global ostomy drainage
bags market report provides market size (Revenue US$ Million 2015 to 2023),
market share and forecasts growth trends (CAGR%, 2018 to 2023). The global
ostomy drainage bags market report also provides the detailed market landscape
(market drivers, restraints, opportunities), market attractiveness analysis and
profiles of major competitors in the global market including company overview,
financial snapshot, key products, technologies and services offered, and recent
developments. The research report is divided by geography into North America
(U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India,
Rest of APAC), and Rest of the World.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Major players included in
this report are Alcare Co., Ltd., B. Braun Melsungen AG, Coloplast A/S,
ConvaTec, Inc., Flexicare Medical Limited, Hollister Incorporated, Pelcin
Healthcare Ltd., Salts Healthcare Ltd., and Welland Medical Ltd.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1. Product</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1 Colostomy Bags</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.2 Ileostomy Bags</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.3 Urostomy Bags</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.4 Continent
Ileostomy Bags</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.5 Continent
Urostomy Bags</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2. Usage</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.1 Single-use
Ostomy Drainage Bags</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.2 Multi-use
Ostomy Drainage Bags</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3. Clinical
Application</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.1 Colorectal
Cancer </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.2 Bladder Cancer
</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.3 Colonic
Diverticulitis </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.4 Inflammatory
Bowel Disease </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.5 Other Diseases
(Crohn’s Disease, Ulcerative Colitis)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>4. Sales Channel</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>4.1 Hospitals </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>4.2 Community </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>5. Geography
(Region, Country)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>5.1 North America
(U.S., Canada)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>5.2 Latin America
(Brazil, Mexico, Rest of LA)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>5.3 Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>5.4 Asia Pacific
(Japan, China, India, Rest of APAC)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>5.5 Rest of the
World</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>6. Company
Profiles</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>6.1 Alcare Co.
Ltd.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>6.2 B. Braun
Melsungen AG</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>6.3 Coloplast A/S</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>6.4 ConvaTec, Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>6.5 Hollister,
Inc. (Dansac)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>6.6 Pelcin
Healthcare Ltd.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>6.7 Salts
Healthcare Ltd.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>6.8 Welland
Medical Ltd.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/ostomy-drainage-bags-market/">https://www.ihealthcareanalyst.com/report/ostomy-drainage-bags-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><b><span lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Obesity
Treatment Devices Market US$ 3.2 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global obesity
treatment devices market expected to reach US$ 3.2 billion by 2023, growing at
CAGR 10.5% over the forecast period.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>Visit the
global obesity treatment devices market by device type (gastric banding
systems, gastric balloon systems, gastric electrical stimulation systems,
gastric emptying systems or gastric aspiration systems, other emerging devices
– endoluminal bypass liners, oral appliances); and surgery procedure (Roux-en-Y
gastric bypass surgery, adjustable gastric band, laparoscopic sleeve
gastrectomy, biliopancreatic diversion with duodenal switch, revisions, other
surgical procedures), </span><span lang=EN-US style='font-size:10.0pt;
line-height:107%'>by geography </span><span lang=EN-US style='font-size:10.0pt;
line-height:107%'>and forecast 2015-2023 </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/obesity-treatment-devices-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/obesity-treatment-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global
obesity treatment devices market research report provides market size (Revenue
US$ Million 2015 to 2023), market share analysis, growth trends and forecast
(CAGR%, 2018 to 2023). The global obesity treatment devices market research
report is further segmented by geography into North America (U.S., Canada),
Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France,
Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC),
and Rest of the World. In addition, the global obesity treatment devices market
report provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.  The report also tracks the
major competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent
developments.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>Major players
include Allergan, Inc., Apollo Endosurgery, Inc., Aspire Medical, Inc. (Aspire
Bariatrics), Boston Scientific Corp., Cousin Biotech, CR Bard, Inc.,
EnteroMedics, Inc., GI Dynamics, Inc., GI Windows, Inc., Johnson &amp; Johnson,
Leptos Biomedical, Mediflex Surgical Products, Medtronic, Inc., ReShape
Medical, Inc., Satiety, Inc., Spatz FGIA, Inc., and TransEnterix, Inc.</span></p>

<p style='background:white'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;color:black'>1.&nbsp;<strong><span
style='font-family:"Calibri",sans-serif'>Device Type</span></strong><br>
1.1. Gastric Banding Systems<br>
1.2. Gastric Balloon Systems<br>
1.3. Gastric Electrical Stimulation Systems<br>
1.4. Gastric Emptying Systems (Gastric Aspiration Systems)<br>
1.5. Other Emerging Devices (Endoluminal bypass liners, Oral appliances)</span></p>

<p style='background:white'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;color:black'>2.&nbsp;<strong><span
style='font-family:"Calibri",sans-serif'>Surgery Procedure</span></strong><br>
2.1. Roux-en-Y Gastric Bypass Surgery (RNY)<br>
2.2. Adjustable Gastric Band<br>
2.3. Laparoscopic Sleeve Gastrectomy<br>
2.4. Biliopancreatic Diversion with Duodenal Switch (BPD/DS)<br>
2.5. Revisions<br>
2.6. Other Surgical Procedures</span></p>

<p style='background:white'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;color:black'>3.&nbsp;<strong><span
style='font-family:"Calibri",sans-serif'>Geography</span></strong><br>
3.1. North America (U.S., Canada)<br>
3.2. Latin America (Brazil, Mexico, Rest of LA)<br>
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)<br>
3.4. Asia Pacific (Japan, China, India, Rest of APAC<br>
3.5. Rest of the World</span></p>

<p style='background:white'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;color:black'>4.&nbsp;<strong><span
style='font-family:"Calibri",sans-serif'>Company Profiles</span></strong><br>
4.1. Allergan, Inc.<br>
4.2. Apollo Endosurgery, Inc.<br>
4.3. Aspire Medical, Inc. (Aspire Bariatrics)<br>
4.4. Boston Scientific Corp.<br>
4.5. Cousin Biotech<br>
4.6. CR Bard, Inc.<br>
4.7. EnteroMedics, Inc.<br>
4.8. GI Dynamics, Inc.<br>
4.9. GI Windows, Inc.<br>
4.10. Johnson &amp; Johnson<br>
4.11. Leptos Biomedical<br>
4.12. Mediflex Surgical Products<br>
4.13. Medtronic, Inc.<br>
4.14. ReShape Medical, Inc.<br>
4.15. Satiety, Inc.<br>
4.16. Spatz FGIA, Inc.<br>
4.17. TransEnterix, Inc.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/obesity-treatment-devices-market/">https://www.ihealthcareanalyst.com/report/obesity-treatment-devices-market/</a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct proprietary
single-client assignments targeted at client’s specific business objectives,
information needs, time frame and budget. Please contact us to receive a
proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey Hill
Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><b><span lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Implantable
Cardiac Rhythm Management (CRM) Devices Market US$ 13.5 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global implantable
cardiac rhythm management devices market expected to reach US$ 13.5 billion by
2023, growing at CAGR 4.5% over the forecast period.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>Cardiac rhythm
management (CRM) includes implantable devices, leads and accessories as well as
external devices to treat and manage arrhythmia-related diseases. Visit global implantable
cardiac rhythm management devices market by device type (cardiac
resynchronization therapy systems – CRT defibrillators, CRT pacemakers;
implantable cardioverter defibrillators systems; implantable pacemaker
systems), </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>by
geography </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>and
Forecast 2015-2023 </span><span lang=EN-US style='font-size:10.0pt;line-height:
107%'>at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/implantable-cardiac-rhythm-management-devices-market/">https://www.ihealthcareanalyst.com/report/implantable-cardiac-rhythm-management-devices-market/</a>
</span></p>

<p style='background:white'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif'>The global implantable CRM devices market
research report is further segmented by geography into North America (U.S.,
Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany,
France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of
APAC), and Rest of the World. In addition, the global implantable cardiac
rhythm management devices market report provides the detailed market landscape
(market drivers, restraints, opportunities), market attractiveness analysis,
and market profitability analysis by key products and regions or countries. 
The report also tracks the major competitors operating in the global market by
company overview, financial snapshot, major products, technologies, services
offered and recent developments.</span></p>

<p style='background:white'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif'>Major players operating in the global
implantable CRM devices market and profiled in this report include Abbott
Laboratories Inc. (St. Jude Medical), Biotronik SE &amp; Co. KG, Boston
Scientific Corp., LivaNova PLC, and Medtronic PLC.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1. Device Type</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.         Cardiac
Resynchronization Therapy (CRT) Systems</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.1.      CRT
Defibrillators (CRTDs)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.2.      CRT
Pacemakers (CRT-Ps)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.2.         Implantable
Cardioverter Defibrillators (ICD) Systems</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.3.         Implantable
Pacemaker Systems</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2. Geography</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.1.         North
America (U.S., Canada)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.2.         Latin
America (Brazil, Mexico, Rest of LA)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.3.         Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.4.         Asia
Pacific (Japan, China, India, Rest of APAC</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.5.         Rest
of the World</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3. Company
Profiles</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.1.         Abbott
Laboratories Inc. (St. Jude Medical)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.2.         Biotronik
SE &amp; Co. KG</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.3.         Boston
Scientific Corp.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.4.         LivaNova
PLC</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.5.         Medtronic
PLC </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/implantable-cardiac-rhythm-management-devices-market/">https://www.ihealthcareanalyst.com/report/implantable-cardiac-rhythm-management-devices-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><b><span lang=EN-US style='font-size:10.0pt;line-height:107%'>Global
Aortic Endografts Market US$ 3 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global
aortic endografts market expected to reach US$ 3 billion by 2023, growing at
CAGR 6.9% over the forecast period.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The endograft
is a fabric-covered metallic stent that is inserted into an abdominal aortic
aneurysm without need for a surgical approach and its resulting side effects.
An endograft comprises one of two types of stented grafts: abdominal aortic aneurysm
(AAA) and thoracic aortic aneurysm (TAA). </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>Visit global
aortic endografts market by device type (abdominal aortic endografts, thoracic
aortic endografts, fenestrated and branched aortic endografts, and flow
diverting aortic endografts), </span><span lang=EN-US style='font-size:10.0pt;
line-height:107%'>by geography </span><span lang=EN-US style='font-size:10.0pt;
line-height:107%'>and Forecast 2015-2023 </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/aortic-endografts-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/aortic-endografts-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global
aortic endografts market research report provides market size (Revenue US$
Million 2015 to 2023), market share analysis, growth trends and forecast
(CAGR%, 2018 to 2023). The global aortic endografts market research report is
further segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. In addition, the global aortic endografts market report provides the
detailed market landscape (market drivers, restraints, opportunities), market
attractiveness analysis, and market profitability analysis by key products and
regions or countries.  The report also tracks the major competitors operating
in the global market by company overview, financial snapshot, major products,
technologies, services offered and recent developments.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>Major players
operating in the global aortic endografts market and profiled in this report
include Bolton Medical, Braile Biomedica, Cardiatis, Cook Medical, Cordis
(Cardinal Health), Endologix, Inc., Endospan, Jotec, Lombard Medical
Technologies Plc, Medtronic Plc, Microport Medical, Nano Endoluminal, Terumo
Medical Corp., Transcatheter Technologies, TriVascular, Inc., Vascutek, and W.
L. Gore and Associates.</span></p>

<p style='background:white'><b><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri Light",sans-serif;color:black'>1.&nbsp;</span></b><strong><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;
color:black;font-weight:normal'>Device Type</span></strong><b><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;color:black'><br>
</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;
color:black'>1.1. Abdominal Aortic Endografts<br>
1.2. Thoracic Aortic Endografts<br>
1.3. Fenestrated and Branched Aortic Endografts<br>
1.4. Flow Diverting Aortic Endografts</span></p>

<p style='background:white'><b><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri Light",sans-serif;color:black'>2.&nbsp;</span></b><strong><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;
color:black;font-weight:normal'>Geography</span></strong><b><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;color:black'><br>
</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;
color:black'>2.1. North America (U.S., Canada)<br>
2.2. Latin America (Brazil, Mexico, Rest of LA)<br>
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)<br>
2.4. Asia Pacific (Japan, China, India, Rest of APAC<br>
2.5. Rest of the World</span></p>

<p style='background:white'><b><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri Light",sans-serif;color:black'>3.&nbsp;</span></b><strong><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;
color:black;font-weight:normal'>Company Profiles</span></strong><b><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;
color:black'><br>
</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri Light",sans-serif;
color:black'>3.1. Bolton Medical<br>
3.2. Braile Biomedica<br>
3.3. Cardiatis<br>
3.4. Cook Medical<br>
3.5. Cordis (Cardinal Health)<br>
3.6. Endologix, Inc.<br>
3.7. Endospan<br>
3.8. Jotec<br>
3.9. Lombard Medical Technologies Plc<br>
3.10. Medtronic Plc<br>
3.11. Microport Medical<br>
3.12. Nano Endoluminal<br>
3.13. Terumo Medical Corp.<br>
3.14. Transcatheter Technologies<br>
3.15. TriVascular Inc.<br>
3.16. Vascutek<br>
3.17. W. L. Gore and Associates</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>To request Table of
Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/aortic-endografts-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/aortic-endografts-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Systemic Lupus
Erythematosus and Lupus Nephritis Drugs Market US$ 2.1 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global systemic
lupus erythematosus and lupus nephritis drugs market expected to reach US$ 2.1
billion by 2023, growing at CAGR 7.2% over the forecast period. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Systemic lupus erythematosus (SLE) is a prototypic
autoimmune disease that is characterized by systemic chronic inflammation that
can affect multiple major organ systems. A major contributor to morbidity and
mortality among patients with SLE is renal involvement, known as lupus
nephritis (LN).</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Visit the global systemic lupus erythematosus and
lupus nephritis drugs market segmentation is based on drug class
(antimalarials, biologics, immunosuppressives, steroids), by geography </span><span
lang=EN-US style='font-size:10.0pt'>and Forecast 2015-2023 </span><span
lang=EN-US style='font-size:10.0pt'>at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/systemic-lupus-erythematosus-lupus-nephritis-drugs-market/">https://www.ihealthcareanalyst.com/report/systemic-lupus-erythematosus-lupus-nephritis-drugs-market/</a> 
</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global systemic lupus erythematosus and lupus
nephritis drugs market research report provides market size (Revenue US$
Million 2015 to 2023), market share analysis, growth trends and forecast
(CAGR%, 2018 to 2023). The global systemic lupus erythematosus and lupus
nephritis drugs market research report is further segmented by geography into
North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA),
Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan,
China, India, Rest of APAC), and Rest of the World. In addition, the global
systemic lupus erythematosus and lupus nephritis drugs market report provides
the detailed market landscape (market drivers, restraints, opportunities),
market attractiveness analysis, and market profitability analysis by key products
and regions or countries.  The report also tracks the major competitors
operating in the global market by company overview, financial snapshot, major
products, technologies, services offered and recent developments.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Major players operating in the global systemic lupus
erythematosus and lupus nephritis drugs market and profiled in this report
include Active Biotech, Anthera, Biogen Idec, Bristol-Myers Squibb, Eli Lilly,
Galapagos NV, Genentech (Roche), GlaxoSmithKline, Immunomedics, ImmuPharma,
Invion, Johnson &amp; Johnson, MedImmune, Merck Serono, Pfizer, SuppreMol, Teva
Pharmaceutical Industries Ltd., and UCB (Union Chimique Belge).</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1. Drug Class</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.         Antimalarials</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.2.         Biologics</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.3.         Immunosuppressives</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.4.         Steroids</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2. Geography</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.1.         North
America (U.S., Canada)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.2.         Latin
America (Brazil, Mexico, Rest of LA)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.3.         Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.4.         Asia
Pacific (Japan, China, India, Rest of APAC)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.5.         Rest
of the World</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3. Company
Profiles</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.1.         Active
Biotech</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.2.         Anthera</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.3.         Biogen
Idec</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.4.         Bristol-Myers
Squibb</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.5.         Eli
Lilly</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.6.         Galapagos
NV</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.7.         Genentech
(Roche)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.8.         GlaxoSmithKline</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.9.         Immunomedics</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.10.       ImmuPharma</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.11.       Invion</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.12.       Johnson
&amp; Johnson</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.13.       MedImmune</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.14.       Merck
Serono</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.15.       Pfizer</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.16.       SuppreMol</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.17.       Teva
Pharmaceutical Industries Ltd.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.18.       UCB
(Union Chimique Belge)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>To request Table
of Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/systemic-lupus-erythematosus-lupus-nephritis-drugs-market/">https://www.ihealthcareanalyst.com/report/systemic-lupus-erythematosus-lupus-nephritis-drugs-market/</a>
</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'><br>
<br>
</span></b></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Osteoporosis
Diagnostics Market US$ 425 Million by 2023</span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Osteoporosis disease is characterized by thinning and
deterioration of bone tissue with loss of calcification and density, and it can
progress over time. Women and older adults are more at risk for developing
osteoporosis. Heredity, low body weight, and chronic use of certain medications
(such as steroids) are also risk factors for the disease. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Visit global osteoporosis diagnostics market by
product type (bone densitometry systems, and bone remodeling biochemical marker
tests), by geography </span><span lang=EN-US style='font-size:10.0pt'>and Forecast
2015-2023 </span><span lang=EN-US style='font-size:10.0pt'>at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/osteoporosis-diagnostics-market/">https://www.ihealthcareanalyst.com/report/osteoporosis-diagnostics-market/</a>
</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global osteoporosis diagnostics market research
report provides market size (Revenue US$ Million 2015 to 2023), market share
analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global
osteoporosis diagnostics market research report is further segmented by
geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global osteoporosis diagnostics market report provides the
detailed market landscape (market drivers, restraints, opportunities), market
attractiveness analysis, and market profitability analysis by key products and
regions or countries.  The report also tracks the major competitors operating
in the global market by company overview, financial snapshot, major products,
technologies, services offered and recent developments.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Major players operating in the global osteoporosis
diagnostics market and profiled in this report include Alere, Inc., BeamMed,
Beckman Coulter, Inc., CompuMed, Inc., Diagnostic Medical Systems, Furuno
Electric Company, GE Healthcare, Hitachi Medical Systems, Hologic,
Immunodiagnostic Systems Ltd., Orion Diagnostica, Quest Diagnostics, Inc.,
Quidel Corp., Roche Diagnostics, Sectra AB, and Swissray International, Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1. Product Type</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.         Bone
Densitometry Systems</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.2.         Bone
Remodeling Biochemical Marker Tests</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2. Geography</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.1.         North
America (U.S., Canada)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.2.         Latin
America (Brazil, Mexico, Rest of LA)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.3.         Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.4.         Asia
Pacific (Japan, China, India, Rest of APAC</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.5.         Rest
of the World</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3. Company
Profiles</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.1.         Alere,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.2.         BeamMed</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.3.         Beckman
Coulter, Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.4.         CompuMed,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.5.         Diagnostic
Medical Systems</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.6.         Furuno
Electric Company</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.7.         GE
Healthcare</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.8.         Hitachi
Medical Systems</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.9.         Hologic</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.10.       Immunodiagnostic
Systems Ltd.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.11.       Orion
Diagnostica</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.12.       Quest
Diagnostics, Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.13.       Quidel
Corp.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.14.       Roche
Diagnostics</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.15.       Sectra
AB</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.16.       Swissray
International, Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>To request Table
of Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/osteoporosis-diagnostics-market/">https://www.ihealthcareanalyst.com/report/osteoporosis-diagnostics-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Global osteosynthesis devices market type of device
used (internal fixation devices – intramedullary rods and nails, screws and
plates, spinal fixation devices, wires and pins; external fixation devices –
fracture fixation devices, radius fracture, tibia fracture and pelvis fracture
fixation devices, bone lengthening devices, etc.), materials used (degradable
and non-degradable).  </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/osteosynthesis-devices-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/osteosynthesis-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Global osteoporosis drugs market by drug classes
(bisphosphonates, calcitonin, parathyroid hormone therapy drugs, RANK ligand
inhibitors, selective estrogen receptor modulators, etc.), clinical pipeline
analysis of phase 1, 2 and 3 drugs (Odanacatib, Romosozumab, etc.). </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/osteoporosis-drugs-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/osteoporosis-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'><br>
<br>
<br>
<br>
</span></b></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Cystic Fibrosis
(CF) Drugs Market US$ 6.9 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global cystic
fibrosis (CF) drugs market expected to reach US$ 6.9 billion by 2023, growing
at CAGR 14.9% over the forecast period. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The CF treatment options include: airway-clearance
techniques and medications to clear mucus from the lungs; proactive treatment
of infections; pancreatic enzyme replacement therapy (PERT); optimal nutrition;
and an active lifestyle. Ivacaftor (Kalydeco) was the first drug approved by
the US Food and Drug Administration (FDA) in 2012, however it remains very
expensive.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Visit the global cystic fibrosis drugs market by drug
class – anti-infectives, CF transmembrane conductance regulator (CFTR)
modulators, mucolytics, and pancreatic enzyme replacement therapy (PERT), by
geography </span><span lang=EN-US style='font-size:10.0pt'>and Forecast
2015-2023 </span><span lang=EN-US style='font-size:10.0pt'>at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/cystic-fibrosis-drugs-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/cystic-fibrosis-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global cystic fibrosis drugs market research
report provides market size (Revenue US$ Million 2015 to 2023), market share
analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global cystic
fibrosis drugs market research report is further segmented by geography into
North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA),
Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan,
China, India, Rest of APAC), and Rest of the World. In addition, the global
cystic fibrosis drugs market report provides the detailed market landscape
(market drivers, restraints, opportunities), market attractiveness analysis,
and market profitability analysis by key products and regions or countries. 
The report also tracks the major competitors operating in the global market by
company overview, financial snapshot, major products, technologies, services
offered and recent developments.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Major players operating in the global cystic fibrosis
drugs market and profiled in this report include AbbVie, AlgiPharma, Aptalis
Pharma, Cystic Fibrosis Foundation (CFF), Eli Lilly, Genentech (Roche), Grifols,
Insmed, KaloBios Pharmaceuticals, N30 Pharmaceuticals, NovaBiotics, Novartis,
Pharmaxis, PTC Therapeutics, Savara Pharmaceuticals, UK Cystic Fibrosis Gene
Therapy Consortium (CFGTC), and Vertex Pharmaceuticals.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.             Drug
Class</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.1.         Anti-infectives</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.2.         CF
Transmembrane Conductance Regulator (CFTR) modulators</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.3.         Mucolytics</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>1.4.         Pancreatic
Enzyme Replacement Therapy (PERT)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.             Geography</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.1.         North
America (U.S., Canada)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.2.         Latin
America (Brazil, Mexico, Rest of LA)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.3.         Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.4.         Asia
Pacific (Japan, China, India, Rest of APAC)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2.5.         Rest
of the World</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.             Company
Profiles</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.1.         AbbVie</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.2.         AlgiPharma</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.3.         Aptalis
Pharma</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.4.         Cystic
Fibrosis Foundation (CFF)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.5.         Eli
Lilly</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.6.         Genentech
(Roche)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.7.         Grifols</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.8.         Insmed</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.9.         KaloBios
Pharmaceuticals</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.10.       N30
Pharmaceuticals</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.11.       NovaBiotics</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.12.       Novartis</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.13.       Pharmaxis</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.14.       PTC
Therapeutics</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.15.       Savara
Pharmaceuticals</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.16.       UK
Cystic Fibrosis Gene Therapy Consortium (CFGTC)</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>3.17.       Vertex
Pharmaceuticals<br>
<br>
</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>To request Table
of Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/cystic-fibrosis-drugs-market/">https://www.ihealthcareanalyst.com/report/cystic-fibrosis-drugs-market/</a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct proprietary
single-client assignments targeted at client’s specific business objectives,
information needs, time frame and budget. Please contact us to receive a
proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey Hill
Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Website: </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com"><span style='font-size:
10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Chronic Lymphocytic
Leukemia (CLL) Drugs Market US$ 7.6 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global chronic
lymphocytic leukemia (CLL) drugs market expected to reach US$ 7.6 billion by
2023, growing at CAGR 13.8% over the forecast period. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Chronic lymphocytic leukemia is one of the most common
forms of leukemia. </span><span lang=EN-US><a href="https://www.cancer.org"><span
style='font-size:10.0pt'>American Cancer Society</span></a></span><span
lang=EN-US style='font-size:10.0pt'> estimates about 20,110 new cases of
chronic lymphocytic leukemia in the United States for 2017. CLL accounts for
about one-quarter of the new cases of leukemia. The main treatments used
includes chemotherapy, monoclonal antibodies, targeted therapy, supportive
care, and stem cell transplant. There are 2 general categories of systemic
therapy used for CLL: chemotherapy and targeted therapy.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Visit Chronic Lymphocytic Leukemia Drugs Market by
Drug Class (Brand) – Chemotherapy (Bendamustine); Kinase Inhibitors - Ibrutinib
(</span><span lang=EN-US style='font-size:10.0pt'>Imbruvica</span><span
lang=EN-US style='font-size:10.0pt'>), Idelalisib (</span><span lang=EN-US
style='font-size:10.0pt'>Zydelig</span><span lang=EN-US style='font-size:10.0pt'>);
Monoclonal Antibodies - Obinutuzumab (</span><span lang=EN-US style='font-size:
10.0pt'>Gazyva</span><span lang=EN-US style='font-size:10.0pt'>), Ofatumumab </span><span
lang=EN-US style='font-size:10.0pt'>(Arzerra), </span><span lang=EN-US
style='font-size:10.0pt'>Rituximab (</span><span lang=EN-US style='font-size:
10.0pt'>Rituxan</span><span lang=EN-US style='font-size:10.0pt'>) and Forecast
2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/chronic-lymphocytic-leukemia-drugs-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/chronic-lymphocytic-leukemia-drugs-market/</span></a></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>chronic lymphocytic
leukemia drugs </span><span lang=EN-US style='font-size:10.0pt;line-height:
107%'>market research report provides market size (Revenue USD Million 2015 to
2023), market share analysis, growth trends and forecast (CAGR%, 2018 to 2023).
The global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>chronic
lymphocytic leukemia drugs </span><span lang=EN-US style='font-size:10.0pt;
line-height:107%'>market research report is further segmented by geography into
North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA),
Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan,
China, India, Rest of APAC), and Rest of the World. In addition, the global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>chronic lymphocytic
leukemia drugs </span><span lang=EN-US style='font-size:10.0pt;line-height:
107%'>market report provides the detailed market landscape (market drivers,
restraints, opportunities), market attractiveness analysis, and market
profitability analysis by key products and regions or countries.  The report
also tracks the major competitors operating in the global market by company overview,
financial snapshot, major products, technologies, services offered and recent
developments.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Major players operating in the global chronic
lymphocytic leukemia drugs market and profiled in this report include AbbVie,
Angstrom Pharmaceuticals, AstraZeneca, Celgene, Cyclacel, Gilead Sciences,
Infinity, MedImmune, MorphoSys, Novartis, NOXXON Pharma, Roche, Teva
Pharmaceutical Industries Ltd., and TG Therapeutics.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Drug Class (Brand)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Chemotherapy</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bendamustine</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Kinase Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Ibrutinib (</span><span
lang=EN-US style='font-size:10.0pt'>Imbruvica</span><span lang=EN-US
style='font-size:10.0pt'>)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Idelalisib (</span><span
lang=EN-US style='font-size:10.0pt'>Zydelig</span><span lang=EN-US
style='font-size:10.0pt'>)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Monoclonal Antibodies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Obinutuzumab (</span><span
lang=EN-US style='font-size:10.0pt'>Gazyva</span><span lang=EN-US
style='font-size:10.0pt'>)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Ofatumumab </span><span
lang=EN-US style='font-size:10.0pt'>(Arzerra)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rituximab (</span><span
lang=EN-US style='font-size:10.0pt'>Rituxan</span><span lang=EN-US
style='font-size:10.0pt'>)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>AbbVie</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Angstrom
Pharmaceuticals</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>AstraZeneca</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Celgene</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cyclacel</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Gilead Sciences</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Infinity</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>MedImmune</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>MorphoSys</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Novartis</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>NOXXON Pharma</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Roche</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Teva Pharmaceutical
Industries Ltd.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>TG Therapeutics</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'><br>
To request Table of Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/chronic-lymphocytic-leukemia-drugs-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/chronic-lymphocytic-leukemia-drugs-market/</span></a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Website:
https://www.ihealthcareanalyst.com<b><br clear=all style='page-break-before:
always'>
</b></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Antithrombotic
Drugs Market US$ 28.5 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global antithrombotic
drugs market expected to reach US$ 28.5 billion by 2023, growing at CAGR 2%
over the forecast period. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Antithrombotic drugs in routine use include
antiplatelet drugs (aspirin, clopidogrel, and glycoprotein IIb/IIIa receptor
antagonists) and anticoagulants (unfractionated and low molecular weight
heparin, warfarin, and direct thrombin inhibitors). The use of antithrombotic
therapy in acute coronary syndromes has reduced the incidence of death and Q
wave myocardial infarction dramatically in recent years. Antithrombotic drugs
are categorized into three broad types: platelet aggregation inhibitors (PAIs),
fibrinolytics and anticoagulants. Antithrombotic therapy has reduced the risk
of blood clots in leg veins (also known as deep-vein thrombosis or DVT), a condition
that can lead to death from pulmonary embolism by more than 70 percent. And
most importantly, it has markedly reduced death from heart attacks, the risk of
stroke in people with heart irregularities (atrial fibrillation), and the risk
of major stroke in patients with mini-strokes.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Visit
Antithrombotic Drugs Market by Drug Type - Platelet Aggregation Inhibitors
(PAIs); Fibrinolytics; Anticoagulants - Low-Molecular-Weight Heparins (LMWHs),
Vitamin K Antagonists (VKAs), Direct Thrombin Inhibitors (DTIs), Direct Factor
Xa Inhibitors (FXa); Other Antithrombotic Agents and Forecast 2015-2023 at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/antithrombotic-drugs-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/antithrombotic-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
106%'><span lang=EN-US style='font-size:10.0pt;line-height:106%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:106%'>antithrombotic drugs </span><span
lang=EN-US style='font-size:10.0pt;line-height:106%'>market research report
provides market size (Revenue USD Million 2015 to 2023), market share analysis,
growth trends and forecast (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:106%'>antithrombotic drugs </span><span
lang=EN-US style='font-size:10.0pt;line-height:106%'>market research report is
further segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. In addition, the global </span><span lang=EN-US style='font-size:10.0pt;
line-height:106%'>antithrombotic drugs </span><span lang=EN-US
style='font-size:10.0pt;line-height:106%'>market report provides the detailed
market landscape (market drivers, restraints, opportunities), market
attractiveness analysis, and market profitability analysis by key products and
regions or countries.  The report also tracks the major competitors operating
in the global market by company overview, financial snapshot, major products,
technologies, services offered and recent developments.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Major players operating in the global antithrombotic
drugs market and profiled in this report include Armetheon, Armetheon, Bayer,
Boehringer Ingelheim, Bristol-Myers Squib, Daiichi Sankyo, D</span><span
lang=EN-US style='font-size:10.0pt;font-family:"MS Gothic"'>&#8209;</span><span
lang=EN-US style='font-size:10.0pt'>Pharm, Endotis Pharma, Janssen, Lundbeck,
Merck &amp; Co., Pfizer, Portola Pharmaceuticals, Regado Biosciences, Roche,
TeaRx, and The Medicines Company.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Drug Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Platelet Aggregation
Inhibitors (PAIs)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Fibrinolytics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Anticoagulants</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Low-Molecular-Weight
Heparins (LMWHs) </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Vitamin K Antagonists
(VKAs)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Direct Thrombin
Inhibitors (DTIs)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Direct Factor Xa
Inhibitors (FXa)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Other Antithrombotic
Agents</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S., Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Armetheon </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Armetheon </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bayer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boehringer Ingelheim</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bristol-Myers Squib </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Daiichi Sankyo</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>D</span><span
lang=EN-US style='font-size:10.0pt;font-family:"MS Gothic"'>&#8209;</span><span
lang=EN-US style='font-size:10.0pt'>Pharm </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Endotis Pharma</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Janssen </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Lundbeck </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Merck &amp; Co. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Pfizer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Portola Pharmaceuticals
</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Regado Biosciences</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Roche </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>TeaRx</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.17.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>The Medicines Company </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'><br>
To request Table of Contents and Sample Pages of this report visit: <br>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/antithrombotic-drugs-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/antithrombotic-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>About Us</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>iHealthcareAnalyst, Inc.
is a global healthcare market research and consulting company providing market
analysis, and competitive intelligence services to global clients. The company
publishes syndicate, custom and consulting grade healthcare reports covering
animal healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>In addition to
multi-client studies, we offer creative consulting services and conduct
proprietary single-client assignments targeted at client’s specific business
objectives, information needs, time frame and budget. Please contact us to
receive a proposal for a proprietary single-client study.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Contact Us</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>iHealthcareAnalyst,
Inc.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>2109, Mckelvey
Hill Drive,</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Maryland Heights,
MO 63043</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Email:
sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Website:
https://www.ihealthcareanalyst.com<b><br clear=all style='page-break-before:
always'>
</b></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Blood Cancer
Molecular Diagnostics Market US$ 4 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global blood
cancer molecular diagnostics market expected to reach US$ 4 billion by 2023,
growing at CAGR 30.1% over the forecast period. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Acute lymphoblastic leukemia (ALL) is characterized by
the production of immature white blood cells, whereas Chronic lymphocytic
leukemia (CLL), leukemia of the B-cells is the most common form of leukemia in
adults. Treatments include chemotherapy, biological agents, and transplant. Lymphomas
are a broad group of blood cancers that affect T and B cell lymphocytes.
Treatments of lymphomas include chemotherapy, radiation therapy, and bone
marrow transplantation. Molecular diagnostic tests detect mutations in DNA or
RNA that are associated with blood cancers. The Federal Drug Administration
(FDA), Centers for Medicare &amp; Medicaid Services, and Clinical Laboratory
Improvement Act (CLIA) regulate clinical molecular tests like all other
clinical laboratory tests.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'><br>
Visit Blood Cancer Molecular Diagnostics Market by Technology Platform (RT-PCR,
DNA Microarray, Lab-On-A-Chip (LOAC), Next Generation Sequencing (NGS),
Multiplex Conventional); by Application or Cancer Type (Leukemia, Lymphoma) and
Forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/blood-cancer-molecular-diagnostics-market/">https://www.ihealthcareanalyst.com/report/blood-cancer-molecular-diagnostics-market/</a>
</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>The global blood </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>cancer molecular
diagnostics </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>market
segmentation is based on</span><span lang=EN-US> </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>technology platform (RT-PCR, DNA
microarray, Lab-On-A-Chip (LOAC), next generation sequencing (NGS), multiplex
conventional); by application or cancer type (leukemia, lymphoma)</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global blood</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> cancer molecular
diagnostics</span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>
market research report provides market size (Revenue USD Million 2015 to 2023),
market share analysis, growth trends and forecast (CAGR%, 2018 to 2023). The
global blood</span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>
cancer molecular diagnostics</span><span lang=EN-US style='font-size:10.0pt;
line-height:107%'> market research report is further segmented by geography
into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA),
Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan,
China, India, Rest of APAC), and Rest of the World. In addition, the global blood</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> cancer molecular
diagnostics</span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>
market report provides the detailed market landscape (market drivers,
restraints, opportunities), market attractiveness analysis, and market
profitability analysis by key products and regions or countries. The report
also tracks the major competitors operating in the global market by company
overview, financial snapshot, major products, technologies, services offered
and recent developments.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Major players operating in the global </span><span
lang=EN-US style='font-size:10.0pt'>blood</span><span lang=EN-US
style='font-size:10.0pt'> cancer molecular diagnostics market and profiled in
this report include Asuragen, Biological Dynamics, BlueGnome (Illumina), Cancer
Genetics, Inc., Cepheid, Inc., Clarient, Inc. (GE Healthcare), Combimatrix
Corp., Foundation One, Insight Genetics, Inc., InVivoScribe Technologies, Inc.,
Ipsogen (Qiagen), Münchner Leukämie Labor, Sequenta, Inc., Signature Genomics,
and SkylineDx BV.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Technology Platform</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>RT-PCR </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>DNA Microarray </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Lab-On-A-Chip (LOAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Next Generation
Sequencing (NGS)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Multiplex Conventional </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Application (Cancer
Type)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Leukemia </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Lymphoma </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography (Region,
Country)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asuragen</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Biological Dynamics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>BlueGnome (Illumina)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cancer Genetics, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cepheid, Inc. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Clarient, Inc. (GE
Healthcare)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Combimatrix Corp.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Foundation One</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Insight Genetics, Inc. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>InVivoScribe
Technologies, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Ipsogen (Qiagen)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Münchner Leukämie Labor</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Sequenta, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Signature Genomics</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>SkylineDx BV</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>To request Table of
Contents and Sample Pages of this report visit:</span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/blood-cancer-molecular-diagnostics-market/">https://www.ihealthcareanalyst.com/report/blood-cancer-molecular-diagnostics-market/</a>
</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><strong><span lang=EN-US
style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>iHealthcareAnalyst,
Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com"><span style='font-size:10.0pt;
line-height:107%'>https://www.ihealthcareanalyst.com</span></a></span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Cancer Molecular
Diagnostics Market US$ 23.3 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global cancer
molecular diagnostics market expected to reach US$ 23.3 billion by 2023,
growing at CAGR 26.6% over the forecast period. </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Diagnostic tests are at
the forefront of medical innovation, providing vital insights into patient
health and transforming cancer care. Molecular diagnostics have transformed the
way to approach cancer care, and promise to be a critical contributor to further
progress. It can help differentiate cancer from benign tumors (i.e., growths
that are not harmful) and can further help identify the type of tissue in which
the cancer originated (e.g., breast, lung, skin, etc.). </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Visit Cancer Molecular
Diagnostics Market by Technology Platform (RT-PCR, DNA Microarray,
Lab-On-A-Chip (LOAC), Next Generation Sequencing (NGS), Multiplex Conventional,
Next Generation Capture, Protein Microarray, Others); by Application or Cancer
Type (Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer,
Precancer, Prostate Cancer, Melanoma, Leukemia, Lymphoma, Pancreatic Cancer,
Bladder Cancer, Chest Cancer, Brain Cancer, Thyroid Cancer, Kidney Cancer,
Ovarian Cancer, Stomach Cancer, Others) and Forecast 2015-2023 at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/cancer-molecular-diagnostics-market/">https://www.ihealthcareanalyst.com/report/cancer-molecular-diagnostics-market/</a>
 </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>cancer molecular
diagnostics</span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>
market research report provides market size (Revenue USD Million 2015 to 2023),
market share analysis, growth trends and forecast (CAGR%, 2018 to 2023). The
global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>cancer
molecular diagnostics</span><span lang=EN-US style='font-size:10.0pt;
line-height:107%'> market research report is further segmented by geography
into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA),
Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan,
China, India, Rest of APAC), and Rest of the World. In addition, the global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>cancer molecular
diagnostics</span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>
market report provides the detailed market landscape (market drivers,
restraints, opportunities), market attractiveness analysis, and market
profitability analysis by key products and regions or countries. The report
also tracks the major competitors operating in the global market by company
overview, financial snapshot, major products, technologies, services offered
and recent developments.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Major players operating in the global cancer molecular
diagnostics market and profiled in this report include Abbott Laboratories,
Becton, Dickinson and Company, Cepheid, Inc., Hoffmann-La Roche Ltd., Hologic,
Inc., Qiagen, Siemens Healthcare, and others.<br>
<br>
</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Technology Platform</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>RT-PCR </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>DNA Microarray </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Lab-On-A-Chip (LOAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Next Generation
Sequencing (NGS)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Multiplex Conventional </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Next Generation Capture
</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Protein Microarray </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Others</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Application (Cancer
Type)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Breast Cancer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Colorectal Cancer </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cervical Cancer </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Lung Cancer </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Precancer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Prostate Cancer </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Melanoma </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Leukemia </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Lymphoma </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Pancreatic Cancer </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Bladder Cancer </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Chest Cancer </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Brain Cancer </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Thyroid Cancer </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Kidney Cancer </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Ovarian Cancer </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.17.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Stomach Cancer </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.18.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Others</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography (Region,
Country)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>7.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Abbott Laboratories</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>7.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Becton, Dickinson and
Company</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>7.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cepheid, Inc. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>7.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Hoffmann-La Roche Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>7.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Hologic, Inc. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>7.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Qiagen </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>7.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Siemens Healthcare</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>To request Table of
Contents and Sample Pages of this report visit:</span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/cancer-molecular-diagnostics-market/">https://www.ihealthcareanalyst.com/report/cancer-molecular-diagnostics-market/</a>
</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><strong><span lang=EN-US
style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>iHealthcareAnalyst,
Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><b><span lang=EN-US
style='font-size:10.0pt;line-height:107%'><br clear=all style='page-break-before:
always'>
</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Global Nebulizer and
Spacer for pMDI Devices Market US$ 1.9 Billion by 2023</span></b></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global nebulizer
and spacer for pMDI devices market expected to reach US$ 1.9 billion by 2023,
growing at CAGR 6.6% over the forecast period. </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global
nebulizer and spacer for pMDI devices market segmentation is based on device
type (nebulizer, spacer for pMDIs), and by geography (region and country). The
report provides market size (Revenue US$ Million) and volume (number of units
in thousand) from 2015 to 2023, market share analysis, growth trends and
forecast (CAGR%, 2018 to 2023). </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>Drug delivery
mechanisms using aerosols are an integral part of the treatment of respiratory
disorders (e.g. asthma, obstructive lung disorders, cystic fibrosis, pulmonary
arterial hypertension, infectious pulmonary disease). Inhalation drug delivery
devices such as MDIs, DPIs and nebulizers have been a large part of asthma/
COPD inhaler success over the last 10 years. </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Visit Nebulizer and Spacer
for pMDI Devices Market by Device Type (Nebulizer, Spacer for MDIs), by
Geography (North America, Europe, Asia Pacific, Latin America, RoW), Key
Competitors, Distribution Channels and Forecast 2015-2023 at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/nebulizer-spacer-pmdi-devices-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/nebulizer-spacer-pmdi-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Visit Inhalation Drug
Delivery Devices Market by Device Type (Asthma Devices, COPD Devices), and
Technology (Dry Powder Inhalers; Metered Dose Inhalers – Breath-actuated MDIs,
Spacers for MDIs; Nebulizers) and Forecast 2015-2023 </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/inhalation-drug-delivery-devices-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/inhalation-drug-delivery-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global
nebulizer and spacer for pMDI devices market research report is further
segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. In addition, the global nebulizer and spacer devices market report
provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.&nbsp; The report also tracks
the major competitors operating in the global market by company overview,
financial snapshot, major products, technologies, services offered and recent
developments.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>Major players
operating in the global nebulization devices market include Philips
Respironics, Omron Healthcare, Graham-Field Health Products, Inc., PARI
Respiratory Equipment, Inc., and Others (Aerogen, Allied Healthcare Products,
GE Healthcare, Drive Medical/DeVilbiss Healthcare, ResMed, Salter Labs Inc.,
etc.).</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>Major players
operating in the global spacer for pMDI devices for pMDIs (open tube and
reverse-flow) market include Monaghan Medical Corporation, Chiesi Farmaceutici
S.p.A., Respiratory Delivery Systems, Inc., Merck &amp; Co., Inc., Smiths
Medical, Inc., Philips Respironics (Respironics, Inc.), and Destal Industries,
Inc.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>Major
manufacturing companies operating in global Valved Holding Chambers (VHCs)
market include GlaxoSmithKline, Monaghan Medical Corporation, AstraZeneca,
SunMed, Mylan Specialty L.P., FSC Pediatrics, AM Systems, Thayer Medical,
Philips Respironics, Salter Labs, Merck &amp; Co., Inc., Menarini Group, PARI
Respiratory Equipment, Inc., nSpire Health Ltd., Rhône-Poulenc S.A., Laboratory
Aldo-Union, S.A., Medical Developments International, and Henry Ford Allegiance
Health.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The report
also includes information on regulatory requirement, medical insurance, and
description on traditional and emerging distribution channels for global
nebulizer and spacer devices market.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Device Type</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Nebulizer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Spacer for MDIs</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.55in;text-align:justify;text-indent:-.3in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Nebulization Devices
Market </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.1.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Aerogen</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.1.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Allied Healthcare Products</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.1.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Drive Medical/DeVilbiss Healthcare</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.1.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>GE Healthcare</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.1.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Graham-Field Health Products, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.1.6.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Omron Healthcare</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.1.7.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>PARI Respiratory Equipment, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.1.8.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Philips Respironics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.1.9.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>ResMed</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.1.10.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Salter Labs Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.55in;text-align:justify;text-indent:-.3in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Spacer for pMDI Devices (Open
Tube and Reverse-Flow) Market </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.2.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Chiesi Farmaceutici S.p.A.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.2.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Destal Industries, Inc. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.2.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Merck &amp; Co., Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.2.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Monaghan Medical Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.2.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Philips Respironics (Respironics,
Inc.)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.2.6.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Respiratory Delivery Systems, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.2.7.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Smiths Medical, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.55in;text-align:justify;text-indent:-.3in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Valved Holding Chambers (VHCs)
Market </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>AM Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>AstraZeneca</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>FSC Pediatrics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>GlaxoSmithKline</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Henry Ford Allegiance Health</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.6.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Laboratory Aldo-Union, S.A. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.7.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Medical Developments International</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.8.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Menarini Group</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.9.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>Merck &amp; Co., Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.10.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Monaghan Medical
Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.11.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Mylan Specialty L.P.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.12.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>nSpire Health Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.13.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>PARI Respiratory
Equipment, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.14.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Philips Respironics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.15.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Rhône-Poulenc S.A.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.16.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Salter Labs</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.17.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>SunMed</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.85in;text-align:justify;text-indent:-.35in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>3.3.18.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Thayer Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>To request Table of
Contents and Sample Pages of this report visit:</span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/nebulizer-spacer-pmdi-devices-market/">https://www.ihealthcareanalyst.com/report/nebulizer-spacer-pmdi-devices-market/</a>
</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><strong><span lang=EN-US
style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>iHealthcareAnalyst,
Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><b><span lang=EN-US
style='font-size:10.0pt;line-height:107%'><br clear=all style='page-break-before:
always'>
</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global
Minimally Invasive Weight Loss (Bariatric) Devices Market US$ 313 Million by
2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global minimally invasive weight loss (bariatric)
devices market expected to reach US$ 313 million by 2023, growing at CAGR 14.8%
over the forecast period, </span><span lang=EN-US style='font-size:10.0pt'>due
to increasing preference and adoption of minimally invasive surgical procedures
worldwide, and technological advancement in developing next-generation robotic
products.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Visit Minimally Invasive Weight Loss (Bariatric)
Devices Market by Device Type (Laparoscopic Adjustable Gastric Banding (LAGB)
Systems / Lap-Band / Realize Band, Intragastric Balloon Systems / BIB System, Implantable
Neuroregulators and Gastric Electrical Stimulation Systems / GES) and Forecast
2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/minimally-invasive-weight-loss-bariatric-devices-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/minimally-invasive-weight-loss-bariatric-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Minimally invasive </span><span lang=EN-US
style='font-size:10.0pt'>bariatric surgeries are performed for patients with
morbid obesity or obesity with secondary medical issues. Laparoscopic </span><span
lang=EN-US style='font-size:10.0pt'>minimally invasive weight loss (bariatric) </span><span
lang=EN-US style='font-size:10.0pt'>approaches offer the same potentially life-saving
results as traditional open obesity surgery, but with significantly less pain
and fewer complications, such as wound infections and hernias. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Laparoscopic Adjustable Gastric Band (LAGB) is the
most common procedure done in Europe, where a silastic band placed around the
proximal stomach percutaneously allowing for tightening or loosening via a
subcutaneous port. Lap-Band System obtained U.S. FDA approval in 2001. The
latest models include Lap-Band AP-L and Lap-Band AP-S. The Realize Adjustable
Gastric Band obtained FDA approval in 2007. Two other adjustable gastric bands
are in use outside of the United States: Heliogast and Midband. Neither band
has been approved by the FDA. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Intragastric Balloon System is a weight-loss system
that uses a gastric balloon that occupies space in the stomach.</span><span
lang=EN-US> </span><span lang=EN-US style='font-size:10.0pt'>Currently there
are three FDA approved balloons in the USA. Gastric balloon devices have been
approved in many countries, among them Australia, Canada, Mexico, India, and
several European and South American countries. Two different balloon devices
available in the United States and approved by the FDA include ReShape
Integrated Dual Balloon System (ReShape Dual Balloon) and Orbera. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Gastric electrical stimulation (GES) for gastroparesis
has been in use for more than a decade with proven beneficial effect on
symptoms, quality of life and nutritional status. Currently the only GES device
used in the U.S. is the Enterra Therapy System, which is approved by the Food
and Drug Administration (FDA) under a humanitarian device exemption. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global </span><span lang=EN-US style='font-size:
10.0pt'>minimally invasive weight loss (bariatric) devices </span><span
lang=EN-US style='font-size:10.0pt'>market segmentation is based on</span><span
lang=EN-US style='font-size:10.0pt'> device type (laparoscopic adjustable
gastric banding systems / lap-band / realize band, intragastric balloon systems
/ BIB system, implantable neuroregulators and gastric electrical stimulation
systems / GES).</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>minimally invasive weight
loss (bariatric) devices </span><span lang=EN-US style='font-size:10.0pt;
line-height:107%'>market research report provides market size (Revenue USD
Million 2015 to 2023), market share analysis, growth trends and forecast
(CAGR%, 2018 to 2023). The global </span><span lang=EN-US style='font-size:
10.0pt;line-height:107%'>minimally invasive weight loss (bariatric) devices </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>market research report is
further segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. In addition, the global </span><span lang=EN-US style='font-size:10.0pt;
line-height:107%'>minimally invasive weight loss (bariatric) devices </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>market report provides the
detailed market landscape (market drivers, restraints, opportunities), market
attractiveness analysis, and market profitability analysis by key products and
regions or countries.  The report also tracks the major competitors operating
in the global market by company overview, financial snapshot, major products,
technologies, services offered and recent developments.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Major players operating in the global minimally
invasive weight loss (bariatric) devices market and profiled in this report
include Allurion Technologies, Apollo Endosurgery, Helioscopie, Obalon
Therapeutics, ReShape Medical, Spatz FGIA, EnteroMedics, MetaCure Inc., Aspire
Bariatrics Inc., BarioSurg Inc., BAROnova Inc., GI Dynamics Inc., GI Windows
Inc., and Scientific Intake Ltd.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Device Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Laparoscopic Adjustable
Gastric Banding (LAGB) Systems / Lap-Band / Realize Band</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Intragastric Balloon
Systems (BIB System)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Implantable
Neuroregulators and Gastric Electrical Stimulation Systems (GES)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Intragastric Balloon
Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>3.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Allurion Technologies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>3.1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Apollo Endosurgery</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>3.1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Helioscopie</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>3.1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Obalon Therapeutics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>3.1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>ReShape Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>3.1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Spatz FGIA</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Implantable
Neuroregulators and Gastric Electrical Stimulation Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>3.2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>EnteroMedics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>3.2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>MetaCure Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Emerging Technologies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>3.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Aspire Bariatrics Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>3.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>BarioSurg Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>3.3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>BAROnova Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>3.3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>GI Dynamics Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>3.3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>GI Windows Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>3.3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Scientific Intake Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>To request Table of
Contents and Sample Pages of this report visit:</span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/minimally-invasive-weight-loss-bariatric-devices-market/">https://www.ihealthcareanalyst.com/report/minimally-invasive-weight-loss-bariatric-devices-market/</a></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><strong><span lang=EN-US
style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><span lang=EN-US
style='font-size:10.0pt'><br clear=all style='page-break-before:always'>
</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global Atopic
Dermatitis (AD) Treatment Market US$ 7 Billion by 2023</span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global atopic dermatitis (AD) treatment market
expected to reach US$ 7 billion by 2023, growing at CAGR 11% over the forecast
period, </span><span lang=EN-US style='font-size:10.0pt'>due to the launch of
new products </span><span lang=EN-US style='font-size:9.0pt;color:#211D1E'>such
as, Dupilumab and Crisaborole, as well as </span><span lang=EN-US
style='font-size:10.0pt'>off-label use of systemic therapies for AD treatment.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Visit Atopic Dermatitis (AD) Treatment Market by Drug
Class (Brand) - Interleukin Inhibitors - Dupilumab (</span><span lang=EN-US
style='font-size:10.0pt'>Dupixent)</span><span lang=EN-US style='font-size:
10.0pt'>; Phosphodiesterase-4 (PDE4) Inhibitors - Crisaborole (</span><span
lang=EN-US style='font-size:10.0pt'>Eucrisa</span><span lang=EN-US
style='font-size:10.0pt'>); Systemic Therapy (Phototherapy); Topical Corticosteroids;
Topical Immunomodulators /</span><span lang=EN-US> </span><span lang=EN-US
style='font-size:10.0pt'>Topical Calcineurin Inhibitors </span><span
lang=EN-US style='color:black;background:white'>(TCI)</span><span lang=EN-US
style='font-size:10.0pt'> - Pimecrolimus (Elidel), Tacrolimus (Protopic) and Forecast
2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/atopic-dermatitis-treatment-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/atopic-dermatitis-treatment-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Atopic dermatitis affects up to 30% of children and
10% of adults, and is common in both developed and developing countries. Two
new medicines on the brink of entering the market — dupilumab, a biologic for
severe disease, and crisaborole, a topical small molecule drug for milder
disease — could herald a new era in the management of this condition, which has
seen no major changes to the way it has been treated for over 15 years.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Atopic dermatitis can have a devastating effect on
quality of life, but there have been no major changes to the way it has been
treated for over 15 years. Now, two new therapies: dupilumab, a biologic for
severe disease, and crisaborole, a topical small molecule drug for milder
disease could herald a new era in the treatment of this distressing condition.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Population-based studies in the United States suggest
that prevalence is about 10.7% for children and 7.2% for adults. Incidence of
AD has increased 2- to 3-fold in industrialized nations, impacting
approximately 15% to 20% of children and 1% to 3% of adults worldwide. AD has a
wide-ranging impact on a patient’s quality of life and the burden from direct
and indirect costs (approximately $37.7 billion in out-of-pocket costs) is
shared by the families and caregivers of patients with AD.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Severe side-effects of current therapies have limited
the growth of AD market, highlighting the unmet need for safe and effective
treatment options. However, recent launch of two breakthrough therapies namely
Pfizer’s Eucrisa (first PDE-4 inhibitor) and Sanofi’s Dupixent (first biologic)
have significantly changed the market dynamics. Characterized by large
under-diagnosed patient pool, high prevalence among adults as well as children
and potential molecules in development, global AD market is anticipated to grow
at a significant rate over the forecast period.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Sanofi’s and Regeneron’s Dupixent (dupilumab), which
was approved by the Food and Drug Administration (FDA) in March 2017, is
estimated to achieve peak annual sales of $4 billion. Pfizer’s Eucrisa (Crisaborole),
which was acquired for $5.2 billion in a merger with Anacor and approved by the
FDA in December 2016, is estimated to achieve peak annual sales of $2 billion. The
majority of its target market is expected to comprise mild-to-moderate cases,
with up to ~60 percent pediatric and adolescent patients.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Factors such as increase in prevalence of atopic
dermatitis, higher treatment compliance, growing prevalence of food allergies
exacerbating atopic dermatitis and favorable reimbursement policies in some
countries are driving the market growth of AD treatment worldwide.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Due to the higher number of unmet needs, vendors in
the market are focusing in developing ideal treatment, promising pipeline
molecule, rising access for the treatment medication in some developing
countries, increase in incidence of atopic dermatitis would fuel the growth of
AD treatment market during forecast period.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>However, generic erosion, poor patient compliance in
some countries and adverse effects associated with the use of medication is
negatively impacting the growth of AD treatment market.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Pipeline molecules in the clinical phases II and III
include Tralokinumab, ANB-020, Baricitinib, BMS-981164, Lebrikizumab, Mepolizumab,
MM36, Nemolizumab, PF-04965842, Tezepelumab, Upadacitinib, ZPL-389, and MEDI-9314
are expected to show strong AD treatment market growth during forecast period. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>North America dominated the global AD treatment market
due to large number of target population, higher treatment awareness, swift
adoption of novel medications, and better reimbursement policies.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global </span><span lang=EN-US style='font-size:
10.0pt'>atopic dermatitis treatment </span><span lang=EN-US style='font-size:
10.0pt'>market segmentation is based on</span><span lang=EN-US
style='font-size:10.0pt'> drug class (brand) - interleukin inhibitors - dupilumab
(</span><span lang=EN-US style='font-size:10.0pt'>Dupixent)</span><span
lang=EN-US style='font-size:10.0pt'>; phosphodiesterase-4 (PDE4) inhibitors - crisaborole
(</span><span lang=EN-US style='font-size:10.0pt'>Eucrisa</span><span
lang=EN-US style='font-size:10.0pt'>); systemic therapy (phototherapy); topical
corticosteroids; topical immunomodulators /</span><span lang=EN-US> </span><span
lang=EN-US style='font-size:10.0pt'>topical calcineurin inhibitors </span><span
lang=EN-US style='color:black;background:white'>(TCI)</span><span lang=EN-US
style='font-size:10.0pt'> - pimecrolimus (Elidel), and tacrolimus (Protopic).</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>atopic dermatitis
treatment</span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>
market research report provides market size (Revenue USD Million 2015 to 2023),
market share analysis, growth trends and forecast (CAGR%, 2018 to 2023). The
global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>atopic
dermatitis treatment</span><span lang=EN-US style='font-size:10.0pt;line-height:
107%'> market research report is further segmented by geography into North
America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe
(U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China,
India, Rest of APAC), and Rest of the World. In addition, the global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>atopic dermatitis
treatment</span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>
market report provides the detailed market landscape (market drivers,
restraints, opportunities), market attractiveness analysis, and market
profitability analysis by key products and regions or countries.  The report
also tracks the major competitors operating in the global market by company
overview, financial snapshot, major products, technologies, services offered
and recent developments.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>Major players
operating in the global atopic dermatitis treatment market and profiled in this
report include AbbVie Inc., AnaptysBio, AstraZeneca</span><span lang=EN-US>, </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Bristol-Myers Squibb, Chugai,
Eli Lilly &amp; Company, Galderma, GlaxoSmithKline, LEO Pharma A/S, Medimetriks,
Novartis, Pfizer, Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Sanofi
S.A., Valeant Pharmaceuticals, and Ziarco.</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Drug Class (Brand)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Interleukin Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Dupilumab (</span><span
lang=EN-US style='font-size:10.0pt'>Dupixent)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Phosphodiesterase-4
(PDE4) Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Crisaborole (</span><span
lang=EN-US style='font-size:10.0pt'>Eucrisa</span><span lang=EN-US
style='font-size:10.0pt'>)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Systemic Therapy
(Phototherapy)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Topical Corticosteroids</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Topical
Immunomodulators/</span><span lang=EN-US> </span><span lang=EN-US
style='font-size:10.0pt'>Topical Calcineurin Inhibitors </span><span
lang=EN-US style='color:black;background:white'>(TCI)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Pimecrolimus (Elidel)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Tacrolimus (Protopic)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>AbbVie Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>AnaptysBio</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>AstraZeneca</span><span lang=EN-US> </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bristol-Myers Squibb</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Chugai</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Eli Lilly &amp; Company</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Galderma</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>GlaxoSmithKline</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>LEO Pharma A/S</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Medimetriks</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Novartis</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Pfizer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Regeneron
Pharmaceuticals Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>F. Hoffmann-La Roche AG
</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Sanofi S.A.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Valeant Pharmaceuticals</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.17.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Ziarco</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>To request Table of
Contents and Sample Pages of this report visit:</span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/atopic-dermatitis-treatment-market/">https://www.ihealthcareanalyst.com/report/atopic-dermatitis-treatment-market/</a></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><strong><span lang=EN-US
style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><span lang=EN-US
style='font-size:10.0pt'><br clear=all style='page-break-before:always'>
</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global Endoscopic
Pelvic Surgery Devices Market US$ 17 Billion by 2023</span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global endoscopic pelvic surgery devices market
expected to reach US$ 17 billion by 2023, growing at CAGR 5.1% over the forecast
period, </span><span lang=EN-US style='font-size:10.0pt'>due to technological
advancements in endoscopic instrumentation and higher demand for minimally
invasive surgeries worldwide</span><span lang=EN-US style='font-size:10.0pt'>. </span><span
lang=EN-US style='font-size:10.0pt'>Moreover, significant demand and FDA
approvals are likely to boost the </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/endoscopy-devices-market/"><span
style='font-size:10.0pt'>global endoscopy devices market</span></a></span><span
lang=EN-US style='font-size:10.0pt'>, which is estimated to reach US$ 42.6 billion
by 2023, growing at a CAGR of 5.3% from 2018 to 2023. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US style='font-size:10.0pt;
line-height:107%'>Visit Endoscopic Pelvic Surgery Devices Market by Device Type
(Access Devices, Access Site Closure Devices, Ancillary Devices, Endoscopes,
Hand Instruments, Insufflation Products), Procedure Volume by Geography (Endoscopic
Surgical Procedures, Obstetric/Gynecologic Surgical Procedures, Urologic
Surgery Procedures) and Forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/endoscopic-pelvic-surgery-devices-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/endoscopic-pelvic-surgery-devices-market/</span></a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>endoscopic pelvic surgery
devices </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>market
research report provides market size (Revenue USD Million 2015 to 2023), market
share analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>endoscopic pelvic surgery
devices </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>market
research report is further segmented by geography into North America (U.S.,
Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany,
France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of
APAC), and Rest of the World. In addition, the global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>endoscopic pelvic surgery devices </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>market report provides the
detailed market landscape (market drivers, restraints, opportunities), market
attractiveness analysis, and market profitability analysis by key products and
regions or countries.  The report also tracks the major competitors operating
in the global market by company overview, financial snapshot, major products,
technologies, services offered and recent developments.</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>Major players
operating in the global endoscopic pelvic surgery devices market and profiled
in this report include B. Braun Melsungen AG, Becton, Dickinson and Company, Boston
Scientific Corporation, ConMed, Cook Incorporated, Daiichi (First) Medical Co.,
Eisai Co. Ltd., Fujinon (Fujifilm), Geiger Medical Technologies, Hitachi Ltd., Jiangsu
Guanchuang Medical Technology, Johnson &amp; Johnson, KARL STORZ GmbH &amp; Co.
KG, Lexion Medical, Medrobotics, Medtronic, Inc., Nikon Corporation, Olympus
Corporation, Pall Corporation, Richard Wolf GmbH, Smith &amp; Nephew, Stryker
Corporation, Sumitomo Bakelite, Synergy Health, Teleflex, Wisap Medical
Technology GmbH, W. L. Gore &amp; Associates, and Zenith Medical.</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Device Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Access Devices </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Access Site Closure
Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Ancillary Devices </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Endoscopes </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Hand Instruments </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Insufflation Products</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Procedure Volume by
Geography </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Endoscopic Surgical
Procedures </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Obstetric/Gynecologic
Surgical Procedures </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Urologic Surgery
Procedures </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>B. Braun Melsungen AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Becton, Dickinson and
Company</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boston Scientific
Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>ConMed</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cook Incorporated</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Daiichi (First) Medical
Co.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Eisai Co. Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Fujinon (Fujifilm)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geiger Medical
Technologies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Hitachi Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Jiangsu Guanchuang
Medical Technology</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Johnson &amp; Johnson</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>KARL STORZ GmbH &amp;
Co. KG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Lexion Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Medrobotics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Medtronic, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.17.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Nikon Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.18.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Olympus Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.19.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Pall Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.20.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Richard Wolf GmbH</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.21.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Smith &amp; Nephew</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.22.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Stryker Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.23.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Sumitomo Bakelite</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.24.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Synergy Health</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.25.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Teleflex</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.26.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Wisap Medical
Technology GmbH</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.27.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>W. L. Gore &amp;
Associates</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.28.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Zenith Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>To request Table of
Contents and Sample Pages of this report visit:</span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'> </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/endoscopic-pelvic-surgery-devices-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/endoscopic-pelvic-surgery-devices-market/</span></a></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><strong><span lang=EN-US
style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><span lang=EN-US
style='font-size:10.0pt'><br clear=all style='page-break-before:always'>
</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global Diagnostic
and Guided Interventional Cardiology Devices Market US$ 6 Billion by 2023 </span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global diagnostic interventional cardiology devices
market expected to reach US$ 6 billion by 2023, growing at CAGR 5.2% over the forecast
period, </span><span lang=EN-US style='font-size:10.0pt'>due to increasing
preference for minimally invasive procedures, growing geriatric population and
higher incidence of cardiovascular diseases worldwide</span><span lang=EN-US
style='font-size:10.0pt'>.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>The global </span><span
lang=EN-US style='font-size:10.0pt'>diagnostic interventional cardiology devices
</span><span lang=EN-US style='font-size:10.0pt'>market research report
provides market size (Revenue USD Million 2015 to 2023), market share analysis,
growth trends and forecast (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt'>diagnostic interventional cardiology devices
</span><span lang=EN-US style='font-size:10.0pt'>market research report is
further segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. In addition, the global </span><span lang=EN-US style='font-size:10.0pt'>diagnostic
interventional cardiology devices </span><span lang=EN-US style='font-size:
10.0pt'>market report provides the detailed market landscape (market drivers,
restraints, opportunities), market attractiveness analysis, and market
profitability analysis by key products and regions or countries.  The report
also tracks the major competitors operating in the global market by company
overview, financial snapshot, major products, technologies, services offered
and recent developments.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Visit Diagnostic
Interventional Cardiology Devices Market by Device Type (Transcatheter
Angiography Devices, Intravascular Ultrasound (IVUS) Devices, Guide Wire-based
Intravascular Stenosis Assessment or Fractional Flow Reserve (FFR) Devices, Intracardiac
Echocardiography (ICE) Devices, Optical Coherence Tomography (OCT) Devices, Robotic-Assisted
Surgical Devices) and Forecast 2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/diagnostic-interventional-cardiology-devices-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/diagnostic-interventional-cardiology-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Major players operating in the global diagnostic interventional
cardiology devices market and profiled in this report include ACIST Medical Systems
(Bracco SPA), Auris Surgical Robotics Inc., B. Braun Medical (B. Braun
Melsungen), Biosense Webster Inc. (Johnson &amp; Johnson), Boston Scientific
Corp., Catheter Precision, Cook Medical, Corindus Vascular Robotics Inc., GE
Healthcare, Hansen Medical Inc., Kaiser Permanente, Medtronic PLC, Merit
Medical Systems, Opsens Inc., Philips Healthcare/ Royal Phillips, Siemens
Healthineers, St. Jude Medical Inc. (Abbott International), Stereotaxis Inc., Shimadzu
Medical Systems, Smiths Medical, Terumo Interventional, and Toshiba America
Medical Systems.</span></p>

<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Device Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Transcatheter
Angiography Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Intravascular Ultrasound
(IVUS) Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Guide Wire-based
Intravascular Stenosis Assessment or Fractional Flow Reserve (FFR) Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Intracardiac
Echocardiography (ICE) Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Optical Coherence
Tomography (OCT) Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Robotic-Assisted
Surgical Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>ACIST Medical Systems
(Bracco SPA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Auris Surgical Robotics
Inc. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>B. Braun Medical (B.
Braun Melsungen)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Biosense Webster Inc.
(Johnson &amp; Johnson)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boston Scientific Corp.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Catheter Precision </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cook Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Corindus Vascular
Robotics Inc. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>GE Healthcare</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Hansen Medical Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Kaiser Permanente</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Medtronic PLC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Merit Medical Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Opsens Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Philips Healthcare/
Royal Phillips</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Siemens Healthineers</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.17.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>St. Jude Medical Inc.
(Abbott International)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.18.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Stereotaxis Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.19.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Shimadzu Medical
Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.20.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Smiths Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.21.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Terumo Interventional</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.22.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Toshiba America Medical
Systems</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>To request Table of
Contents and Sample Pages of this report visit:</span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'> </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/diagnostic-interventional-cardiology-devices-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/diagnostic-interventional-cardiology-devices-market/</span></a></span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><strong><span lang=EN-US
style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><span lang=EN-US
style='font-size:10.0pt'><br clear=all style='page-break-before:always'>
</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global Antibody
Drug Conjugates Market US$ 5 Billion by 2023 </span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global antibody drug conjugates market expected to
reach US$ 5 billion by 2023, growing at CAGR 22% over the forecast period, </span><span
lang=EN-US style='font-size:10.0pt'>owing to increasing drug prices and rapid
approval of new treatments</span><span lang=EN-US style='font-size:10.0pt'>.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Antibody–drug conjugates (ADCs), which consist of a
mAb chemically linked to a small-molecule therapeutics, are a niche class of
drugs that offer promise, particularly as oncology drugs. ADCs are one of the
fastest growing classes of oncology therapeutics. In the quest for more
targeted therapies and potentially more clinically efficacious drugs,
bio/pharmaceutical companies are increasing their research and product
development in biologics. Although the majority of this work is focused on
monoclonal antibodies (mAbs) and recombinant proteins, progress is being made
in specialized drug types.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>In 2011, US-FDA approved Seattle Genetics/Takeda’s
Adcetris (brentuximab vedotin) for treating Hodgkin lymphoma and anaplastic
large cell lymphoma, followed by, Roche’s Kadcyla (trastuzumab emtansine) approval
in 2013 for the treatment of breast cancer. Advancements over the past several
decades have led to a new generation of ADCs comprising non-immunogenic mAbs, linkers
with balanced stability and highly potent cytotoxic agents. In the recent years,
with the popularity and growth of ADC pipelines, companies have invested in the
required supply chains for raw materials and services to support the highly
specialized skills required for ADC containment, development, manufacturing,
and analysis. With a number of ADCs in clinical development, the key question
is whether ADCs will be able to fill a role in biopharmaceutical development. The
future of ADCs in the biopharmaceutical market will ultimately depend on their
clinical success.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Visit </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/antibody-drug-conjugates-market/"><span
style='font-size:10.0pt'>Antibody Drug Conjugates Market</span></a></span><span
lang=EN-US style='font-size:10.0pt'> by Marketed Drugs - Adcetris or SGN-35 (Brentuximab
vedotin), Kadcyla or T-DM1 (Trastuzumab emtansine), Pipeline Drugs - Rova-T or SC16LD6.5
(Rovalpituzumab tesirine), CDX</span><span lang=EN-US style='font-size:10.0pt;
font-family:"MS Gothic"'>&#8209;</span><span lang=EN-US style='font-size:10.0pt'>011
(Glembatumumab vedotin), Besponsa or CMC-544 (Inotuzumab ozogamicin), IMGN853 (Mirvetuximab
soravtansine), SGN</span><span lang=EN-US style='font-size:10.0pt;font-family:
"MS Gothic"'>&#8209;</span><span lang=EN-US style='font-size:10.0pt'>CD33A (Vadastuximab
talirine) and Forecast 2015-2023. </span><span lang=EN-US style='font-size:
10.0pt'>The global </span><span lang=EN-US style='font-size:10.0pt'>antibody
drug conjugates </span><span lang=EN-US style='font-size:10.0pt'>market
research report provides market size (Revenue USD Million 2015 to 2023), market
share analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt'>antibody drug conjugates </span><span
lang=EN-US style='font-size:10.0pt'>market research report is further segmented
by geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global </span><span lang=EN-US style='font-size:10.0pt'>antibody
drug conjugates </span><span lang=EN-US style='font-size:10.0pt'>market report
provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.  </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The report also tracks the major competitors operating
in the global market by company overview, financial snapshot, major products,
technologies, services offered and recent developments. </span><span
lang=EN-US style='font-size:10.0pt'>Major players operating in the global antibody
drug conjugates market and profiled in this report include AbbVie, Agensys,
Inc., Bayer AG, Concortis Biotherapeutics, F. Hoffman-La Roche Ltd., ImmunoGen,
Inc., Immunomedics, Inc., NBE-Therapeutics, Novartis AG, Pfizer, Sanofi, Seattle
Genetics, Inc., and Takeda Pharmaceutical Company Limited.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Marketed Drugs</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Adcetris or SGN-35
(Brentuximab vedotin)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Kadcyla or T-DM1 (Trastuzumab
emtansine)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Pipeline Drugs</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rova-T or SC16LD6.5
(Rovalpituzumab tesirine)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>CDX</span><span
lang=EN-US style='font-size:10.0pt;font-family:"MS Gothic"'>&#8209;</span><span
lang=EN-US style='font-size:10.0pt'>011 (Glembatumumab vedotin)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Besponsa or CMC-544
(Inotuzumab ozogamicin) </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>IMGN853 (Mirvetuximab
soravtansine) </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>SGN</span><span
lang=EN-US style='font-size:10.0pt;font-family:"MS Gothic"'>&#8209;</span><span
lang=EN-US style='font-size:10.0pt'>CD33A (Vadastuximab talirine)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>AbbVie</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Agensys, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bayer AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Concortis
Biotherapeutics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>F. Hoffman-La Roche
Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>ImmunoGen, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Immunomedics, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>NBE-Therapeutics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Novartis AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Pfizer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Sanofi</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Seattle Genetics, Inc.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Takeda Pharmaceutical
Company Limited</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>To request Table of
Contents and Sample Pages of this report visit:</span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/antibody-drug-conjugates-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/antibody-drug-conjugates-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><span lang=EN-US
style='font-size:10.0pt'><br clear=all style='page-break-before:always'>
</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global
Idiopathic Pulmonary Fibrosis (IPF) Treatment Market US$ 4.6 Billion by 2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global idiopathic pulmonary fibrosis treatment market
expected to reach US$ 4. billion by 2023, growing at CAGR 13.1% over the forecast
period, </span><span lang=EN-US style='font-size:10.0pt'>owing to increasing
drug prices and rapid approval of new treatments</span><span lang=EN-US
style='font-size:10.0pt'>.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Idiopathic pulmonary fibrosis (IPF) is a rare, but
serious lung disease. According to the </span><span lang=EN-US><a
href="https://ghr.nlm.nih.gov/condition/idiopathic-pulmonary-fibrosis#statistics"><span
style='font-size:10.0pt'>National Institutes of Health</span></a></span><span
lang=EN-US style='font-size:10.0pt'>, about 100,000 people in the United States
have IPF, and approximately 30,000 to 40,000 new cases are found each year.
Worldwide, IPF affects 13 to 20 out of every 100,000 people. Common comorbid
medical conditions found in patients with idiopathic pulmonary fibrosis include
chronic obstructive pulmonary disease, obstructive sleep apnea,
gastroesophageal reflux disease, and coronary artery disease. According to </span><span
lang=EN-US><a
href="http://www.pulmonaryfibrosis.org/life-with-pf/pulmonary-fibrosis-treatment-options"><span
style='font-size:10.0pt'>Pulmonary Fibrosis Foundation</span></a></span><span
lang=EN-US style='font-size:10.0pt'>, the mon-pharmacologic management of pulmonary
fibrosis (PF) to manage symptoms and prevent future complications includes home
pulse oximetry, pulmonary rehabilitation, vaccination, weight management, and lung
transplantation. In the United States; in 2013, PF accounted for nearly half of
all lung transplants performed. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Several different medications have been used for the
treatment of PF. Corticosteroids (prednisone), Cyclophosphamide (Cytoxan),
Azathioprine (Imuran), Mycophenolate mofetil (Cellcept, Myfortic), N-acetylcysteine
(NAC), Nintedanib (Ofev), Pirfenidone (Esbriet, Pirfenex, Pirespa), and Proton
pump inhibitors (Prilsec OTC, Nexium, others). Some of the therapeutic
approaches currently being studied include anti-fibrotic therapies, inhibitors
of “growth factor” proteins, stem cell therapies, and genetic research. In
2014, </span><span lang=EN-US><a
href="https://blogs.fda.gov/fdavoice/index.php/2014/10/two-fda-drug-approvals-for-idiopathic-pulmonary-fibrosis-ipf/"><span
style='font-size:10.0pt'>US-FDA</span></a></span><span lang=EN-US
style='font-size:10.0pt'> approved two anti-fibrotic medications are drugs that
inhibit or reduce fibrosis in the lung: Ofev (nintedanib) and Esbriet
(pirfenidone) for the treatment of patients with IPF. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Visit </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/idiopathic-pulmonary-fibrosis-treatment-market/"><span
style='font-size:10.0pt'>Idiopathic Pulmonary Fibrosis (IPF) Treatment Market</span></a></span><span
lang=EN-US style='font-size:10.0pt'> by Treatment Type - Pharmacological
Treatment (Pirfenidone (Esbriet), Nintedanib (Ofev), Generic Pirfenidone);
Non-pharmacological Treatment (Oxygen Therapy, Pulmonary Rehabilitation,
Mechanical Ventilation, Lung Transplantation, Other Non-Pharmacological
Treatment); Patients by Disease Severity (Mild, Moderate, Severe); Drug
Pipeline Analysis (AEOL-10150, Lebrikizumab, Tipelukast, Tralokinumab, FG-3019,
Simtuzumab, BMS-986020, AF-219, SAR156597, BG00011, PRM-151, PBI-4050)</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>and Forecast 2015-2023. </span><span lang=EN-US
style='font-size:10.0pt'>The global </span><span lang=EN-US style='font-size:
10.0pt'>idiopathic pulmonary fibrosis treatment</span><span lang=EN-US
style='font-size:10.0pt'> market research report provides market size (Revenue
USD Million 2015 to 2023), patient numbers by disease severity and by country
(U.S., Japan, U.K. Germany, France, Italy, Spain, 2015 to 2023), market share
analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt'>idiopathic pulmonary fibrosis treatment</span><span
lang=EN-US style='font-size:10.0pt'> market research report is further
segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. In addition, the global </span><span lang=EN-US style='font-size:10.0pt'>idiopathic
pulmonary fibrosis treatment</span><span lang=EN-US style='font-size:10.0pt'>
market report provides the detailed market landscape (market drivers,
restraints, opportunities), market attractiveness analysis, and market
profitability analysis by key products and regions or countries.  The report
also tracks the major competitors operating in the global market by company
overview, financial snapshot, major products, technologies, services offered
and recent developments. </span><span lang=EN-US style='font-size:10.0pt'>Major
players operating in the global idiopathic pulmonary fibrosis treatment market
and profiled in this report include Aeolus Pharmaceuticals, Baxter
International, Biogen, Inc., Boehringer Ingelheim, F. Hoffmann-La Roche,
FibroGen, Inc., Gilead Sciences, Inventiva Pharma, MediciNova, Inc., Merck
&amp; Co. (Afferent Pharmaceuticals, Inc.), Promedior, Inc., Prometheus
Laboratories, Inc., and Shionogi &amp; Company.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Treatment Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Pharmacological
Treatment - Drug (Brand)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Pirfenidone (Esbriet)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Nintedanib (Ofev)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Generic Pirfenidone</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Non-pharmacological
Treatment</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Oxygen Therapy</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Pulmonary
Rehabilitation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Mechanical Ventilation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Lung Transplantation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Other
Non-Pharmacological Treatment</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Patients (Disease
Severity) </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Mild</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Moderate</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Severe</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Pipeline Analysis</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>AEOL-10150</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Lebrikizumab</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Tipelukast</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Tralokinumab</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>FG-3019</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Simtuzumab</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>BMS-986020</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>AF-219</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>SAR156597</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>BG00011</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>PRM-151</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>PBI-4050 </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Aeolus Pharmaceuticals</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Baxter International</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Biogen, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boehringer Ingelheim</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>F. Hoffmann-La Roche</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>FibroGen, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Gilead Sciences</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Inventiva Pharma</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>MediciNova, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Merck &amp; Co.
(Afferent Pharmaceuticals, Inc.)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Promedior, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Prometheus
Laboratories, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Shionogi &amp; Company</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>To request Table of
Contents and Sample Pages of this report visit:</span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'> </span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/idiopathic-pulmonary-fibrosis-treatment-market/"><span
style='font-size:10.0pt;font-family:"Calibri",sans-serif'>https://www.ihealthcareanalyst.com/report/idiopathic-pulmonary-fibrosis-treatment-market/</span></a></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span><span lang=EN-US
style='font-size:10.0pt'><br clear=all style='page-break-before:always'>
</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global Acute
Myeloid Leukemia (AML) Treatment Market US$ 1.55 Billion 2021</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global acute myeloid leukemia treatment market
expected to reach US$ 1.55 billion by 2023, growing at CAGR 14.8% over the forecast
period, </span><span lang=EN-US style='font-size:10.0pt'>owing to introduction
of high-priced products and strong pipeline of upcoming drugs.  During the
forecast period, the marketed drugs, pipeline drugs and others are predicted to
contribute 55%, 35%, and 10% market share of the global </span><span
lang=EN-US style='font-size:10.0pt'>acute myeloid leukemia drugs market,
respectively.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Acute myeloid leukemia (AML) is the second most common
type of leukemia diagnosed in adults and children. In 2017, in the </span><span
lang=EN-US><a
href="http://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/statistics"><span
style='font-size:10.0pt'>United States</span></a></span><span lang=EN-US
style='font-size:10.0pt'>, an estimated 21,380 people will be diagnosed with
AML. Most patients with newly diagnosed AML are offered the combination of
standard-dose cytarabine with an anthracycline (daunorubicin or idarubicin)
regimen, whereas those with adverse-risk disease are offered allogeneic
stem-cell transplant (SCT) in first remission. The treatment of AML is divided
into categories based on their mechanisms of action: cytotoxic agents,
small-molecule inhibitors, and targeted therapies. These drug candidates range
from cytotoxic chemotherapies, targeted small-molecule inhibitors, and
monoclonal antibodies. Currently available hypomethylating agents azacitidine
and decitabine are FDA-approved for use in the United States. Tyrosine kinase
inhibitors (TKIs) or FLT3 inhibitors, such as midostaurin (Rydapt) were
developed as targeted therapies that interferes with aberrant tyrosine kinase
activation in malignant cells. </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Chemotherapy is the major form of remission induction
therapy for acute myeloid leukemia. Some of the other chemo drugs that may be
used to treat AML include: Cladribine (Leustatin), Fludarabine (Fludara), Topotecan,
Etoposide (VP-16), 6-thioguanine (6-TG), Hydroxyurea (Hydrea), Corticosteroid
drugs, such as prednisone or dexamethasone (Decadron), Methotrexate (MTX), 6-mercaptopurine
(6-MP), Azacitidine (Vidaza), and Decitabine (Dacogen). Arsenic trioxide
(Trisenox) and all-trans retinoic acid (ATRA) are anti-cancer drugs that can be
used alone or in combination with chemotherapy for remission induction of a
certain subtype of AML called promyelocytic leukemia. A stem cell transplant or
bone marrow transplant, may be used for consolidation therapy. In 2017, the
U.S. Food and Drug Administration approved </span><span lang=EN-US><a
href="https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm555778.htm"><span
style='font-size:10.0pt'>Rydapt (midostaurin</span></a></span><span lang=EN-US
style='font-size:10.0pt'>) as a target therapy for the treatment of adult
patients with newly diagnosed acute myeloid leukemia. There are several
promising drug currently in the phase III pipeline include </span><span
lang=EN-US style='font-size:10.0pt'>chemotherapy drugs such as </span><span
lang=EN-US style='font-size:10.0pt'>CC-486, Guadecitabine (SGI-110), Liposomal
cytarabine– daunorubicin (Vyxeos), Sapacitabine, Vosaroxin (Qinprezo), </span><span
lang=EN-US style='font-size:10.0pt'>fixed-combination drugs such as </span><span
lang=EN-US style='font-size:10.0pt'>AG-221, Ganetespib, Idasanutlin, Vadastuximab
talirine (SGN-CD33A), </span><span lang=EN-US style='font-size:10.0pt'>and
kinase inhibitor</span><span lang=EN-US style='font-size:10.0pt'> candidates
such as </span><span lang=EN-US style='font-size:10.0pt'>Gedatolisib, Gilteritinib,
Midostaurin, Quizartinib, and Volasertib</span><span lang=EN-US
style='font-size:10.0pt'>. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Visit </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/acute-myeloid-leukemia-drugs-market/"><span
style='font-size:10.0pt'>Acute Myeloid Leukemia Treatment Market</span></a></span><span
lang=EN-US style='font-size:10.0pt'> by Drug Type - Hypomethylating Agents -
Vidaza (Azacitidine), Dacogen (Decitabine), Cytarabine-based Chemotherapy
Drugs, Others; by Pipeline Analysis (Phase III Drugs) - Chemotherapy Drugs,
Vyxeos (Fixed-combination Drugs: Daunorubicin and Cytarabine); Kinase
Inhibitors (Midostaurin, Quizartinib) and Forecast 2015-2023. </span><span
lang=EN-US style='font-size:10.0pt'>The global </span><span lang=EN-US
style='font-size:10.0pt'>acute myeloid leukemia treatment </span><span
lang=EN-US style='font-size:10.0pt'>market research report provides market size
(Revenue USD Million 2015 to 2023), market share analysis, growth trends and
forecast (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt'>acute myeloid leukemia treatment </span><span
lang=EN-US style='font-size:10.0pt'>market research report is further segmented
by geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global </span><span lang=EN-US style='font-size:10.0pt'>acute
myeloid leukemia treatment </span><span lang=EN-US style='font-size:10.0pt'>market
report provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.  The report also tracks the
major competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent
developments. </span><span lang=EN-US style='font-size:10.0pt'>Major players
operating in the global acute myeloid leukemia treatment market and profiled in
this report include Astellas Pharma, Astex Pharmaceuticals, Bayer, Boehringer
Ingelheim, Celgene (Agios–Celgene), Cyclacel Pharmaceuticals, Daiichi Sankyo,
Jazz Pharmaceuticals, Novartis, Onyx Pharma, Otsuka Pharmaceuticals, Pfizer,
Roche, Seattle Genetics, Sunesis Pharmaceuticals, and Synta Pharmaceuticals.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Drug Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Hypomethylating Agents</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Vidaza (Azacitidine)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Dacogen (Decitabine)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cytarabine-based
Chemotherapy Drugs</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Others</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Pipeline Analysis
(Phase III Drugs)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Chemotherapy Drugs</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Vyxeos
(Fixed-combination Drugs: Daunorubicin and Cytarabine)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Kinase Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>2.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Midostaurin</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>2.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Quizartinib</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Astellas Pharma </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Astex Pharmaceuticals </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bayer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boehringer Ingelheim </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Celgene (Agios–Celgene)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cyclacel
Pharmaceuticals </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Daiichi Sankyo </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Jazz Pharmaceuticals</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Novartis </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Onyx Pharma</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Otsuka Pharmaceuticals</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Pfizer </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Roche</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Seattle Genetics </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Sunesis Pharmaceuticals
</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Synta Pharmaceuticals </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>To request Table of
Contents and Sample Pages of this report visit:</span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/acute-myeloid-leukemia-drugs-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/acute-myeloid-leukemia-drugs-market/</span></a></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>U.S.
Therapeutic Interventional Cardiology Devices Market US$ 2.64 Billion by 2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The U.S. therapeutic interventional cardiology devices
market expected to reach US$ 2.64 billion by 2023, growing at CAGR 0.2% over
the forecast period. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>For more details on U.S. </span><span lang=EN-US
style='font-size:10.0pt'>Therapeutic Interventional Cardiology Devices Market
by Devices Type (Coronary Stent Systems, Percutaneous Transluminal Coronary
Angioplasty Devices, Coronary Atherectomy Systems - Laser Atherectomy Systems,
Mechanical Atherectomy Systems, ­Transcatheter Septal Defect Repair Devices, ­Coronary
Thrombectomy Systems) and Forecast 2015-2023, contact us at </span><span
lang=EN-US><a href="https://www.ihealthcareanalyst.com/contact/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/contact/</span></a></span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'><br>
The global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>U.S.
therapeutic interventional cardiology devices </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>market research report provides
market size (Revenue USD Million 2015 to 2023), procedure volumes, market share
analysis, growth trends and forecast (CAGR%, 2018 to 2023). In addition, the </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>U.S. therapeutic
interventional cardiology devices </span><span lang=EN-US style='font-size:
10.0pt;line-height:107%'>market report provides the detailed market landscape
(market drivers, restraints, opportunities), market attractiveness analysis,
and market profitability analysis by key products and regions or countries. 
The report also tracks the major competitors operating in the global market by
company overview, financial snapshot, major products, technologies, services
offered and recent developments.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Major players operating in the global therapeutic
interventional cardiology devices market and profiled in this report include
Abbott Laboratories, Inc., B. Braun Melsungen AG, Bayer AG, Boston Scientific
Corporation, BVM Medical Ltd., Cardiovascular Systems Inc., Cook Medical, Inc.,
C.R. Bard, Inc., Edwards Lifesciences, Getinge Group, iVascular, Johnson &amp;
Johnson (Cordis Corporation/ Cardinal Health, Inc.), Kyoto Medical Planning
Corporation Ltd., Lepu Medical Technology, Medtronic, Inc., Merit Medical
Systems, Inc., Siemens AG, Smiths Medical, Spectranetics Corp., Terumo
Corporation, Vascular Solutions, Inc., and W. L. Gore &amp; Associates.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Device Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Coronary Stent Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Percutaneous
Transluminal Coronary Angioplasty (PTCA) Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Coronary Atherectomy
Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Laser Atherectomy
Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Mechanical Atherectomy
Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>­Transcatheter Septal
Defect Repair Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>­Coronary Thrombectomy
Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Abbott Laboratories,
Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>B. Braun Melsungen AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bayer AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boston Scientific
Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>BVM Medical Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cardiovascular Systems
Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cook Medical, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>C.R. Bard, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Edwards Lifesciences</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Getinge Group</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>iVascular</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Johnson &amp; Johnson
(Cordis Corporation/ Cardinal Health, Inc.)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Kyoto Medical Planning
Corporation Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Lepu Medical Technology</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Medtronic, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Merit Medical Systems,
Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.17.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Siemens AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.18.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Smiths Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.19.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Spectranetics Corp.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.20.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Terumo Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.21.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Vascular Solutions,
Inc.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.55in;text-indent:-.3in;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>2.22.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>W. L. Gore &amp; Associates</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>To request
Table of Contents and Sample Pages of this report, contact us:</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>  </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/contact/"><span style='font-size:10.0pt;
line-height:107%'>https://www.ihealthcareanalyst.com/contact/</span></a></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global
Inhalation Drug Delivery Devices Market US$ 15.39 Billion by 2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global inhalation drug delivery devices market
expected to reach US$ 15.3 billion by 2023, growing at CAGR 1.2% over the forecast
period, </span><span lang=EN-US style='font-size:10.0pt'>owing to rising
prevalence of asthma, cystic fibrosis, and chronic obstructive pulmonary
disease worldwide</span><span lang=EN-US style='font-size:10.0pt'>. North
America accounted for the highest 54.8% share, followed by Europe 12.8% share
of the global market. The key driving factors for growth include generic
erosion, increasing incidence of pulmonary diseases and an increasing awareness
of the inherent benefits offered by introduction of novel products.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Respiratory conditions such as asthma, chronic
obstructive pulmonary, and emphysema disease are classical therapeutic areas of
the pulmonary sector. Asthma and chronic obstructive pulmonary disease (COPD) represent
the leading chronic respiratory diseases in the world, owing to their high
prevalence and high burden on the health system. Asthma prevalence is still
increasing in both developed and developing countries, for different reasons.
While in developed countries the increase in asthma prevalence is mainly
related to their lifestyle (exposure to indoor allergens, low levels of
exercise, diets that are poor in antioxidants and obesity), in developing
countries the increased prevalence is mainly related to the air pollution and
high rates of smoking. According to </span><span lang=EN-US><a
href="http://www.globalasthmareport.org/burden/burden.php"><span
style='font-size:10.0pt'>global asthma report</span></a></span><span
lang=EN-US style='font-size:10.0pt'> as many as 334 million people have asthma,
and that the burden of disability is high. According to </span><span
lang=EN-US><a href="http://www.who.int/respiratory/copd/burden/en/"><span
style='font-size:10.0pt'>WHO</span></a></span><span lang=EN-US
style='font-size:10.0pt'> estimates, 65 million people have moderate to severe
chronic obstructive pulmonary disease (COPD). Currently, an estimated 300
million people worldwide have asthma and up to 10% of adults older than 40 years
of age may have COPD, with perhaps millions remaining undiagnosed.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global asthma and chronic obstructive pulmonary
disease (COPD) drugs market expected to reach US$ 57.5 billion by 2023, growing
at CAGR 5.1% over the forecast period, whereas the global </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/inhalation-nasal-spray-generic-drugs-market/"><span
style='font-size:10.0pt'>inhalation and nasal spray generic drugs market</span></a></span><span
lang=EN-US style='font-size:10.0pt'> expected to reach US$ 39 billion by 2023,
growing at CAGR 6.6% over the forecast period. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Inhalation drug delivery covers many different types
of devices: nebulizers, pressurized metered dose inhalers (MDIs),
breath-activated inhalers (including dry powder inhalers), and emerging novel
delivery systems. The number of inhaler devices available in the market for
inhaled therapies has increased significantly in the past decade. There are two
types of nebulizers, jet and ultrasonic, that differ in the force used to
generate the aerosol from the respective liquid. Some of the newest nebulizer
models in the market include breath-enhanced jet nebulizers such as the Pari LC</span><span
lang=EN-US> </span><span lang=EN-US style='font-size:10.0pt'>or Respironics
SideStream; breath-actuated nebulizers such as the AeroEclipse; vibrating mesh
nebulizers such as Pari eFlow rapid, Omron U22, AKITA2, APIXNEB. Pressurized
metered-dose inhalers (pMDIs) can be classified as breath-actuated or
coordination devices. Breath-actuated pMDIs, such as the Easibreathe, are
designed to address the problem of poor coordination between inhaler actuation
and patient’s breathe. Spacers and valved holding chambers (VHCs) are used with
pMDIs to increase the efficiency of aerosol delivery. Multi-dose liquid
inhalers (Respimat Soft Mist inhaler) combines the advantages of pMDIs and
nebulizers. Dry powder inhalers (DPIs) are portable devices that require
minimum patient coordination between breathing and actuation of the device to
deliver powder medications. Thermal vaporization aerosol devices such as
STACCATO uses heat to vaporize a thin film of the drug, which later condenses
in the lungs into droplets or particles depending on the nature of the drug. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Visit </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/inhalation-drug-delivery-devices-market/"><span
style='font-size:10.0pt'>Inhalation Drug Delivery Devices Market</span></a></span><span
lang=EN-US style='font-size:10.0pt'> by Device Type (Asthma Devices, COPD
Devices), and Technology (Dry Powder Inhalers; Metered Dose Inhalers -
Breath-actuated MDIs, Spacers for MDIs; Nebulizers) and Forecast 2015-2023.  </span><span
lang=EN-US style='font-size:10.0pt'>The global </span><span lang=EN-US
style='font-size:10.0pt'>inhalation drug delivery devices </span><span
lang=EN-US style='font-size:10.0pt'>market research report provides market size
(Revenue USD Million 2015 to 2023), market share analysis, growth trends and
forecast (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt'>inhalation drug delivery devices </span><span
lang=EN-US style='font-size:10.0pt'>market research report is further segmented
by geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global </span><span lang=EN-US style='font-size:10.0pt'>inhalation
drug delivery devices </span><span lang=EN-US style='font-size:10.0pt'>market
report provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.  The report also tracks the
major competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent
developments. </span><span lang=EN-US style='font-size:10.0pt'>Major players
operating in the global inhalation drug delivery devices market and profiled in
this report include Activaero GmbH, AstraZeneca Plc, Boehringer Ingelheim GmbH,
Chiesi Farmaceutici SpA, GlaxoSmithKline Plc, Koninklijke Philips NV, Merck
&amp; Co, Inc., Monaghan Medical Corporation, Novartis AG, OMRON Healthcare
Europe BV, PARI international, Pfizer, Inc., Roche Pharmaceuticals/F.
Hoffman-La Roche Ltd., SkyePharma PLC/Vectura Group Plc, Sunovion
Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd.</span></p>

<p class=MsoNormal><span lang=EN-US> </span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Device Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asthma Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>COPD Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Technology</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Dry Powder Inhalers
(DPIs)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>2.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Metered Dose Inhalers
(MDIs)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>2.1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Breath-actuated MDIs </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Spacers for MDIs </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Nebulizers</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Activaero GmbH</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>AstraZeneca Plc</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boehringer Ingelheim
GmbH</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Chiesi Farmaceutici SpA</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>GlaxoSmithKline Plc</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Koninklijke Philips NV</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Merck &amp; Co, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Monaghan Medical
Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Novartis AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>OMRON Healthcare Europe
BV</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>PARI international</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Pfizer, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Roche Pharmaceuticals/F.
Hoffman-La Roche Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>SkyePharma PLC/Vectura
Group Plc</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Sunovion
Pharmaceuticals, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Teva Pharmaceutical
Industries Ltd. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.25in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%;color:black'>To request Table of
Contents and Sample Pages of this report visit:</span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/inhalation-drug-delivery-devices-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/inhalation-drug-delivery-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
8.0pt;margin-left:0in;line-height:107%'><span lang=EN-US style='font-size:10.0pt;
line-height:107%'>&nbsp;</span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global Biopsy
Devices Market US$ 2.5 billion by 2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global </span><span lang=EN-US style='font-size:
10.0pt'>biopsy devices </span><span lang=EN-US style='font-size:10.0pt'>market
expected to reach US$ 2.5 billion by 2023, growing at CAGR 5.6% over the forecast
period, </span><span lang=EN-US style='font-size:10.0pt'>owing to increased
rates of cancer, higher preference for minimal invasive technologies and rising
geriatric population worldwide</span><span lang=EN-US style='font-size:10.0pt'>.
</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>According to </span><span lang=EN-US><a
href="https://www.cancer.gov/about-cancer/understanding/statistics"><span
style='font-size:10.0pt'>National Cancer Institute</span></a></span><span
lang=EN-US style='font-size:10.0pt'>, in 2016, an estimated 1,685,210 new cases
of cancer are diagnosed in the United States alone. The most common cancers in
2016 are projected to be breast cancer, lung and bronchus cancer, prostate
cancer, colon and rectum cancer, bladder cancer, melanoma of the skin,
non-Hodgkin lymphoma, thyroid cancer, kidney and renal pelvis cancer, leukemia,
endometrial cancer, and pancreatic cancer. The US currently holds the largest
market share, but sales in the Asia Pacific and rest of the world is expected
to experience the largest amount of growth over the forecast period. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Biopsies are performed in several different ways. Some
biopsies involve removing a small amount of tissue with a needle while others
involve surgically removing an entire lump, or nodule, that is suspicious. </span><span
lang=EN-US style='font-size:10.0pt'>For the majority of cancers, the only way
to make a definitive diagnosis is to perform a biopsy to collect cells for
closer examination. Biopsies are usually performed to identify and diagnose
cancerous tumor and to design a suitable treatment plan for the patients.
Biopsies are performed using image-guidance modalities such as X-ray imaging,
magnetic resonance imaging (MRI), computed tomography (CT) and ultrasound
imaging. Bone marrow biopsy is commonly used to diagnose both noncancerous and
cancerous diseases including blood cancers, such as leukemia, lymphoma and
multiple myeloma. Through the use of imaging methods such as X-ray or
ultrasound, a breast abnormality or breast lump can be detected, even in its
earliest stages. Breast biopsy devices can also be used for fibroadenomas (non-cancerous
breast lumps). Skin biopsies are for some basal cell or squamous cell skin
cancers. Examples of endoscopic biopsy procedures include cystoscopy,
bronchoscopy and colonoscopy. Needle biopsy procedures include fine-needle
aspiration, core needle biopsy, vacuum-assisted biopsy, and image-guided biopsy.
These procedures can be performed using manually guided systems as well as
robotic systems.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Browse </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/biopsy-devices-market/"><span
style='font-size:10.0pt'>Biopsy Devices Market</span></a></span><span
lang=EN-US style='font-size:10.0pt'> by Product Types (Needle-Based Guns
-Vacuum-Assisted, Core Needle, Fine Needle Aspiration; Biopsy Needles –
Disposable, Reusable; Biopsy Forceps – Cold and Hot; Guidance Systems – Manual
and Robotic) and Forecast 2015-2023. The global biopsy devices market report
provides market size estimates (Revenue USD million - 2015 to 2023) for key
market segments based on product type (needle-based guns -vacuum-assisted, core
needle, fine needle aspiration; biopsy needles – disposable, reusable; biopsy
forceps – cold and hot; guidance systems – manual and robotic), and forecasts
growth trends (CAGR% - 2018 to 2023). The global biopsy devices market report
also provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis and profiles of major
competitors in the global market including company overview, financial
snapshot, key products, technologies and services offered, and recent
developments. The global biopsy devices market research report is further
segmented by geography into North America (U.S., Canada), Latin America
(Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest
of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the
World. Major players operating in the global biopsy devices market and included
in this report are Angiotech, C R Bard Inc., CareFusion Corporation, Devicor
Medical Products Inc. and Hologic Inc. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><b><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-US style='font-size:10.0pt'>Device Type</span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Needle-based Biopsy
Guns</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Vacuum-assisted Biopsy
(VA) Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Core Needle Biopsy (CN)
Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Fine Needle Aspiration
Biopsy (FNA) Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Biopsy Needles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Disposable</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Reusable</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Biopsy Forceps</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cold (General) Biopsy
Forceps</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Hot Biopsy Forceps</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Biopsy Guidance Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Manual Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Robotic Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Others (Brushes,
Curettes, Punches)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><b><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-US style='font-size:10.0pt'>Geography (Region,
Country)</span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><b><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Angiotech</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>C. R. Bard, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cardinal Health Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Carefusion Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Devicor Medical
Products, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>DTR Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Hologic, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>INRAD, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>UK Biopsy</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>To request
Table of Contents and Sample Pages of this report visit:</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/biopsy-devices-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/biopsy-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:#00B050'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:#00B050'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global Stem
Cell Therapy Market US$ 9.4 billion by 2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global stem cell therapy market expected to reach
US$ 9.4 billion by 2023, growing at CAGR 10.6% over the forecast period, </span><span
lang=EN-US style='font-size:10.0pt'>owing to advancement in human development,
genetic and chromosomal disorders, human reproduction, and new disease
therapies</span><span lang=EN-US style='font-size:10.0pt'>.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Stem cells are being studied for a number of medical
applications such as neurodegeneration, brain and spinal cord injury,
generation of heart muscle cells, blood-cell formation, re-growing teeth,
cochlear hair cell regrowth, blindness and vision impairment, pancreatic beta
cells, transplantation, orthopedics, wound healing, Infertility, and HIV/AIDS.
Ancillary materials (AMs) are components or reagents used during the
manufacture of cell therapy products but are not intended to be part of the
final products. AMs for cell- and tissue-based therapies include serum
derivatives, antibiotics, cytokines, growth factors, culture media, antibodies,
and enzymes. Continued growth in the cell therapy industry and
commercialization of cell therapies through clinical trials has led to
increased awareness around the need for specialized and complex materials
utilized for stem cell therapies.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Although, bone marrow transplant is the most widely
used stem cell therapy, some therapies derived from umbilical cord blood are in
development for treating neurodegenerative diseases and conditions such as
diabetes, heart disease, and other conditions. Most of the stem cell therapies involving
osteobiologic products on the market and in development utilize multipotent
mesenchymal SCs (MSCs), such as Osteocel (NuVasive), Trinity (Orthofix) and
LiquidGen (Skye Orthbiologics). Several stem cell therapy products are in the
late-stage (phase III) pipeline including Ixmyelocel</span><span lang=EN-US
style='font-size:10.0pt;font-family:"MS Gothic"'>&#8209;</span><span
lang=EN-US style='font-size:10.0pt'>T (patient-specific autologous
multicellular therapy) for treatment of critical limb ischaemia, ‘Off-the-shelf’
mesenchymal precursors for HSCT in haematological malignancies, Prochymal
(adult human mesenchymal stem cells) for treating Crohn’s disease and graft
versus host disease, Auto-CD34+ cells (adult autologous CD34+ cells) for chronic
myocardial ischaemia, Cx601 (adipose-derived allogeneic stem cell suspension)
for complex perianal fistula , and C</span><span lang=EN-US style='font-size:
10.0pt;font-family:"MS Gothic"'>&#8209;</span><span lang=EN-US
style='font-size:10.0pt'>Cure (BM-derived stem cells treated with cardiopoietic
cocktail) for treatment of congestive heart failure. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/stem-cells-market/"><span
style='font-size:10.0pt'>stem cells market</span></a></span><span lang=EN-US
style='font-size:10.0pt'> was approximately 13 billion dollars in 2016, and from
2017, the expected annual growth rate is 14.7%, which would expand the market
to 29.6 billion dollars by 2023. The global stem cells market is segmented by type
of stem cells (adult stem cells, human embryonic stem cells, induced
pluripotent stem cells, rat neural stem cells), by stem cell technologies (stem
cells isolation, culture, cryopreservation, IVF), and by therapeutic applications
(cardiology, diabetes, hematology, neurology, oncology, and orthopedics
diseases and disorders).</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Visit </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/stem-cell-therapy-market/"><span
style='font-size:10.0pt'>Stem Cell Therapy Market</span></a></span><span
lang=EN-US style='font-size:10.0pt'> by Geography – North America (U.S.,
Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany,
France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of
APAC), Rest of the World and Forecast 2015-2023. </span><span lang=EN-US
style='font-size:10.0pt'>The global </span><span lang=EN-US style='font-size:
10.0pt'>stem cell therapy </span><span lang=EN-US style='font-size:10.0pt'>market
research report provides market size (Revenue USD Million 2015 to 2023), market
share analysis, growth trends and forecast (CAGR%, 2018 to 2023). In addition,
the global </span><span lang=EN-US style='font-size:10.0pt'>stem cell therapy </span><span
lang=EN-US style='font-size:10.0pt'>market report provides the detailed market
landscape (market drivers, restraints, opportunities), market attractiveness
analysis, and market profitability analysis by key products and regions or
countries.  The report also tracks the major competitors operating in the
global market by company overview, financial snapshot, major products,
technologies, services offered and recent developments. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Major players operating in the global stem cell
therapy market and profiled in this report include Aastrom Biosciences,
Alliancells Bioscience Co. Ltd., AlloCure, Inc., Anterogen Co. Ltd., Astellas
Pharma (Ocata Therapeutics/Advanced Cell Technology), Baxter Healthcare,
Bioheart, BrainStorm Therapeutics, Caladrius Biosciences, Cardio3 Sciences,
Cellonis Biotechnology, Cytori Therapeutics, FCB-Pharmicell Co. Ltd., Gamida
Cell, Geron Corporation, LifeCell, Ixion Biotechnology, Medipost Co. Ltd.,
Mesoblast, Neuralstem, Inc., NeuroGeneration, Inc., NuVasive, Inc., Orthofix,
Osiris Therapeutics, Pfizer, ReNeuron, Skye Orthbiologics, LLC, Stem Cell
Therapeutics, STEMCELL Technologies, StemCells, Inc., Stemedica Cell
Technologies, Inc., Stempeutics Research, TiGenix, and ViaCyte.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Aastrom Biosciences</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Alliancells Bioscience
Co. Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>AlloCure, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Anterogen Co. Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Astellas Pharma (Ocata
Therapeutics/Advanced Cell Technology)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Baxter Healthcare</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bioheart</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>BrainStorm Therapeutics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Caladrius Biosciences</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Cardio3 Sciences</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Cellonis Biotechnology</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Cytori Therapeutics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>FCB-Pharmicell Co. Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Gamida Cell</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Geron Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>LifeCell </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.17.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Ixion Biotechnology </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.18.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Medipost Co. Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.19.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Mesoblast</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.20.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Neuralstem, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.21.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>NeuroGeneration, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.22.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>NuVasive, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.23.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Orthofix</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.24.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Osiris Therapeutics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.25.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Pfizer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.26.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>ReNeuron</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.27.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Skye Orthbiologics, LLC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.28.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Stem Cell Therapeutics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.29.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>STEMCELL Technologies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.30.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>StemCells, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.31.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Stemedica Cell
Technologies, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.32.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Stempeutics Research</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.33.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>TiGenix</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.34.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>ViaCyte</span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-US style='font-size:
10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>To request
Table of Contents and Sample Pages of this report visit:</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/stem-cell-therapy-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/stem-cell-therapy-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global Head and
Neck Squamous Cell Carcinoma Drugs Market US$ 2.3 Billion by 2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global head and neck squamous cell carcinoma drugs
market expected to reach US$ 2.3 billion by 2023, growing at CAGR 23.6% over
the forecast period, </span><span lang=EN-US style='font-size:10.0pt'>mainly
due to rising epidemic of oropharynx cancer associated with the human
papillomavirus</span><span lang=EN-US style='font-size:10.0pt'>.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US><a
href="http://www.cancer.net/cancer-types/head-and-neck-cancer/statistics"><span
style='font-size:10.0pt'>Head and neck cancer</span></a></span><span
lang=EN-US style='font-size:10.0pt'> is common in several regions of the world.
The annual incidence of head and neck cancers worldwide is more than 550,000
cases each year. About 90% of all head and neck cancers are squamous cell
carcinomas. HNSCC is the sixth leading cancer by incidence worldwide. The
primary risk factors associated with head and neck cancer include tobacco use,
alcohol consumption, human papillomavirus (HPV) infection (for oropharyngeal
cancer), and Epstein-Barr virus (EBV) infection (for nasopharyngeal cancer).
Head and neck cancer accounts for about 3% of all cancers in the United States.
In 2016, an estimated 63,030 people (46,290 men and 16,740 women) have
developed head and neck cancer, whereas in 2017, an estimated 129,800 patients
will be diagnosed with SCCHN in the United States, five major European markets
and Japan.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Treatment options include single-agent therapy and
combination regimens using either conventional cytotoxic chemotherapy and/or
molecularly targeted agents combined with best supportive care. Checkpoint
inhibitor immunotherapy is an option for patients with progressive disease after
their initial chemotherapy regimen. Historically, the most widely used agents
include platinum compounds (cisplatin, carboplatin), taxanes (docetaxel,
paclitaxel, abraxane), methotrexate, fluorouracil, and cetuximab. Pembrolizumab
and nivolumab, checkpoint inhibitors of programmed cell death protein 1 (PD-1)
have also been approved. Keytruda (pembrolizumab); Merck; For the treatment of
head and neck squamous cell cancer, Approved August 2016. On November 10, 2016,
the U. S. Food and Drug Administration approved nivolumab (OPDIVO Injection,
Bristol-Myers Squibb Company), for the treatment of patients with recurrent or
metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease
progression on or after a platinum-based therapy.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The management of advanced head and neck squamous cell
carcinoma (HNSCC) consists of multiple-modality therapy with surgery,
radiation, and chemotherapy. Palliative radiation therapy is beneficial for
treating symptomatic metastatic sites. Selective drugs have been developed that
target either the extracellular ligand-binding region of the EGFR (including a
number of monoclonal antibodies, immunotoxins, and ligand-binding cytotoxic
agents) or the intracellular tyrosine kinase region (including various
small-molecule inhibitors). Targeted therapies such as cetuximab, panitumumab,
zalutumumab, nimotuzumab, erlotinib, gefitinib and lapatinib against the
epidermal growth factor receptor (EGFR) are the most promising molecular
therapeutics for head and neck squamous cell carcinoma. Drugs commonly used as
single agents in the treatment include docetaxel, paclitaxel, cetuximab,
capecitabine, pemetrexed, and methotrexate. Two checkpoint inhibitors or
programmed cell death protein 1 (PD1) inhibitors, Pembrolizumab (Keytruda), manufactured
by Merck &amp; Co. and Nivolumab (Opdivo), manufactured by Bristol-Myers Squibb
received FDA accelerated approval in 2016. New therapies include mTOR
inhibitors, anti-angiogenic agents, and IGF1R inhibitors.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Drugs approved for head and neck cancer include
Abitrexate (Methotrexate), Blenoxane (Bleomycin), Bleomycin, Cetuximab,
Docetaxel, Erbitux (Cetuximab), Folex (Methotrexate), Folex PFS (Methotrexate),
Hydrea (Hydroxyurea), Hydroxyurea, Keytruda (Pembrolizumab), Methotrexate,
Methotrexate LPF (Methotrexate), Mexate (Methotrexate), Mexate-AQ
(Methotrexate), Nivolumab, Opdivo (Nivolumab), Pembrolizumab, Taxotere
(Docetaxel). Drug combinations used in head and neck cancer include TPF -
Docetaxel (Taxotere), Cisplatin (Platinol), and Fluorouracil. <span
style='color:#221E1F'>Drugs in the phase III clinical pipeline for SCCHN
include Avelumab, Durvalumab, Gilotrif/Giotrif (afatinib), Multikine (leukocyte
interleukin), Tremelimumab, and Yervoy (ipilimumab). The immune checkpoint
inhibitors (durvalumab, tremelimumab, ipilimumab and avelumab) are expected to
obtain approval by 2023.</span></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Browse Head and
Neck Squamous Cell Carcinoma Drugs Market by Drug Class - Cytotoxic Agents,
Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death
Protein 1 (PD1) Inhibitors, PD1 Ligand 1 (PDL1) Inhibitors, Cytotoxic T
Lymphocyte Antigen 4 (CTLA4) Inhibitors and Forecast 2015-2023 at </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/head-neck-squamous-cell-carcinoma-drugs-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/head-neck-squamous-cell-carcinoma-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>head and neck squamous
cell carcinoma drugs </span><span lang=EN-US style='font-size:10.0pt;
line-height:107%'>market research report provides market size (Revenue USD
Million 2015 to 2023), market share analysis, growth trends and forecast
(CAGR%, 2018 to 2023). The global </span><span lang=EN-US style='font-size:
10.0pt;line-height:107%'>head and neck squamous cell carcinoma drugs </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>market research report is
further segmented by geography into North America (U.S., Canada), Europe (U.K.,
Germany, France, Italy, Spain), Latin America (Brazil, Mexico, Rest of LA),
Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition,
the global </span><span lang=EN-US style='font-size:10.0pt;line-height:107%'>head
and neck squamous cell carcinoma drugs </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>market report provides the detailed
market landscape (market drivers, restraints, opportunities), market
attractiveness analysis, and market profitability analysis by key products and
regions or countries.  The report also tracks the major competitors operating
in the global market by company overview, financial snapshot, major products,
technologies, services offered and recent developments. </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>Major players operating in
the global head and neck squamous cell carcinoma drugs market and profiled in
this report include Advaxis, AstraZeneca, Boehringer Ingelheim, Bristol-Myers
Squibb, CEL-SCI, Five Prime Therapeutics, Incyte, IRX Therapeutics,
MacroGenics, Merck KGaA, Novartis, Ono Pharmaceuticals (BMS), and Pfizer.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-align:justify;
text-indent:-.25in'><span lang=EN-US style='font-size:10.0pt'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Drug Class</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>1.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Cytotoxic Agents</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>1.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Epidermal Growth Factor Receptor (EGFR)
Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>1.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Programmed Cell Death Protein 1 (PD1)
Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>1.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>PD1 Ligand 1 (PDL1) Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>1.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Cytotoxic T Lymphocyte Antigen 4 (CTLA4)
Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Advaxis</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>AstraZeneca</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boehringer Ingelheim</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bristol-Myers Squibb</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>CEL-SCI</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Five Prime Therapeutics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Incyte</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>IRX Therapeutics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>MacroGenics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Merck KGaA</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Novartis</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Ono Pharmaceuticals
(BMS)</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Pfizer</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>To request
Table of Contents and Sample Pages of this report visit:</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/head-neck-squamous-cell-carcinoma-drugs-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/head-neck-squamous-cell-carcinoma-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:#00B050'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:#00B050'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global
Rheumatoid Arthritis Drugs Market US$ 42.8 billion by 2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global rheumatoid arthritis drugs</span><span
lang=EN-US style='font-size:10.0pt'> </span><span lang=EN-US style='font-size:
10.0pt'>market expected to reach US$ 42.8 billion by 2023, growing at CAGR 8.6%
over the forecast period, </span><span lang=EN-US style='font-size:10.0pt'>mainly
due to number of promising RA therapies are in development and drug approvals</span><span
lang=EN-US style='font-size:10.0pt'>.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Rheumatoid arthritis (RA) is a chronic autoimmune
condition of the connective tissue in synovial joints characterized by
inflammation that can lead to impaired movement and disability. Small-molecule
disease-modifying anti-rheumatic drugs (DMARDs) include methotrexate (Trexall,
Otrexup, Rasuvo), leflunomide (Arava), hydroxychloroquine (Plaquenil) and
sulfasalazine (Azulfidine). Biological drugs such as inhibitors of tumor
necrosis factor (TNF) blocks the activity of key inflammatory mediators that
give rise to the main characteristics of RA. These include infliximab
(Remicade), adalimumab (Humira), etanercept (Enbrel), golimumab (Simponi) and
certolizumab pegol (Cimzia). Several other biological response modifiers such
as checkpoint inhibitor, cytotoxic T lymphocyte-associated protein 4 (CTLA4)
inhibits the production of inflammatory cytokines such as TNF,
interferon-&#947; and interleukin-2 (IL-2). These include abatacept (Orencia),
Rituximab (MabThera), and Tocilizumab (Actemra/RoActemra). Janus Kinase (JAK)
inhibitors such as Tofacitinib (Xeljanz), Filgotinib and baricitinib are
recently approved by the US FDA, while a number of promising RA therapies are
in development. The RA therapies by category in clinical pipeline (phase II and
III) include JAK inhibitors (ABT-494, Baricitinib, Filgotinib), IL-6 inhibitors
or IL-6R antagonists (ALX 0061, Clazakizumab, Sarilumab, Sirukumab), and Others
(Denosumab, Mavrilimumab). </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Browse </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/rheumatoid-arthritis-drugs-market/"><span
style='font-size:10.0pt'>Rheumatoid Arthritis Drugs Market</span></a></span><span
lang=EN-US style='font-size:10.0pt'> by Drug Class - Disease-Modifying
Anti-Rheumatic Drugs (DMARDs), </span><span lang=EN-US style='font-size:10.0pt'>Tumor
Necrosis Factor</span><span lang=EN-US style='font-size:10.0pt'> (TNF)
Inhibitors, </span><span lang=EN-US style='font-size:10.0pt'>Janus Kinase (JAK)</span><span
lang=EN-US style='font-size:10.0pt'> Inhibitors, Other Biologics and Forecast
2015-2023. </span><span lang=EN-US style='font-size:10.0pt'>The global </span><span
lang=EN-US style='font-size:10.0pt'>rheumatoid arthritis drugs</span><span
lang=EN-US style='font-size:10.0pt'> market research report provides market
size (Revenue USD Million 2015 to 2023), market share analysis, growth trends
and forecast (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt'>rheumatoid arthritis drugs</span><span lang=EN-US
style='font-size:10.0pt'> market research report is further segmented by
geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global </span><span lang=EN-US style='font-size:10.0pt'>rheumatoid
arthritis drugs</span><span lang=EN-US style='font-size:10.0pt'> market report
provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.  The report also tracks the
major competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent
developments. </span><span lang=EN-US style='font-size:10.0pt'>Major players
operating in the global rheumatoid arthritis drugs market and profiled in this
report include AbbVie, Ablynx, Alder Biopharmaceuticals, Amgen, Bristol-Myers
Squibb, Centocor, Daiichi Sankyo, Eli Lilly, Galapagos NV, Genentech (Roche),
Gilead, GlaxoSmithKline, Incyte Corp., Janssen Biotech, Johnson &amp; Johnson,
MedImmune, Merck &amp; Co., Pfizer, Regeneron, Sanofi, and UCB.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Drug Class</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Disease-Modifying
Anti-Rheumatic Drugs (DMARDs)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Tumor Necrosis Factor</span><span
lang=EN-US style='font-size:10.0pt'> (TNF) Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Janus Kinase (JAK)
Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Other Biologics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>AbbVie </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Ablynx </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Alder
Biopharmaceuticals</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Amgen</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bristol-Myers Squibb</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Centocor</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Daiichi Sankyo</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Eli Lilly</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Galapagos NV</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Genentech (Roche)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Gilead</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>GlaxoSmithKline</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Incyte Corp. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Janssen Biotech</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Johnson &amp; Johnson</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>MedImmune</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.17.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Merck &amp; Co.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.18.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Pfizer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.19.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Regeneron</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.20.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Sanofi </span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.21.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>UCB</span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-US style='font-size:
10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>To request
Table of Contents and Sample Pages of this report visit:</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/rheumatoid-arthritis-drugs-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/rheumatoid-arthritis-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:#00B050'> </span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:#00B050'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:#00B050'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global Genomic
Sequencing Technologies Market US$ 9.4 Billion by 2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global genomic sequencing technologies market
expected to reach US$ 9.4 billion by 2023, growing at CAGR 14% over the forecast
period, </span><span lang=EN-US style='font-size:10.0pt'>mainly due to
high-throughput - next generation sequencing technologies, and advances in
personalized medicine</span><span lang=EN-US style='font-size:10.0pt'>.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>In recent years, there has been an increasing
fragmentation of the genomic sequencing (GS) technologies market as several
competing manufacturers launched NGS platforms. The high-throughput - next
generation sequencing (HT-NGS) technologies are currently the hottest topic in
the field of human and animal genomics researches, which can produce over 100
times more data compared to the most sophisticated capillary sequencers based
on the Sanger method. These technologies are revolutionizing the analysis of
chromatin immunoprecipitation coupled to DNA microarray (ChIP-chip) or
sequencing (ChIP-seq), RNA sequencing (RNA-seq), whole genome genotyping,
genome wide structural variation, de novo assembling and re-assembling of
genome, mutation detection and carrier screening, detection of inherited
disorders and complex human diseases. The transition of GS technologies
requires a radical overhaul of the existing pharmaceutical research and
development (R&amp;D) model, involving a more collaborative approach with shared
resources between drug developers during the early stages of target validation.
Over the years, innovations in sequencing protocols, molecular biology and
automation increased the technological capabilities of sequencing while
decreasing the cost. Today, newer pyrosequencing methods have drastically cut
the cost of sequencing and allowed the possibility of personalized genome
information. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The second generation HT-NGS platforms can generate
about five hundred million bases of raw sequence (Roche) to billions of bases
in a single run (Illumina, SOLiD). Third-generation long-range DNA sequencing
and mapping technologies are creating a renaissance in high-quality genome
sequencing. Third-generation technologies have been used to produce highly
accurate de novo assemblies of hundreds of microbial genomes, and highly
contiguous reconstructions of many dozens of plant and animal genomes, enabling
new insights into evolution and sequence diversity. They have also been applied
to resequencing analyses, to create detailed maps of structural variations8 and
phasing variants across large regions of human chromosomes. The three
commercially available third-generation DNA sequencing technologies are Pacific
Biosciences (PacBio) Single Molecule Real Time (SMRT) sequencing, the Illumina
Tru-seq Synthetic Long-Read technology and the Oxford Nanopore Technologies
sequencing platform. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Browse </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/genomic-sequencing-technologies-market/"><span
style='font-size:10.0pt'>Genomic Sequencing Technologies Market</span></a></span><span
lang=EN-US style='font-size:10.0pt'> by Product Type (Sequencing Instruments,
Reagents &amp; Consumables, Sequencing Services), Application (Commercial,
Healthcare, Research) and Forecast 2015-2023. </span><span lang=EN-US
style='font-size:10.0pt'>The global </span><span lang=EN-US style='font-size:
10.0pt'>genomic sequencing technologies </span><span lang=EN-US
style='font-size:10.0pt'>market research report provides market size (Revenue
USD Million 2015 to 2023), market share analysis, growth trends and forecast
(CAGR%, 2018 to 2023). The global </span><span lang=EN-US style='font-size:
10.0pt'>genomic sequencing technologies </span><span lang=EN-US
style='font-size:10.0pt'>market research report is further segmented by
geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global </span><span lang=EN-US style='font-size:10.0pt'>genomic
sequencing technologies </span><span lang=EN-US style='font-size:10.0pt'>market
report provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis, and market profitability
analysis by key products and regions or countries.  The report also tracks the
major competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent
developments. </span><span lang=EN-US style='font-size:10.0pt'>Major players
operating in the global genomic sequencing technologies market and profiled in
this report include Agilent Technologies, Genia, Illumina (BlueGnome/
Verinata), International Business Machines Corp., Knome, Inc., Oxford Nanopore
Technologies, Pacific Biosciences, Raindance Technologies, Inc., Roche, Thermo
Fisher Scientific (Life Technologies/Navigenics), and Torrent Systems.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Product Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Sequencing Instruments,
reagents and consumables</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Sequencing Services </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Application</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Commercial </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Healthcare </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Research </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S., Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Agilent Technologies </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Genia</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Illumina (BlueGnome/
Verinata)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>International Business
Machines Corp.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Knome, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Oxford Nanopore
Technologies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Pacific Biosciences</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Raindance Technologies,
Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Roche</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Thermo Fisher
Scientific (Life Technologies/Navigenics)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Torrent Systems</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.25in;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>To request
Table of Contents and Sample Pages of this report visit:</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/genomic-sequencing-technologies-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/genomic-sequencing-technologies-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>References:</span></b></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.25in;text-align:justify;text-indent:-.25in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/next-generation-sequencing-market/"><span
style='font-size:10.0pt;line-height:107%'>Next-Generation Sequencing Market</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> by NGS Platforms
(Illumina – HiSeq Series, HiSeq X Ten &amp; HiSeq X Five, MiSeq Series, NextSeq
500, Thermo Fisher – SOLiD Series, Ion PGM, Ion Proton, Ion S5 &amp; Ion S5 XL,
Pacific Biosciences – PacBio RS II, Sequel System), NGS Data Analysis (ChIP
Sequencing, De Novo Sequencing, Exome Sequencing, Methyl Sequencing, RNA
Sequencing, Targeted Resequencing, Whole Genome Sequencing), Technology (Ion
Semiconductor Sequencing, Pyrosequencing, Sequencing by Ligation, Sequencing by
Synthesis, Single-Molecule Real-time Sequencing), Applications (Agriculture and
Animal Research, Biomarker Discovery, Diagnostics, Drug Discovery, Personalized
Medicine), and End Users (Academic and Research Institutes, Hospitals &amp;
Clinics, Pharmaceutical and Biotechnology Companies) and Forecast 2015-2023</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.25in;text-align:justify;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.25in;text-align:justify;text-indent:-.25in;
line-height:107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/cancer-genome-sequencing-market/"><span
style='font-size:10.0pt;line-height:107%'>Cancer Genome Sequencing Market</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> by Technology Types
(Second and Third Generation Sequencing), and Cancer Types (Breast Cancer,
Prostate Cancer, Colorectal Cancer) and Forecast 2015-2023</span></p>

<p class=MsoListParagraphCxSpLast><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
8.0pt;margin-left:.25in;text-align:justify;line-height:107%'><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:#92D050'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:#92D050'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global Heart
Valve Repair and Replacement Devices Market US$ 9.8 Billion by 2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global heart valve repair and replacement devices
market expected to reach US$ 9.8 billion by 2023, growing at CAGR 9.9% over the
forecast period, </span><span lang=EN-US style='font-size:10.0pt'>mainly due to
new device approvals, technological advancements, and rising geriatric
population</span><span lang=EN-US style='font-size:10.0pt'>.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>In the United States, about 106,000 heart valve
operations are performed each year. Nearly all of these operations are done to
repair or replace the mitral or aortic valves. Heart valve repair is a surgical
technique used to fix defects in heart valves in valvular heart diseases, and
provides an alternative to valve replacement. Minimally invasive heart valve
surgery technique uses smaller incisions to repair or replace heart valves,
which also reduces the length of the hospital stay and the recovery time.
Transcatheter aortic valve implantation (TAVI) or transcatheter aortic valve
replacement (TAVR) is a minimally invasive procedure to repair a damaged or
diseased aortic valve. Percutaneous aortic valve replacement (PAVR), or TAVI or
TAVR involves replacement of the aortic valve of the heart through the blood
vessels. The most common valve surgical procedure is aortic valve replacement
for aortic stenosis, or narrowing of the aortic valve. More recently,
transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve
regurgitation therapy (TMVrep) has become a reality. In the recent years,
transcatheter heart-valve management procedures with TAVR and TMVrep systems
are gaining significant boost in terms of number of procedures performed
worldwide. Compared to invasive or surgical systems, the emerging
transcatheter-based, minimally invasive TAVR and TMVrep systems are accounted
for higher market share over the forecast period. The heart valve repair and
replacement devices market is driven by the growing numbers of valvular disease
resulting from rising obesity rates and growing prevalence of diabetes
worldwide. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Browse </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/heart-valve-repair-replacement-devices-market/"><span
style='font-size:10.0pt'>Heart Valve Repair and Replacement Devices Market</span></a></span><span
lang=EN-US style='font-size:10.0pt'> by Device Type - Percutaneous Balloon
Valvuloplasty (PBV), Heart Valve Surgery, Transcatheter Devices - Transcatheter
Aortic Valve Replacement (TAVR), Transcatheter Mitral Valve Regurgitation
Therapy (TMVrep) and Forecast 2015-2023. </span><span lang=EN-US
style='font-size:10.0pt'>The global </span><span lang=EN-US style='font-size:
10.0pt'>heart valve repair and replacement devices </span><span lang=EN-US
style='font-size:10.0pt'>market research report provides market size (Revenue
USD Million 2015 to 2023), market share analysis, growth trends and forecast
(CAGR%, 2018 to 2023). The global </span><span lang=EN-US style='font-size:
10.0pt'>heart valve repair and replacement devices </span><span lang=EN-US
style='font-size:10.0pt'>market research report is further segmented by
geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global </span><span lang=EN-US style='font-size:10.0pt'>heart
valve repair and replacement devices </span><span lang=EN-US style='font-size:
10.0pt'>market report provides the detailed market landscape (market drivers,
restraints, opportunities), market attractiveness analysis, and market
profitability analysis by key products and regions or countries.  The report
also tracks the major competitors operating in the global market by company
overview, financial snapshot, major products, technologies, services offered
and recent developments. </span><span lang=EN-US style='font-size:10.0pt'>Major
players operating in the global heart valve repair and replacement devices
market and profiled in this report include Abbott Laboratories, B. Braun
Melsungen, Boston Scientific Corporation, Braile Biomedica, C.R. Bard,
CarboMedics/LivaNova, Cardiac Dimension, CardiaMed, Cardiosolutions, Cook
Medical, CryoLife, Edwards Lifesciences, FOC Medical, InterValve, JenaValve
Technology, Labcor, Lanzhou Lanfei Medical Instrument, Lepu Medical, Medtronic,
NeoChord, ON-X Life Technologies, Osypka Medical, Siemens Healthcare, Symetis,
Toray Medical, TTK Healthcare, Valtech Cardio, and Vascutek/Terumo Corporation.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Device Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Percutaneous Balloon
Valvuloplasty (PBV)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Heart Valve Surgery</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Transcatheter Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Transcatheter Aortic
Valve Replacement (TAVR) </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Transcatheter Mitral Valve
Regurgitation Therapy (TMVrep)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Abbott Laboratories</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>B. Braun Melsungen</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boston Scientific
Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Braile Biomedica</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>C.R. Bard</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>CarboMedics (LivaNova)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cardiac Dimension</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>CardiaMed</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cardiosolutions</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Cook Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>CryoLife</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Edwards Lifesciences</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>FOC Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>InterValve</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>JenaValve Technology</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Labcor</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.17.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Lanzhou Lanfei Medical
Instrument</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.18.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Lepu Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.19.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Medtronic</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.20.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>NeoChord</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.21.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>ON-X Life Technologies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.22.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Osypka Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.23.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Siemens Healthcare</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.24.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Symetis</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.25.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Toray Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.26.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>TTK Healthcare</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.27.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Valtech Cardio</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.28.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Terumo Corporation
(Vascutek)</span></p>

<p class=MsoNormal style='margin-left:.25in'><span lang=EN-US style='font-size:
10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>To request
Table of Contents and Sample Pages of this report visit:</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/heart-valve-repair-replacement-devices-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/heart-valve-repair-replacement-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:#92D050'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:#92D050'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global
Interventional Cardiology Diagnostic and Therapeutic Devices Market Analysis
and Forecast 2015-2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Diagnostic interventional cardiology includes coronary
angiogram to determine any blockage to arteries and intravascular ultrasound
(IVUS) to evaluate a heart’s arteries. Minimally-invasive heart surgery and
treatment consists of cardiac catheterization to diagnose or treat certain
heart conditions, angioplasty and stent placement (percutaneous coronary
intervention or PCI) to restore healthy blood flow to the heart, carotid
angioplasty and stenting (CAS) to open narrowed or blocked carotid arteries,
angioplasty and stent placement to open narrowed or blocked peripheral
arteries, rotational atherectomy to remove calcified lesions from arteries,
percutaneous balloon valvuloplasty to open a narrowed or blocked heart valve,
transcatheter aortic valve replacement (TAVR/TAVI)  to replace an aortic valve,
also as an alternative to open-heart surgery for high-risk patients, and adult
heart structural procedures to treat congenital heart defects such as aortic
valve stenosis, atrial septal defect, ventricular septal defect, or pulmonary
valve stenosis and other adult congenital heart defects. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Browse </span><span lang=EN-US style='font-size:10.0pt'>Interventional
Cardiology Diagnostic and Therapeutic Devices Market by Diagnostic Devices
(Coronary Angiography, Intravascular Ultrasound, Guidewire-Based Physiologic, Intravascular
Stenosis Assessment, Optical Coherence Tomography, Intracardiac
Echocardiography), Therapeutic Devices Type (Coronary Stent Systems,
Percutaneous Transluminal Coronary Angioplasty Devices, Coronary Atherectomy
Systems - Laser Atherectomy Systems, Mechanical Atherectomy Systems, ­Transcatheter
Septal Defect Repair Devices, ­Coronary Thrombectomy Systems) and Forecast
2015-2023 at </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/interventional-cardiology-diagnostic-therapeutic-devices-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/interventional-cardiology-diagnostic-therapeutic-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;text-align:justify;line-height:
107%'><span lang=EN-US style='font-size:10.0pt;line-height:107%'>The global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>interventional cardiology
diagnostic and therapeutic devices </span><span lang=EN-US style='font-size:
10.0pt;line-height:107%'>market research report provides market size (Revenue
USD Million 2015 to 2023), procedure volumes, market share analysis, growth
trends and forecast (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>interventional cardiology diagnostic
and therapeutic devices </span><span lang=EN-US style='font-size:10.0pt;
line-height:107%'>market research report is further segmented by geography into
North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA),
Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan,
China, India, Rest of APAC), and Rest of the World. In addition, the global </span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>interventional cardiology
diagnostic and therapeutic devices </span><span lang=EN-US style='font-size:
10.0pt;line-height:107%'>market report provides the detailed market landscape
(market drivers, restraints, opportunities), market attractiveness analysis,
and market profitability analysis by key products and regions or countries. 
The report also tracks the major competitors operating in the global market by
company overview, financial snapshot, major products, technologies, services
offered and recent developments.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Major players operating in the global interventional
cardiology diagnostic and therapeutic devices market and profiled in this
report include Abbott Laboratories, Inc., B. Braun Melsungen AG, Bayer AG,
Boston Scientific Corporation, BVM Medical Ltd., Cardiovascular Systems Inc.,
Cook Medical, Inc., C.R. Bard, Inc., Edwards Lifesciences, Getinge Group, iVascular,
Johnson &amp; Johnson (Cordis Corporation/ Cardinal Health, Inc.), Kyoto
Medical Planning Corporation Ltd., Lepu Medical Technology, Medtronic, Inc.,
Merit Medical Systems, Inc., Siemens AG, Smiths Medical, Spectranetics Corp.,
Terumo Corporation, Vascular Solutions, Inc., and W. L. Gore &amp; Associates.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Diagnostic Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Coronary Angiography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Intravascular
Ultrasound</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Guidewire-Based
Physiologic</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Intravascular Stenosis
Assessment</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Optical Coherence
Tomography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Intracardiac
Echocardiography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Therapeutic Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Coronary Stent Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Percutaneous
Transluminal Coronary Angioplasty (PTCA) Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Coronary Atherectomy
Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>4.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Laser Atherectomy
Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>4.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Mechanical Atherectomy
Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>­Transcatheter Septal
Defect Repair Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>­Coronary Thrombectomy
Systems</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Abbott Laboratories,
Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>B. Braun Melsungen AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bayer AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boston Scientific
Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>BVM Medical Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cardiovascular Systems
Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cook Medical, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>C.R. Bard, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Edwards Lifesciences</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Getinge Group</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>iVascular</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Johnson &amp; Johnson
(Cordis Corporation/ Cardinal Health, Inc.)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Kyoto Medical Planning
Corporation Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Lepu Medical Technology</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Medtronic, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Merit Medical Systems,
Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.17.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Siemens AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.18.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Smiths Medical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.19.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Spectranetics Corp.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.20.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Terumo Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.21.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Vascular Solutions,
Inc.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:8.0pt;margin-left:.55in;text-indent:-.3in;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>6.22.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt;line-height:107%'>W. L. Gore &amp; Associates</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>To request
Table of Contents and Sample Pages of this report visit:</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/interventional-cardiology-diagnostic-therapeutic-devices-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/interventional-cardiology-diagnostic-therapeutic-devices-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global
Colorectal Cancer Drugs Market US$ 7.2 Billion by 2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global colorectal cancer drugs market expected to
reach US$ 7.2 billion by 2023, growing at CAGR 2.3% over the forecast period, </span><span
lang=EN-US style='font-size:10.0pt'>mainly due to colorectal polyps screening
and improved treatment over the last few decades</span><span lang=EN-US
style='font-size:10.0pt'>.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Colorectal cancer (CRC) is a significant challenge to
the healthcare system as one of the leading forms of cancer around the world the
third most frequently diagnosed malignancy, after lung and breast cancer. According
to </span><span lang=EN-US><a
href="https://www.cancer.org/research/cancer-facts-statistics/colorectal-cancer-facts-figures.html"><span
style='font-size:10.0pt'>American Cancer Society</span></a></span><span
lang=EN-US style='font-size:10.0pt'> (2017), in the US, an estimated 135,430
people will be diagnosed with colorectal cancer. The American Cancer Society’s
estimates number of 95,520 new cases of colon cancer and 39,910 new cases of
rectal cancer in the United States for 2017. Several lifestyle-related factors
have been linked to colorectal cancer such as age, family history of colorectal
cancer or adenomatous polyps, being overweight or obese, physical inactivity, certain
types of diets, smoking, and heavy alcohol use. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The early stages of non-metastatic CRC (stages I-III)
can be treated with surgical resection followed by radiotherapy and/or
chemotherapy, whereas patients with mCRC generally receive systemic chemotherapy.
</span><span lang=EN-US style='font-size:10.0pt'>The drugs approved by USFDA for
colon cancer include Avastin (Bevacizumab), Bevacizumab, Camptosar (Irinotecan
Hydrochloride), Capecitabine, Cetuximab, Cyramza (Ramucirumab), Eloxatin
(Oxaliplatin), Erbitux (Cetuximab), 5-FU (Fluorouracil Injection), Fluorouracil
Injection, Irinotecan Hydrochloride, Leucovorin Calcium, Lonsurf (Trifluridine
and Tipiracil Hydrochloride), Nivolumab, Opdivo (Nivolumab), Oxaliplatin, Panitumumab,
Ramucirumab, Regorafenib, Stivarga (Regorafenib), Trifluridine and Tipiracil Hydrochloride,
Vectibix (Panitumumab), Wellcovorin (Leucovorin Calcium), Xeloda (Capecitabine),
Zaltrap (Ziv-Aflibercept), Ziv-Aflibercept. Drug combinations used and approved
by USFDA in colon cancer include Capox, Folfiri, Folfiri-Bevacizumab, Folfiri-Cetuximab,
Folfox, Fu-Lv, Xeliri, Xelox.  </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Some common chemotherapy drugs used for colorectal
cancer include: 5-Fluorouracil (5-FU), Capecitabine (Xeloda), Irinotecan
(Camptosar), Oxaliplatin (Eloxatin), Trifluridine and tipiracil (Lonsurf). </span><span
lang=EN-US style='font-size:10.0pt'>Targeted therapy drugs for colorectal
cancer include anti- vascular endothelial growth factor (VEGF) therapies that
stops VEGF from forming new blood vessels and pass nutrients to tumor cells
(also known as, anti-angiogenesis therapy). These include</span><span
lang=EN-US style='font-size:10.0pt'> </span><span lang=EN-US style='font-size:
10.0pt'>monoclonal antibody therapy such as, Bevacizumab (Avastin), Ramucirumab
(Cyramza), Ziv-aflibercept (Zaltrap), and Ramucirumab (Cyramza). Anti-
epidermal growth factor receptor (EGFR) therapies target EGFR protein that
often appears in high amounts on the surface of cancer cells and helps them
grow. These include: Cetuximab (Erbitux), and Panitumumab (Vectibix). </span><span
lang=EN-US style='font-size:10.0pt'>Regorafenib (Stivarga) is a type of
targeted therapy known as a kinase inhibitor, used to treat advanced colorectal
cancer. It blocks several kinase proteins that either help tumor cells grow or
help form new blood vessels to feed the tumor. Immune checkpoint inhibitors
such as Pembrolizumab (Keytruda) targets PD-1, a protein on immune system cells
that normally prevents cells from attacking other cells in the body. Dabrafenib
and trametinib, the first BRAF and MEK inhibitor combination drugs are in
clinical development. Similarly, Atezolizumab, Binimetinib, Cobimetinib,
Encorafenib, Fruquintinib, Lefitolimod, Masitinib, Napabucasin, Nintedanib,
Nivolumab, OncoVax, and Pembrolizumab are some of the drugs that are in active
phase II and phase III clinical development for colorectal cancer. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Browse </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/colorectal-cancer-drugs-market/"><span
style='font-size:10.0pt'>Colorectal Cancer Drugs Market</span></a></span><span
lang=EN-US style='font-size:10.0pt'> by Drug Class - Vascular Endothelial
Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR)
Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors,
B-Raf Kinase (BRAF) or MEK Inhibitors - Mitogen-activated Protein Kinase (MAPK)
/ Extracellular Signal-Regulated Kinase (ERK), Tyrosine Kinase (TKI)
Inhibitors, Immunomodulators, Chemotherapies and Forecast 2015-2023. </span><span
lang=EN-US style='font-size:10.0pt'>The global </span><span lang=EN-US
style='font-size:10.0pt'>colorectal cancer drugs </span><span lang=EN-US
style='font-size:10.0pt'>market research report provides market size (Revenue
USD Million 2015 to 2023), market share analysis, growth trends and forecast
(CAGR%, 2018 to 2023). The global </span><span lang=EN-US style='font-size:
10.0pt'>colorectal cancer drugs </span><span lang=EN-US style='font-size:10.0pt'>market
research report is further segmented by geography into North America (U.S.,
Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany,
France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of
APAC), and Rest of the World. In addition, the global </span><span lang=EN-US
style='font-size:10.0pt'>colorectal cancer drugs </span><span lang=EN-US
style='font-size:10.0pt'>market report provides the detailed market landscape
(market drivers, restraints, opportunities), market attractiveness analysis,
and market profitability analysis by key products and regions or countries. 
The report also tracks the major competitors operating in the global market by
company overview, financial snapshot, major products, technologies, services
offered and recent developments. </span><span lang=EN-US style='font-size:10.0pt'>Major
players operating in the global colorectal cancer drugs market and profiled in
this report include AB Science, Amgen, Array BioPharma, Bayer, Boehringer
Ingelheim, Bristol-Myers Squibb, Elli Lilly, Genentech (Roche), Hutchison
MediPharma, Merck &amp; Co., Mologen, Regeneron, Sanofi, Sumitomo Dainippon,
Taiho Pharmaceutical, and Vaccinogen.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Drug Class</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Vascular Endothelial
Growth Factor (VEGF) Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Epidermal Growth Factor
Receptor (EGFR) Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Programmed Cell Death
Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>BRAF or MEK Inhibitors
(MAPK/ERK kinase)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Tyrosine Kinase (TKI)
Inhibitors </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Immunomodulators</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Chemotherapies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>AB Science</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Amgen</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Array BioPharma</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bayer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boehringer Ingelheim</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bristol-Myers Squibb</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Elli Lilly</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Genentech (Roche)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Hutchison MediPharma </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Merck &amp; Co.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Mologen</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Regeneron </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Sanofi</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Sumitomo Dainippon</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Taiho Pharmaceutical</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Vaccinogen</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:#70AD47'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>To request
Table of Contents and Sample Pages of this report visit:</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/colorectal-cancer-drugs-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/colorectal-cancer-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:#70AD47'> </span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:#70AD47'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:#70AD47'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global
Endocrine Disorders Testing Market US$ 12.2 Billion by 2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global endocrine disorders testing</span><span
lang=EN-US style='font-size:10.0pt'> </span><span lang=EN-US style='font-size:
10.0pt'>market expected to reach US$ 12.2 billion by 2023, growing at CAGR 7.7%
over the forecast period, due to increasing incidences of endocrine disorders
and rising geriatric population worldwide. The major driving factors of
endocrine laboratory testing market includes increasing health care awareness
rise of endocrine disorders such as diabetes, thyroid disorders, and
infertility, and advancement of the technology. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The endocrine system uses a variety of hormones to
regulate many different functions in the body such as growth, metabolism, and
reproduction. Endocrine disorders can result in hormone overproduction
(hyperfunction) or underproduction (hypofunction) or dysfunction</span><span
lang=EN-US> </span><span lang=EN-US style='font-size:10.0pt'>because of the
feedback mechanisms involved in the endocrine system. Every gland of the
endocrine system such as pineal, pituitary, and thyroid and secretory organs
such as hypothalamus and pancreas, releases specific hormones into bloodstream
to regulate the body functioning. Some hormones (cortisol, follicle-stimulating
hormone, luteinizing hormone) have a daily or monthly pattern of release. Other
hormones are generally present in very small quantities in the blood and are
released in specific situations, such as the release of epinephrine
(adrenaline) from the adrenal glands in response to stress. The endocrine disorder
tests help in detecting the deviations in the secretion of the hormones to
understand the disorders like infertility, menopause, thyroid dysfunction. Although,
there are many different types of endocrine disorders, diabetes is the most
common endocrine disorder diagnosed in the U.S. There are many diagnostic tests
including radiologic evaluations and biochemical procedures for measuring
circulating hormones to determine problems in the endocrine system. Maximum
number of diagnostic tests are performed in commercial laboratories followed by
hospital settings. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Browse </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/endocrine-laboratory-testing-market/"><span
style='font-size:10.0pt'>Endocrine Disorders Testing Market</span></a></span><span
lang=EN-US style='font-size:10.0pt'> by Test Type (Cortisol Test,
Dehydroepiandrosterone Sulfate Test, Estradiol Test, Follicle Stimulating
Hormone Test, Human Chorionic Gonadotropin Test, Insulin Test, Luteinizing
Hormone Test, Progesterone Test, Prolactin Test, Testosterone Test, Thyroid
Stimulating Hormone Test, Others - Gastrin, Thymosin, Secretin), Technology
(Tandem Mass Spectrometry, Immunoassay Technologies, Monoclonal and Polyclonal
Antibody Technologies, Sensor Technologies, Clinical Chemistry Technologies,
Other Technologies), End Users (Hospitals, Commercial Laboratories, Ambulatory
Care Centers, Home-based Tests, Physician Offices, Others) and Forecast
2015-2023. </span><span lang=EN-US style='font-size:10.0pt'>The global </span><span
lang=EN-US style='font-size:10.0pt'>endocrine disorders testing</span><span
lang=EN-US style='font-size:10.0pt'> market report provides market size
(Revenue USD Million 2015 to 2023), market share, trends and forecasts growth
trends (CAGR%, 2018 to 2023). The global </span><span lang=EN-US
style='font-size:10.0pt'>endocrine disorders testing</span><span lang=EN-US
style='font-size:10.0pt'> market research report is further segmented by
geography into North America (U.S., Canada), Europe (U.K., Germany, France,
Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC),
Latin America (Brazil, Mexico, Rest of LA), and Rest of the World. The global </span><span
lang=EN-US style='font-size:10.0pt'>endocrine disorders testing</span><span
lang=EN-US style='font-size:10.0pt'> market report also provides the detailed
market landscape (market drivers, restraints, opportunities), market
attractiveness analysis and also tracks the major competitors operating in the
market by company overview, financial snapshot, key products, technologies and
services offered, market share analysis and recent trends in the global market.
</span><span lang=EN-US style='font-size:10.0pt'>Major players operating in the
global endocrine disorders testing market and profiled in this report include
Abbott Laboratories, AB Sciex Pte. Ltd., Agilent Technologies, Biomedical
Diagnostics, bioMerieux SA, Bio-Rad Laboratories, DiaSorin S.p.A., F.
Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings (LabCorp),
Ortho-Clinical Diagnostics, Quest Diagnostics, Siemens Healthcare GmbH (Siemens
AG), Sysmex Corporation., and Thermo Fisher Scientific, Inc. </span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Test Type</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Cortisol Test</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Dehydroepiandrosterone
Sulfate (DHEAS) Test</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Estradiol (E2) Test</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Follicle Stimulating
Hormone (FSH) Test</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Human Chorionic Gonadotropin
(hCG) Test</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Insulin Test</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Luteinizing Hormone
(LH) Test</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Progesterone (P4) Test</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Prolactin Test</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Testosterone Test</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Thyroid Stimulating
Hormone (TSH) Test</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Others (Gastrin,
Thymosin, Secretin, etc.)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Technology</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Clinical Chemistry
Technologies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Immunoassay
Technologies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Monoclonal and
Polyclonal Antibody Technologies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Sensor Technologies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Tandem Mass
Spectrometry</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Other Technologies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>End Users</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Ambulatory Care Centers</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Commercial Laboratories</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Home-based Tests</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Hospitals</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Physician Offices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Others</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography (Region,
Country)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World
(Middle East &amp; Africa)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Abbott Laboratories</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>AB Sciex Pte. Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Agilent Technologies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Biomedical Diagnostics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>bioMerieux SA</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bio-Rad Laboratories</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>DiaSorin S.p.A.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>F. Hoffmann-La Roche
Ltd.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Laboratory Corporation
of America Holdings (LabCorp)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Ortho-Clinical
Diagnostics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Quest Diagnostics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Siemens Healthcare GmbH
(Siemens AG)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Sysmex Corporation.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Thermo Fisher
Scientific, Inc.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>To request
Table of Contents and Sample Pages of this report visit:</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/endocrine-laboratory-testing-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/endocrine-laboratory-testing-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:#70AD47'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:#70AD47'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global Antihypertensive
Drugs Market US$ 23.1 Billion 2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global antihypertensive drugs market expected to
reach US$ 24.3 billion by 2023, steadily declining at CAGR 2.5% over the forecast
period, mainly due to patent expiration of blockbuster drugs and increasing
generic competition worldwide.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Hypertension is the leading preventable cause of
premature death worldwide. It is an important public health challenge in both
economically developing and developed countries. The worldwide prevalence of
hypertension is estimated to be about 40% in all adults. This represented a
5.2% increase in the global prevalence between 2000 and 2010, where the
prevalence of hypertension decreased by 2.6% in high-income countries, but
increased by 7.7% in low/middle–income countries due to numerous and varied obstacles
in healthcare delivery and limited resources. Measures are required to prevent
the development of hypertension and to improve awareness, treatment and control
of hypertension globally. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Antihypertensive drugs are used to treat high blood
pressure and its complications, such as stroke and myocardial infarction. The
most important and most widely used drugs include thiazide diuretics, calcium
channel blockers, ACE inhibitors, angiotensin II receptor antagonists (ARBs),
and beta blockers. These drugs can prevent heart failure, kidney failure and
acute stroke induced by hypertension and delay the development of
atherosclerosis by controlling the blood pressure. Although clinical evidence
shows calcium channel blockers and thiazide-type diuretics are preferred
first-line treatments, an ACE inhibitor is recommended by NICE in the UK for
those under 55 years old. Angiotensin II receptor blockers (ARBs) comprises
several leading brands such as Benicar (olmesartan medoxomil), Diovan
(valsartan) and Micardis (telmisartan). The ‘others’ category includes
endothelin receptor antagonists such as Tracleer, Opsumit (bosentan and
macitentan) and Letairis (ambrisentan). All drug classes, except </span><span
lang=EN-US style='font-size:10.0pt;color:#221E1F'>fixed-dose combinations
(FDCs),</span><span lang=EN-US style='font-size:10.0pt'> represent sales of
monotherapies. The antihypertensive drugs currently in the phase III clinical
development includes Amlodipine/celecoxib, Azilsartan/amlodipine/
hydrochlorothiazide, Bardoxolone methyl, Candesartan cilexetil/nifedipine,
Candesartan cilexetil/rosuvastatin, CS 3150, Esuberaprost,
Fimasartan/amlodipine, Fimasartan/hydrochlorothiazide, HCP 1401 and HCP1305,
Nitric oxide inhalation (INOpulse), Telmisartan/amlodipine/ chlorthalidone,
Telmisartan/chlorthalidone, alsartan/amlodipine/rosuvastatin, and
Valsartan/pitavastatin.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Browse </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/antihypertensive-drugs-market/"><span
style='font-size:10.0pt'>Antihypertensive Drugs Market</span></a></span><span
lang=EN-US style='font-size:10.0pt'> by Drug Class - Angiotensin II Receptor
Blockers (ARBs), Angiotensin-converting Enzyme (ACE) Inhibitors,
&#946;-blockers, Calcium Channel Blockers (CCBs), Diuretics, Fixed-dose
Combinations (FDCs), Others and Forecast 2015-2023. </span><span lang=EN-US
style='font-size:10.0pt'>The global </span><span lang=EN-US style='font-size:
10.0pt'>antihypertensive drugs </span><span lang=EN-US style='font-size:10.0pt'>market
research report provides market size (Revenue USD Million 2015 to 2023), market
share analysis, growth trends and forecast (CAGR%, 2018 to 2023). The global </span><span
lang=EN-US style='font-size:10.0pt'>antihypertensive drugs </span><span
lang=EN-US style='font-size:10.0pt'>market research report is further segmented
by geography into North America (U.S., Canada), Latin America (Brazil, Mexico,
Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia
Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In
addition, the global </span><span lang=EN-US style='font-size:10.0pt'>antihypertensive
drugs </span><span lang=EN-US style='font-size:10.0pt'>market report provides
the detailed market landscape (market drivers, restraints, opportunities),
market attractiveness analysis, and market profitability analysis by key
products and regions or countries.  The report also tracks the major
competitors operating in the global market by company overview, financial
snapshot, major products, technologies, services offered and recent
developments. </span><span lang=EN-US style='font-size:10.0pt'>Major players
operating in the global antihypertensive drugs market and profiled in this
report include </span><span lang=EN-US style='font-size:10.0pt'>Actelion
(Nippon Shinyaku), </span><span lang=EN-US style='font-size:10.0pt'>Alvogen,
Bayer, Bellerophon Therapeutics, </span><span lang=EN-US style='font-size:10.0pt'>Boehringer
Ingelheim, </span><span lang=EN-US style='font-size:10.0pt'>Boryung Pharmaceutical
(Stendhal), CJ Healthcare, </span><span lang=EN-US style='font-size:10.0pt'>Daiichi
Sankyo, Gilead, Eli Lilly</span><span lang=EN-US style='font-size:10.0pt'>,
HanAll Biopharma (Yuhan), Hanmi Pharmaceutical, JW Pharmaceutical, Kitov
Pharmaceuticals, Kyowa Hakko Kirin, Lung Biotechnology, Nippon Shinyaku, </span><span
lang=EN-US style='font-size:10.0pt'>Novartis, </span><span lang=EN-US
style='font-size:10.0pt'>Pfizer, Stendhal, Reata Pharmaceuticals (Kyowa Hakko
Kirin), Takeda, </span><span lang=EN-US style='font-size:10.0pt'>United
Therapeutics, and </span><span lang=EN-US style='font-size:10.0pt'>Yuhan.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Drug Class</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Angiotensin II Receptor
Blockers (ARBs) </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Angiotensin-converting
Enzyme (ACE) Inhibitors </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>&#946;-blockers</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Calcium Channel
Blockers (CCBs)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Diuretics </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Fixed-dose Combinations
(FDCs)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Others </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Actelion </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Alvogen</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bayer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bellerophon
Therapeutics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boehringer Ingelheim</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boryung Pharmaceutical </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>CJ Healthcare</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Daiichi Sankyo</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Gilead</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Eli Lilly</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>HanAll Biopharma </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Hanmi Pharmaceutical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>JW Pharmaceutical</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Kitov Pharmaceuticals</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Kyowa Hakko Kirin</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Lung Biotechnology</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.17.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Nippon Shinyaku</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.18.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Novartis</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.19.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Pfizer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.20.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Stendhal</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.21.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Reata Pharmaceuticals </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.22.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Takeda</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.23.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>United Therapeutics</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>6.24.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Yuhan</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>To request
Table of Contents and Sample Pages of this report visit:</span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/antihypertensive-drugs-market/"><span
style='font-size:10.0pt;line-height:107%'>https://www.ihealthcareanalyst.com/report/antihypertensive-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;line-height:107%'> </span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary single-client
study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></b></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-US
style='font-size:10.0pt'>Global Transcatheter Arterial Chemoembolization (TACE)
Market USD 17.7 Billion by 2023 </span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;color:#5B9BD5'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global transcatheter arterial chemoembolization
(TACE) market to reach US$ 17.7 Billion by 2023, growing at 5.1% CAGR over the forecast
period. Increase in adoption of minimally invasive surgeries due to technological
innovations and worldwide increasing cancer prevalence is projected to drive
the transcatheter arterial chemoembolization market. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Hepatocellular carcinomas (HCC) and renal cell
carcinomas are one of the commonest malignancies world-wide, largely due to the
high prevalence of hepatitis B infection in the developing world. Transcatheter
arterial chemoembolization or transarterial chemoembolization (TACE) is a
minimally invasive procedure performed in interventional radiology to restrict
a tumor’s blood supply. Small embolic particles coated with chemotherapeutic
drugs are injected selectively through a catheter into an artery directly
supplying the tumor. These particles both block the blood supply and induce
cytotoxicity, attacking the tumor in several ways. Transarterial
chemoembolization is also increasingly being used for patients on the
transplant waiting list to prevent further tumor growth. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>North America accounted for a major share of the
market in 2016 due to gradually increasing cases of HCC, increasing investment,
novel drug delivery systems development and presence of major market players in
the region. Most of the major players operating in the region have made a
series of strategic acquisitions leading to the increase in their market share.
Increasing cancer prevalence in the region is the one of the key factors
contributing to the growth of TACE market. The TACE market has been estimated
based on HCC prevalence and incidence in each country/region using the Barcelona
Clinic Liver cancer (BCLC) staging system and treatment strategy and Clinical
Practice Guidelines for the Management of Hepatocellular Carcinoma, proposed by
the Japan Society of Hepatology (JSH), 2012. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>To request Table of Contents and Sample Pages of this
report, contact us:</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/contact/"><span style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/contact/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global transcatheter arterial chemoembolization
(TACE) market provides market size (revenue US$ million) and number of
procedures for TACE, market size (revenue US$ million) and volume (number of
units) for micro catheter, micro guidewire used in TACE procedures, market
share analysis by key players, growth trends and forecast (CAGR%, 2018 to 2023).
The global transcatheter arterial chemoembolization market research report is
further segmented by geography into North America (U.S., Canada), Europe (U.K.,
Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, South
Korea, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of
the World. The global transcatheter arterial chemoembolization market report
also provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis and also tracks the major
competitors operating in the market by company overview, financial snapshot,
key products, technologies and services offered. Major players operating in the
global embolization in interventional oncology market and included in this
report are Boston Scientific, BTG International, Cook Medical, Covidien, Depuy
Synthes, Merit Medical Systems, Inc., Sequent Medical, Stryker, Surefire
Medical, Inc., and Terumo Medical Corporation.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-align:justify;
text-indent:-.25in'><b><span lang=EN-US style='font-size:10.0pt'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></b><b><span
lang=EN-US style='font-size:10.0pt'>Transcatheter Arterial Chemoembolization</span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>1.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Market size by Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>1.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Number of Procedures by Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-align:justify;
text-indent:-.25in'><b><span lang=EN-US style='font-size:10.0pt'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></b><b><span
lang=EN-US style='font-size:10.0pt'>Device Type</span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>2.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Micro Catheter</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-align:justify;
text-indent:-.35in'><span lang=EN-US style='font-size:10.0pt'>2.1.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt'>Market size by Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-align:justify;
text-indent:-.35in'><span lang=EN-US style='font-size:10.0pt'>2.1.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt'>Number of Units Sold by Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>2.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Micro Guidewire</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-align:justify;
text-indent:-.35in'><span lang=EN-US style='font-size:10.0pt'>2.2.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt'>Market size by Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-align:justify;
text-indent:-.35in'><span lang=EN-US style='font-size:10.0pt'>2.2.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt'>Number of Units Sold by Geography</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-align:justify;
text-indent:-.25in'><b><span lang=EN-US style='font-size:10.0pt'>3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></b><b><span
lang=EN-US style='font-size:10.0pt'>Geography (Region, Country)</span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>3.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>North America (U.S., Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>3.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany, France, Italy,
Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>3.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Latin America (Brazil, Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>3.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan, China, South Korea,
Rest of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>3.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Middle East &amp; Africa</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify'><span
lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-align:justify;
text-indent:-.25in'><b><span lang=EN-US style='font-size:10.0pt'>4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></b><b><span
lang=EN-US style='font-size:10.0pt'>Company Profiles</span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Abbott Laboratories, Inc., USA </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>ABK Biomedical, Inc., Canada </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Asahi Intecc Co., Ltd., Japan </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>BioSphere Medical, Inc., USA (Merit Medical
Systems, Inc.) </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Blockade Medical, USA (BALT International) </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.6.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Boston Scientific Corporation </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.7.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Braile Biomedica, Brazil </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.8.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>BTG International </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.9.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt'>Cook Medical, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.10.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>Covidien plc (Medtronic plc)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.11.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>Depuy Synthes (JnJ) </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.12.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>Guerbet Group, France </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.13.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>Magle Life Science, Sweden </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.14.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>Medtronic, Inc. (Covidien), USA </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.15.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>Merit Medical Systems, Inc. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.16.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>Penumbra, Inc., USA </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.17.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>Pfizer, Inc., USA </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.18.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>PharmaCept, Germany </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.19.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>Piolax Medical Devices, Inc. (Piolax, Inc.)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.20.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>Sequent Medical (Terumo Corporation) </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.21.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>Sirtex Medical Limited, Australia</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.22.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>St. Jude Medical, Inc., USA </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.23.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>Stryker Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.24.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>Surefire Medical, Inc. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.25.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>Terumo Medical Corporation </span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-align:justify;
text-indent:-.3in'><span lang=EN-US style='font-size:10.0pt'>4.26.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt'>Vascular Solutions, Inc., USA </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>To request Table of Contents and Sample Pages of this
report, contact us:</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/contact/"><span style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/contact/</span></a></span><span
lang=EN-US style='font-size:10.0pt'> </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-US
style='font-size:10.0pt'>About Us</span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>iHealthcareAnalyst, Inc. is a global healthcare market
research and consulting company providing market analysis, and competitive
intelligence services to global clients. The company publishes syndicate,
custom and consulting grade healthcare reports covering animal healthcare,
biotechnology, clinical diagnostics, healthcare informatics, healthcare
services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>In addition to multi-client studies, we offer creative
consulting services and conduct proprietary single-client assignments targeted
at client’s specific business objectives, information needs, time frame and
budget. Please contact us to receive a proposal for a proprietary single-client
study.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-US
style='font-size:10.0pt'>Contact Us</span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>iHealthcareAnalyst, Inc.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>2109, Mckelvey Hill Drive,</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Maryland Heights, MO 63043</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>United States</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Email: sales@ihealthcareanalyst.com</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Website: https://www.ihealthcareanalyst.com</span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:#5B9BD5'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:#5B9BD5'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global Ovarian
Cancer Drugs Market US$ 5.6 Billion by 2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global </span><span lang=EN-US style='font-size:
10.0pt'>ovarian cancer drugs </span><span lang=EN-US style='font-size:10.0pt'>market
expected to reach US$ 5.6 billion by 2023, steadily growing at CAGR 19.1% over
the forecast period, mainly due to <span style='color:#211D1E'>continued uptake
and expected launces of the approved PARP inhibitors, owing to their impressive
efficacy, long treatment duration and the large number of treatment
opportunities in the first-line advanced setting. Although angiogenesis
inhibitors accounted for the majority of the 2016 market, this drug class is
expected to capture a minority market share in 2021.</span></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>In 2017, according to </span><span lang=EN-US><a
href="https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html"><span
style='font-size:10.0pt'>American Cancer Society</span></a></span><span
lang=EN-US style='font-size:10.0pt'> estimates about 22,280 new cases of
ovarian cancer will be diagnosed, whereas in 2016, an estimated ~20,000
patients were diagnosed with ovarian cancer in the United States alone. In
2015, it was present in 1.2 million women and resulted in 161,100 deaths
worldwide. The risk of ovarian cancer increases in women with aged 55-64 years.
Ovarian cancer is the 8th most common cancer among women and ranks 5th in
cancer deaths among women, accounting for more deaths than any other cancer of
the female reproductive system. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The most common preliminary tests include blood test (CA-125,
OVA-1, Inhibin B and Inhibin A), transvaginal ultrasound, CT scan or
computerized tomography and biopsy. A diagnosis of ovarian cancer is confirmed
through a biopsy of tissue, usually removed during surgery. The Pap test does
not test for ovarian cancer; it screens for cervical cancer. Treatment usually
includes some combination of surgery, radiation therapy, and chemotherapy.
Chemotherapy in ovarian cancer typically consists of platins, a group of
platinum-based drugs, combined with non-platins. Common therapies can include
paclitaxel, cisplatin, topotecan, doxorubicin, epirubicin, and gemcitabine. The
vascular endothelial growth factor (VEGF) inhibitor, bevacizumab (Avastin;
Roche/ Genentech), is approved (excluding the United States) as a first-line
treatment in combination with standard chemotherapy. In Europe and the United
States, bevacizumab is also approved for recurrent ovarian cancer. Currently,
ovarian cancer drugs in active development (clinical phase II and III pipeline)
includes Acalabrutinib, Atezolizumab, Avelumab, AZD1775, Cediranib, Epacadostat,
Fosbretabulin, Gemogenovatucel-T, Lurbinectedin, Micellular paclitaxel,
Mirvetuximab soravtansine, Trametinib, and Veliparib.  </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Browse </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/ovarian-cancer-drugs-market/"><span
style='font-size:10.0pt'>Ovarian Cancer Drugs Market</span></a></span><span
lang=EN-US style='font-size:10.0pt'> by Drug Class (Angiogenesis inhibitors,
Poly (ADP Ribose) Polymerase Inhibitors, Programmed Cell Death Protein 1 Ligand
1 Inhibitors), Pipeline Analysis by Target and Development Stage and Forecast
2015-2023. </span><span lang=EN-US style='font-size:10.0pt'>The global ovarian
cancer drugs market segmentation is based on drug class (angiogenesis
inhibitors, poly (ADP ribose) polymerase inhibitors, programmed cell death
protein 1 ligand 1 inhibitors), and pipeline analysis by target and development
stage. The global ovarian cancer drugs market report provides market size
(Revenue USD Million 2015 to 2023), market share, trends and forecasts growth
trends (CAGR%, 2018 to 2023). The global ovarian cancer drugs market research
report is further segmented by geography into North America (U.S., Canada),
Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France,
Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC),
and Rest of the World. The global ovarian cancer drugs market report also
provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis and also tracks the major
competitors operating in the market by company overview, financial snapshot,
key products, technologies and services offered, market share analysis and
recent trends in the global market. Major players operating in the global
ovarian cancer drugs market and profiled in this report include AbbVie,
AstraZeneca (Acerta Pharma), Boehringer Ingelheim GmbH, Five Prime
Therapeutics, Gradalis, Incyte Corporation, MacroGenics, Mateon Therapeutics,
Merck KGaA, Novartis, Novogen, Inc., Oasmia Pharmaceuticals, Pfizer, Inc.,
PharmaMar (Chugai), and Roche (Genentech).</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;
margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Drug Class</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>1.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Angiogenesis
inhibitors</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>1.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Poly
(ADP Ribose) Polymerase (PARP) Inhibitors</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>1.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Programmed
Cell Death Protein 1 Ligand 1 (PDL1) Inhibitors</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>1.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Pipeline
Analysis by Target and Development Stage</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>&nbsp;</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;
margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Geography (Region, Country)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>2.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>North
America (U.S., Canada)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>2.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>2.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Asia
Pacific (Japan, China, India, Rest of APAC)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>2.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Latin
America (Brazil, Mexico, Rest of LA)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>2.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Rest
of the World</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>&nbsp;</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;
margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Company Profiles</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>AbbVie</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>AstraZeneca
(Acerta Pharma)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Boehringer
Ingelheim GmbH</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Five
Prime Therapeutics</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Gradalis</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.6.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Incyte
Corporation</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.7.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>MacroGenics</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.8.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Mateon
Therapeutics</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.9.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Merck
KGaA</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.10.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Novartis</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.11.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Oasmia
Pharmaceuticals</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.12.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Pfizer,
Inc.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.13.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>PharmaMar
(Chugai)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.14.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Roche
(Genentech)</span></p>

<p style='margin:0in;margin-bottom:.0001pt'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>&nbsp;</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>To request Table of Contents and Sample Pages of this report
visit:</span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif'>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/ovarian-cancer-drugs-market/"><span
style='font-size:10.0pt;font-family:"Calibri",sans-serif'>https://www.ihealthcareanalyst.com/report/ovarian-cancer-drugs-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif'> <span
style='color:black'>    </span></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare
services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%'>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt'>Global
Infectious Disease Vaccines Market US$ 27.4 Billion by 2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global infectious disease vaccines market expected
to reach US$ 27.4 billion by 2023, steadily growing at CAGR 3.4% over the forecast
period, mainly due to successful launch of new products and highest-selling
vaccines. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Vaccines are known to be the safest, most effective
way to prevent infectious diseases. DTP combination vaccines include vaccines
against diphtheria, tetanus and pertussis (DTP) that also contain one or more
components to provide protection against other infections, including hepatitis
B, Haemophilus influenzae type B and/or polio. Meningococcal vaccines include
meningococcal group A, C, W-135 and Y vaccines, meningococcal group B vaccines
and meningococcal group C vaccines. Pentacel is a DTP, Haemophilus influenzae
type B and polio vaccine. Pediarix is a DTP, hepatitis B and polio vaccine.
Menactra and Menveo are meningococcal type A, C, W-135 and Y vaccines. Bexsero
and Trumenba are meningococcal type B vaccines. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Overall, pneumococcal vaccines widely used in
childhood vaccination programs are the highest-selling vaccines within all the
categories. The herpes zoster (shingles) vaccines market is predicted to have
the highest growth rate during the forecast period. Prevnar 13 (pneumococcal
vaccine), Gardasil (HPV vaccine), Pentacel (DTaP, Hib &amp; polio vaccine), Fluzone
(influenza vaccine), and Bexsero (meningococcal b vaccine) are the
highest-selling vaccines in 2016. Other promising vaccines that are in the
active clinical development include Shingrix (herpes zoster vaccine), RSV F
Vaccine (respiratory syncytial virus vaccine), Combination Respiratory Vaccine
(influenza and RSV vaccine), and GEN-003 (herpes simplex virus vaccine). </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>Browse </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/infectious-disease-vaccines-market/"><span
style='font-size:10.0pt'>Infectious Disease Vaccines Market</span></a></span><span
lang=EN-US style='font-size:10.0pt'> by Type (Brand) - Diphtheria, Tetanus and
Pertussis (DTP) Combination Vaccines (Boostrix, Pediarix, Pentacel, Other,
Herpes Zoster Vaccines (Zostavax, Shingrix, Other); Human Papilloma Virus
Vaccines (Gardasil, Other); Influenza Vaccines (FluLaval, Fluzone, Other);
Meningococcal Vaccines (Menveo, Bexsero, Menactra, Trumenba, Other);
Pneumococcal Vaccines (Pneumovax, Synflorix, Prevnar/Prevnar 13, Other);
Rotavirus Vaccines (Rotarix, RotaTeq, Other) and Forecast 2015-2023. </span><span
lang=EN-US style='font-size:10.0pt'>The global </span><span lang=EN-US
style='font-size:10.0pt'>infectious disease vaccines </span><span lang=EN-US
style='font-size:10.0pt'>market report provides market size (Revenue USD
Million 2015 to 2023), market share, trends and forecasts growth trends (CAGR%,
2018 to 2023). The global </span><span lang=EN-US style='font-size:10.0pt'>infectious
disease vaccines </span><span lang=EN-US style='font-size:10.0pt'>market
research report is further segmented by geography into North America (U.S.,
Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany,
France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of
APAC), and Rest of the World. The global </span><span lang=EN-US
style='font-size:10.0pt'>infectious disease vaccines </span><span lang=EN-US
style='font-size:10.0pt'>market report also provides the detailed market
landscape (market drivers, restraints, opportunities), market attractiveness
analysis and also tracks the major competitors operating in the market by
company overview, financial snapshot, key products, technologies and services
offered, market share analysis and recent selected vaccine product licensing
deals in the last two years in the global market. </span><span lang=EN-US
style='font-size:10.0pt'>Major players operating in the global infectious
disease vaccines market and profiled in this report include Astellas Pharma,
CSL Behring, Dynavax Technologies, Emergent BioSolutions, GlaxoSmithKline,
Merck, Mitsubishi Tanabe Pharma, Novavax, Pfizer, and Sanofi.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Type (Brand)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>DTP Combination
Vaccines</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Boostrix</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Pediarix</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Pentacel</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Other</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Herpes Zoster Vaccines</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Zostavax</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Shingrix</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Other</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Human Papilloma Virus
Vaccines</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Gardasil</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Other</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Influenza Vaccines</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>FluLaval</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Fluzone</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Other</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Meningococcal Vaccines</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Menveo</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Bexsero</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Menactra</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Trumenba</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Other</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Pneumococcal Vaccines</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.6.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Pneumovax</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.6.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Synflorix</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.6.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Prevnar/Prevnar 13</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.6.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Other</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rotavirus Vaccines</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.7.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rotarix</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.7.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>RotaTeq</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in'><span
lang=EN-US style='font-size:10.0pt'>1.7.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Other</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.85in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;
margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Geography (Region, Country)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>2.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>North
America (U.S., Canada)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>2.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>2.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Asia
Pacific (Japan, China, India, Rest of APAC)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>2.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Latin
America (Brazil, Mexico, Rest of LA)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>2.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Rest
of the World</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Company Profiles </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Astellas Pharma</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>CSL Behring</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Dynavax Technologies</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Emergent BioSolutions</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>GlaxoSmithKline</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Merck</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Mitsubishi Tanabe
Pharma</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Novavax</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Pfizer</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>3.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt'>Sanofi</span></p>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black;background:
white'>&nbsp;</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>To request Table of Contents and Sample Pages of this report
visit:</span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif'>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/infectious-disease-vaccines-market/"><span
style='font-size:10.0pt;font-family:"Calibri",sans-serif'>https://www.ihealthcareanalyst.com/report/infectious-disease-vaccines-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>   
</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:black;background:white'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black;background:
white'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><b><span lang=EN-US
style='font-size:10.0pt;background:white'>Global Multiple Sclerosis Treatment
Market </span></b><b><span lang=EN-US style='font-size:10.0pt'>US$ 23.2 Billion
by 2023</span></b></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;color:black;
background:white'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global multiple sclerosis drugs market to reach
US$ 23.2 billion by 2023, steadily growing at CAGR 0.7% during forecast period,
mainly due to large number of&nbsp;both existing therapeutics and<br>
new entrants.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;color:black;background:white'>Multiple sclerosis (MS)
is the most widespread disabling neurological condition of young adults around
the world. MS is more common among people in Europe, the United States, Canada,
New Zealand, and sections of Australia and less common among people in Asia and
the tropics. The </span><span lang=EN-US><a href="https://msfocus.org/"><span
style='font-size:10.0pt;background:white'>Multiple Sclerosis Foundation</span></a></span><span
lang=EN-US style='font-size:10.0pt;color:black;background:white'> estimates
that more than 400,000 people in the United States and about 2.5 million people
around the world have MS. Although, an increasing number of people are being
diagnosed with MS, there is increased awareness of MS and better diagnostic
tools, such as magnetic resonance imaging (MRI), for diagnosing the disease. MS
is also an expensive disease to treat. direct and indirect healthcare costs
range from $8,528 to $54,244 per patient per year in the United States.</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;color:black;background:white'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;color:black;background:white'>Treatment for MS depends
on the specific symptoms and may include: treating relapses of MS symptoms
(with steroid medication), treating specific MS symptoms, and treatment to
reduce the number of relapses (disease-modifying therapies). Treatment options
for relapsing-remitting MS include: Beta interferons are among the most
commonly prescribed medications to treat MS and can reduce the frequency and
severity of relapses. Glatiramer acetate (Copaxone) may help block your immune
system's attack on myelin. Dimethyl fumarate (Tecfidera) can reduce relapses.
Fingolimod (Gilenya) and Teriflunomide (Aubagio) oral medications reduces
relapse rate. Natalizumab (Tysabri) blocks the movement of potentially damaging
immune cells from your bloodstream to your brain and spinal cord. Alemtuzumab
(Lemtrada) drug helps reduce relapses of MS by targeting a protein on the
surface of immune cells and depleting white blood cells. In the past few years’
considerable improvements to slow MS disease progression has been made, as
drugs such as fingolimod, dimethyl fumarate (Tecfidera), alemtuzumab (Lemtrada)
and ocrelizumab have been launched. Currently, multiple sclerosis drugs in
active development (clinical phase II and III pipeline) includes ARGX-113,
GNbAC1, IB-MS, Imilecleucel-T, M2951, MIS416, Ofatumumab, Opicinumab, Ozanimod,
Ponesimod, Siponimod, and Ublituximab. </span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt;color:black;background:white'>Browse </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/multiple-sclerosis-treatment-market/"><span
style='font-size:10.0pt;background:white'>Multiple Sclerosis Treatment Market</span></a></span><span
lang=EN-US style='font-size:10.0pt;color:black;background:white'> by </span><span
lang=EN-US style='font-size:10.0pt'>Drug Class (Brand) - Alemtuzumab
(Lemtrada), Dimethyl Fumarate (Tecifidera), Gilneya (Fingolimod), Glatiramer
Acetate (Copaxone), Interferon-&#946;1a (Avonex), Interferon-&#946;1a (Rebif),
Interferon-&#946;1b (Betaseron/Extavia), Natalizumab (Tysabri),
Peginterferon-&#946;1a (Plegridy), Teriflunomide (Aubagio), Clinical Pipeline
(Phase III) - Daclizumab (Zinbryta), Ocrelizumab (Ocrevus), Ozanimod (RPC-1063)
and Forecast 2015-2023. </span><span lang=EN-US style='font-size:10.0pt'>The
global </span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>multiple sclerosis treatment</span><span lang=EN-US style='font-size:
10.0pt'> market report provides market size (Revenue USD Million 2015 to 2023),
market share, trends and forecasts growth trends (CAGR%, 2018 to 2023). The
global </span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>multiple sclerosis treatment</span><span lang=EN-US style='font-size:
10.0pt'> market research report is further segmented by geography into North
America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe
(U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China,
India, Rest of APAC), and Rest of the World. The global </span><span
lang=EN-US style='font-size:10.0pt;color:black;background:white'>multiple
sclerosis treatment</span><span lang=EN-US style='font-size:10.0pt'> market
report also provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis and also tracks the major
competitors operating in the market by company overview, financial snapshot,
key products, technologies and services offered, market share analysis and
recent trends in the global market. Major players operating in the global </span><span
lang=EN-US style='font-size:10.0pt;color:black;background:white'>multiple
sclerosis drugs</span><span lang=EN-US style='font-size:10.0pt'> market and
included in this report are </span><span lang=EN-US style='font-size:10.0pt;
color:black;background:white'>Actelion, arGEN-x, Bayer Healthcare, Biogen Idec,
Celgene, GeNeuro, Innate Immunotherapeutics, InnoBioscience, Merck, Novartis,
Opexa Therapeutics, Pfizer, Sanofi-Aventis, Teva Pharmaceuticals, and TG
Therapeutics.</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;color:black;
background:white'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt;color:black'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>Drug Class (Brand)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;background:white'>Alemtuzumab
(Lemtrada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;background:white'>Dimethyl
Fumarate (Tecifidera)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;background:white'>Gilneya
(Fingolimod)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;background:white'>Glatiramer
Acetate (Copaxone)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;background:white'>Interferon-&#946;1a
(Avonex)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;background:white'>Interferon-&#946;1a
(Rebif)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;background:white'>Interferon-&#946;1b
(Betaseron/Extavia)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;background:white'>Natalizumab
(Tysabri)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;background:white'>Peginterferon-&#946;1a
(Plegridy)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>1.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt;background:white'>Teriflunomide
(Aubagio)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in'><span lang=EN-US
style='font-size:10.0pt;color:#92D050;background:white'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;background:white'>Clinical
Pipeline (Phase III)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;background:white'>Daclizumab
(Zinbryta)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;background:white'>Ocrelizumab
(Ocrevus)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;background:white'>Ozanimod
(RPC-1063)</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.85in'><span lang=EN-US
style='font-size:10.0pt;color:black;background:white'>&nbsp;</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;
margin-bottom:.0001pt;text-indent:-.25in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Geography (Region, Country)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>North
America (U.S., Canada)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Asia
Pacific (Japan, China, India, Rest of APAC)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Latin
America (Brazil, Mexico, Rest of LA)</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt;text-indent:-.3in'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif;color:black'>3.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>Rest
of the World</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.55in;
margin-bottom:.0001pt'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>Company Profiles </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>Actelion</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>arGEN-x</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>Bayer Healthcare</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>Biogen Idec</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>Celgene</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>GeNeuro</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>Innate Immunotherapeutics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>InnoBioscience</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>Merck</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>Novartis</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>Opexa Therapeutics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>Pfizer</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>Sanofi-Aventis</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>Teva Pharmaceuticals</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt;color:black;background:
white'>TG Therapeutics</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>&nbsp;</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>To request Table of Contents and Sample Pages of this report
visit:</span><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif'>
</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/multiple-sclerosis-treatment-market/"><span
style='font-size:10.0pt;font-family:"Calibri",sans-serif'>https://www.ihealthcareanalyst.com/report/multiple-sclerosis-treatment-market/</span></a></span><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'>
</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>&nbsp;</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><b><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif'>Global Psoriasis Drugs Market US$ 10.5 Billion by 2023</span></b></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>The global psoriasis drugs market largely
driven by high-priced biologics is expected to reach US$ 10.5 billion, with a
CAGR of 3.8% during forecast period. With a number of branded specialty
biologics set to lose their exclusivity status in many of the larger markets,
growth is likely to be affected by biosimilar erosion.</span></p>

<p style='text-align:justify'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;color:black'>Psoriasis is a chronic
immune-mediated skin disorder that affects about 2–3% of the population
worldwide. Psoriasis is the most prevalent autoimmune disease in the United
States. According to the </span><span lang=EN-US><a href="https://ifpa-pso.com/"><span
style='font-size:10.0pt;font-family:"Calibri",sans-serif'>International
Federation of Psoriasis Associations</span></a></span><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:black'> (IFPA),
about 3 percent of the world’s population has some form of psoriasis. In the
United States, there are about 150,000 new cases every year.</span></p>

<p style='text-align:justify'><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif;color:black'>A range of agents are available
for the symptomatic treatment of psoriasis.&nbsp;Topical treatments such as
form of lotions, foams, creams, ointments, gels, and shampoos containing
steroids, tar preparations, and calcium- modulating drugs are very useful because
they are relatively safe, fairly effective, and can be applied directly to the
affected skin. Most oral medications act by targeting portions of the immune
system. Phototherapy or light therapy, involves exposing the skin to
ultraviolet light on a regular basis and under medical supervision. Biologic
drugs are usually prescribed for moderate to severe psoriasis and psoriatic
arthritis that has not responded to other treatments. The first biologic agent
for psoriasis, the tumour necrosis factor (TNF) antagonist etanercept (Enbrel;
Amgen), was approved in 2004. Biosimilar infliximab (Remsima; Celltrion, or
Inflectra; Hospira) is already available in several markets, including the
European Union and Japan, and is under review by the FDA. Biosimilars of
etanercept and biosimilar adalimumab are also likely to be launched during the
forecast period. Currently, psoriasis drugs in active development (clinical
phase II and III pipeline) includes topical antipsoriatics (Benvitimod, DFD-01,
M8010, Pefcalcitol, Ulobetasol lotion), oral antipsoriatics (LAS-41008,
FP-187), and antipsoriatic biologics for systemic use (Brodalumab, Ixekizumab,
Guselkumab, Tildrakizumab).</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>Browse </span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/psoriasis-treatment-market/"><span
style='font-size:10.0pt;font-family:"Calibri",sans-serif'>Psoriasis Drugs
Market</span></a></span><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'> by Drug Class (Interleukin Blockers, TNF
Inhibitors, Vitamin D Analogues or Combinations, Others), Therapy Type
(Systemic Therapeutic Drugs, Topical Therapeutic Drugs, Combinations, Others),
Distribution Channel (Hospital Pharmacy, Online Sales, Retail Pharmacy, Others)
and Forecast 2015-2023. The global psoriasis drugs market segmentation is based
on drug class (interleukin blockers, TNF inhibitors, vitamin d analogues or
combinations, others), therapy type (systemic therapeutic drugs, topical
therapeutic drugs, combinations, others), distribution channel (hospital
pharmacy, online sales, retail pharmacy, others). </span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>The global psoriasis drugs market report
provides market size (US$ million 2015-2023), market share, trends and
forecasts growth trends (CAGR%, 2018-2023). The global psoriasis drugs market
research report is further segmented by geography into North America (U.S.,
Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany,
France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of
APAC), and Rest of the World. The global psoriasis treatment market report also
provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis and also tracks the major
competitors operating in the market by company overview, financial snapshot,
key products, technologies and services offered, market share analysis and
recent trends in the global market. Major players operating in the global
psoriasis drugs market and profiled in this report include AbbVie, Inc.,
Almirall, Amgen, Inc., AstraZeneca, Biogen, Eli Lilly &amp; Company, Forward
Pharma, GlaxoSmithKline, Johnson &amp; Johnson (Janssen Biotech), LEO Pharma
A/S, Maruho, Merck &amp; Co., Inc., Novartis AG, Pfizer, Inc., Promius Pharma,
and Therapeutics, Inc.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt;color:black'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Drug Class</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>1.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Interleukin
Blockers</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>1.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>TNF
Inhibitors</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>1.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Vitamin D
Analogues or Combinations</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>1.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Others</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt;color:black'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Therapy
Type</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>2.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Systemic
Therapeutic Drugs</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>2.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Topical
Therapeutic Drugs</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>2.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Combinations</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>2.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Others</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt;color:black'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Distribution
Channel</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>3.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Hospital
Pharmacy</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>3.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Online
Sales</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>3.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Retail Pharmacy</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>3.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Others</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Geography
(Region, Country)</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>North
America (U.S., Canada)</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Latin
America (Brazil, Mexico, Rest of LA)</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Europe
(U.K., Germany, France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Asia
Pacific (Japan, China, India, Rest of APAC)</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Rest of the
World</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Company
Profiles</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>AbbVie,
Inc.</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Almirall</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Amgen, Inc.</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>AstraZeneca</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Biogen</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Eli Lilly
&amp; Company</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.7.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Forward
Pharma</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.8.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>GlaxoSmithKline</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.9.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Johnson
&amp; Johnson (Janssen Biotech)</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.10.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>LEO Pharma
A/S</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.11.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Maruho</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.12.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Merck &amp;
Co., Inc.</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.13.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Novartis AG</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.14.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Pfizer,
Inc.</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.15.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Promius
Pharma</span></p>

<p class=MsoNormal style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt;color:black'>5.16.<span style='font:7.0pt "Times New Roman"'>
</span></span><span lang=EN-US style='font-size:10.0pt;color:black'>Therapeutics,
Inc.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>To request Table of Contents and Sample Pages of this report
visit:&nbsp;</span><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/psoriasis-treatment-market/"><span
style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:#0131BF'>https://www.ihealthcareanalyst.com/report/psoriasis-treatment-market/</span></a></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global healthcare
market research and consulting company providing market analysis, and
competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<b><span lang=EN-US style='font-size:10.0pt;line-height:107%;font-family:"Calibri",sans-serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-bottom:8.0pt;line-height:107%'><b><span
lang=EN-US style='font-size:10.0pt;line-height:107%;color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:15.0pt;background:white'><b><span
lang=EN-US style='font-size:10.0pt;color:black'>Global Novel Drug Delivery
Systems for Cancer Therapy Market US$ 21.2 Billion by 2023</span></b></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>The global </span><span lang=EN-US style='font-size:
10.0pt;color:black'>novel drug delivery systems for cancer therapy </span><span
lang=EN-US style='font-size:10.0pt'>market expected to reach US$ 21.2 billion
by 2023, growing at CAGR 16.6% over the forecast period, due to increasing
incidences of various types of cancer such as bile duct, colorectal, liver,
pancreatic cancers, and its significant benefits over other conventional
therapies.</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;color:black'><br>
According to the online cancer database </span><span lang=EN-US><a
href="http://globocan.iarc.fr/Default.aspx"><span style='font-size:10.0pt'>GLOBOCAN</span></a></span><span
lang=EN-US style='font-size:10.0pt;color:black'> by the International Agency
for Research on Cancer (IARC), globally 14.1 million people were diagnosed with
cancers (excluding non-melanoma skin cancer) during 2012 as compared to 12.7
million in 2008. The incidence rate is expected to reach 15.2 million and 17.1
million in 2015 and 2020, respectively. In terms of geographic distribution,
the novel drug delivery systems for cancer therapy market has been segmented
into five major regions: North America, Europe, Latin America, Asia Pacific,
and Rest of the World. Additionally, each region has been segmented into respective
major countries such as the U.S. and Canada (North America); Germany, the U.K.,
(Europe); Brazil, Mexico (Latin America); Japan, China, India (Asia Pacific),
and Rest of the World. North America accounted for the largest share of global market
in 2016 followed by Europe region.</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;color:black'>Novel drug
delivery systems (NDDS) are capable of controlling the rate of drug delivery,
sustaining the duration of therapeutic activity and targeting the drug to the
disease tissue leading to better therapeutic effect with minimum side effects.
Novel Drug Delivery Systems (NDDS) have numerous points of interest, which
comprise better therapy by increasing the efficacy and duration of drug
activity, improved patient compliance through reduced dosing frequency. It
provides appropriate routes of administration and enhanced targeting for a particular
site to anticipate hurtful reactions. The Different types of advanced drug
delivery approach like polymeric Nano capsules, nanoparticles, liposomes,
nanoemulsion, microsphere, microcapsules, hydrogels have been expressed
utilizing bioactive and plant extracts. NDDS have significant advantages over
conventional therapy for cancer treatment, which include improved solubility
and bioavailability, low toxicity, maximum therapeutic effect, sustained and
controlled drug delivery, improvement of stability and batter security from
physical and biochemical degradation. Lipoproteins, nanoparticles, Microspheres
etc. as advanced drug delivery systems have become an attractive field of new
research and measured excellent candidates with great potential in the area of
novel drug delivery systems.</span></p>

<p class=MsoNormal style='margin-bottom:15.0pt;text-align:justify;background:
white'><span lang=EN-US style='font-size:10.0pt;color:black'>Visit </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/novel-drug-delivery-systems-cancer-therapy-market/"><span
style='font-size:10.0pt'>Novel Drug Delivery Systems for Cancer Therapy Market</span></a></span><span
lang=EN-US style='font-size:10.0pt;color:black'> by Technology (Embolization
Particles – Drug Eluting Beads, Polyvinyl Alcohol Particles, Microspheres,
Gelatin-Based Embolization Devices, Selective Internal Radiation Therapy,
Holmium-Based Microspheres; Liquid Embolics – Onyx (LES and HD-500), TRUFILL
nBCA LES; Nanoparticles, and Forecast 2015-2023. The global novel drug delivery
systems for cancer therapy market report provides market size (Revenue USD
Million 2015 to 2023), market share and forecasts growth trends (CAGR%, 2018 to
2023). The global novel drug delivery systems for cancer therapy market report
also provides the detailed market landscape (market drivers, restraints,
opportunities), market attractiveness analysis and profiles of major
competitors in the global market including company overview, financial
snapshot, key products, technologies and services offered, and recent
developments. Major players operating in the global novel drug delivery systems
for cancer therapy market and included in this report are Advanced Medical
Isotope Corporation, Bind Therapeutics, Boston Scientific Corporation, BTG plc,
CeloNova BioSciences, Inc., Cook Medical, Inc., Cospheric LLC, Covidien, plc,
Eckert &amp; Ziegler BEBIG, EmboMedics, Inc., Kobo Products, Inc., Merit
Medical Systems, Inc., Mo-Sci Corporation, Nanobiotix, Polysciences, Inc.,
Sirtex Medical, Inc. and Terumo Medical Corporation.</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Technology</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>1.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Embolization Particles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>1.1.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Drug Eluting Beads</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>1.1.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Polyvinyl Alcohol (PVA) Particles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>1.1.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Microspheres</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>1.1.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Gelatin-Based Embolization Devices</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>1.1.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Selective Internal Radiation Therapy
(SIRT)/ Radioembolization</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>1.1.6.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Holmium-based Microspheres</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>1.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Liquid Embolics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>1.2.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Onyx (LES and HD-500)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>1.2.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>TRUFILL nBCA LES</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>1.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Nanoparticles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Geography (Region, Country)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>2.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>North America (U.S., Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>2.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Latin America (Brazil, Mexico,
Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>2.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Europe (U.K., Germany, France,
Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>2.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Asia Pacific (Japan, China, India,
Rest of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>2.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Company Profiles</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Advanced Medical Isotope
Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Bind Therapeutics</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Boston Scientific Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>BTG plc</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>CeloNova BioSciences, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.6.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Cook Medical, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.7.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Cospheric LLC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.8.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Covidien, plc</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.9.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Eckert &amp; Ziegler BEBIG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.10.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>EmboMedics, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.11.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Kobo Products, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.12.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Merit Medical Systems, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.13.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Mo-Sci Corporation</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.14.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Nanobiotix</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.15.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Polysciences, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.16.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Sirtex Medical, Inc.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in;
background:white'><span lang=EN-US style='font-size:10.0pt;color:black'>3.17.<span
style='font:7.0pt "Times New Roman"'> </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Terumo Medical Corporation</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-US style='font-size:
10.0pt;color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>To request Table of Contents and Sample Pages of this
report visit: </span></p>

<p class=MsoNormal><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/novel-drug-delivery-systems-cancer-therapy-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/novel-drug-delivery-systems-cancer-therapy-market/</span></a></span></p>

<p class=MsoNormal><span class=MsoHyperlink><span lang=EN-US style='font-size:
10.0pt'><span style='text-decoration:none'>&nbsp;</span></span></span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;color:#333333'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;color:#333333'>Global
Primary Immunodeficiency Diseases Market US$ 7 Billion by 2023</span></b></p>

<p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;color:#333333'> </span></b></p>

<p style='margin:0in;margin-bottom:.0001pt;text-align:justify'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif'>The global
primary immunodeficiency diseases market expected to reach US$ 7 billion by 2023,
growing at CAGR 6.4% over the forecast period, due to higher incidence
of&nbsp;primary immunodeficiency disorders worldwide. </span></p>

<p style='margin:0in;margin-bottom:.0001pt;text-align:justify'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif'>&nbsp;</span></p>

<p style='margin:0in;margin-bottom:.0001pt;text-align:justify'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif'>Primary
immunodeficiency diseases or disorders (PIDD or PI) are caused as part of the
body's immune system is missing or does not function normally, such that it is
an inherited flaw in the immune system that increases the susceptibility to
infections. Besides susceptibility to infections, PIDD may cause other health
problems as well, including allergies, asthma, swollen joints, digestive tract
problems, growth problems or an enlarged liver and spleen. </span></p>

<p style='margin:0in;margin-bottom:.0001pt;text-align:justify'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif'>&nbsp;</span></p>

<p style='margin:0in;margin-bottom:.0001pt;text-align:justify'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif'>The global
primary immunodeficiency diseases market report estimates the market size in
US$ million for 2015-2023, and forecasts growth trends over a period of 2018-2023.
The market for key market segments has been estimated based on epidemiology
approach considering patient diagnosis rates, patient treatment rate
(IVIG/SCIG), average cost of treatment by regions. The highlights of the report
include global number of PID patients, by disease (including subclasses),
global number of patient population for treatment or therapy, global number of
PID patients, by 15 most commonly identified PIDs by region, and by country,
and PID patient’s gender and age by global comparative analysis. The global
primary immunodeficiency disease (PIDD or PID or PI) market is dominated by
North America and Europe, collectively accounting for major share of the market
in 2016. National PID registries worldwide, increasing healthcare expenditure
and government support are the major factors driving the global primary
immunodeficiency diseases market during the forecast period.</span></p>

<p style='margin:0in;margin-bottom:.0001pt'><span lang=EN-US style='font-size:
10.0pt;font-family:"Calibri",sans-serif'>&nbsp;</span></p>

<p style='margin:0in;margin-bottom:.0001pt;text-align:justify'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif'>Browse </span><span
lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/primary-immunodeficiency-diseases-market/"><span
style='font-size:10.0pt;font-family:"Calibri",sans-serif'>Primary
Immunodeficiency Diseases Market</span></a></span><span lang=EN-US
style='font-size:10.0pt;font-family:"Calibri",sans-serif;color:#333333'> by
Disease Type (Antibody Deficiency – Agammaglobulinaemia, Common Variable Immune
Deficiency, IgG Subclass Deficiency, SIgAD; Cellular Immunodeficiency – Ataxia
Telangiectasia, DiGeorge Syndrome, Hyper IgM Syndromes, Wiskott-Aldrich
Syndrome; Innate Immune Disorders – Complement Deficiencies, and Hyper IgE
Syndrome) and Test Type (Blood and Prenatal Testing), and Treatment Type
(Immunoglobulin Replacement Therapy, Antibiotics Therapy, Stem Cell and Gene
Therapy) and Forecast 2015-2023. </span><span lang=EN-US style='font-size:10.0pt;
font-family:"Calibri",sans-serif'>The report also provides the detailed market
landscape and profiles of major competitors in the global market including
company overview, financial snapshot, major products and services offered, and
recent trends in strategic management.  The major companies profiled in the
report include <span style='color:black'>Baxter nternational, Inc., Bio
Products Laboratory, Biotest AG, CSL Behring LLC, Grifols S.A., Kedrion S.p.A.,
LFB S.A., Octapharma AG, and others.</span></span></p>

<p style='margin:0in;margin-bottom:.0001pt;text-align:justify'><span
lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-left:.25in;text-indent:-.25in;
text-autospace:none'><b><span lang=EN-US style='font-size:10.0pt;color:black'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></b><b><span
lang=EN-US style='font-size:10.0pt;color:black'>Disease Type</span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Antibody Deficiency</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.1.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Agammaglobulinaemia </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.1.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Common Variable Immune Deficiency </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.1.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>IgG Subclass Deficiency </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.1.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Selective IgA Deficiency (SIgAD) </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.1.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Others </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Cellular Immunodeficiency</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.2.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Ataxia Telangiectasia </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.2.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>DiGeorge Syndrome </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.2.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Hyper IgM Syndromes </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.2.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Wiskott-Aldrich Syndrome </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.2.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Others </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Innate Immune Disorder</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.3.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Complement Deficiencies </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.3.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Hyper IgE Syndrome </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-indent:-.35in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>1.3.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><span lang=EN-US
style='font-size:10.0pt;color:black'>Others </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.85in;text-autospace:
none'><span lang=EN-US style='font-size:10.0pt;color:black'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in;
text-autospace:none'><b><span lang=EN-US style='font-size:10.0pt;color:black'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></b><b><span
lang=EN-US style='font-size:10.0pt;color:black'>Test Type</span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>2.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Blood Testing</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>2.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Prenatal Testing</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-autospace:
none'><span lang=EN-US style='font-size:10.0pt;color:black'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in;
text-autospace:none'><b><span lang=EN-US style='font-size:10.0pt;color:black'>3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></b><b><span
lang=EN-US style='font-size:10.0pt;color:black'>Treatment Type</span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>3.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Immunoglobulin Replacement
Therapy </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>3.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Antibiotics Therapy </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>3.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Stem cell and Gene Therapy </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>3.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Others</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-autospace:
none'><span lang=EN-US style='font-size:10.0pt;color:black'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in'><b><span
lang=EN-US style='font-size:10.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></b><b><span lang=EN-US style='font-size:10.0pt'>Geography
(Region, Country)</span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>North America (U.S.,
Canada)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Europe (U.K., Germany,
France, Italy, Spain, Rest of EU)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Asia Pacific (Japan,
China, India, Rest of APAC)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Latin America (Brazil,
Mexico, Rest of LA)</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in'><span
lang=EN-US style='font-size:10.0pt'>4.5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US style='font-size:10.0pt'>Rest of the World</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.25in;text-indent:-.25in;
text-autospace:none'><b><span lang=EN-US style='font-size:10.0pt;color:black'>5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></b><b><span
lang=EN-US style='font-size:10.0pt;color:black'>Company Profiles</span></b></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>5.1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Baxter International, Inc.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt'>5.2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Bio Products Laboratory</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>5.3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Biotest AG</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>5.4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>CSL Behring LLC</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>5.5.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Grifols S.A.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>5.6.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Kedrion S.p.A.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>5.7.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>LFB S.A.</span></p>

<p class=MsoListParagraphCxSpLast style='margin-left:.55in;text-indent:-.3in;
text-autospace:none'><span lang=EN-US style='font-size:10.0pt;color:black'>5.8.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-US style='font-size:10.0pt;color:black'>Octapharma AG</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-US
style='font-size:10.0pt'>To request Table of Contents and Sample Pages of this
report visit: </span></p>

<p class=MsoNormal><span lang=EN-US><a
href="https://www.ihealthcareanalyst.com/report/primary-immunodeficiency-diseases-market/"><span
style='font-size:10.0pt'>https://www.ihealthcareanalyst.com/report/primary-immunodeficiency-diseases-market/</span></a></span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>About Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>iHealthcareAnalyst, Inc. is a global
healthcare market research and consulting company providing market analysis,
and competitive intelligence services to global clients. The company publishes
syndicate, custom and consulting grade healthcare reports covering animal
healthcare, biotechnology, clinical diagnostics, healthcare informatics,
healthcare services, medical devices, medical equipment, and pharmaceuticals.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in;text-align:justify'><span lang=EN-US style='font-size:10.0pt;font-family:
"Calibri",sans-serif;color:black'>In addition to multi-client studies, we offer
creative consulting services and conduct proprietary single-client assignments
targeted at client’s specific business objectives, information needs, time
frame and budget. Please contact us to receive a proposal for a proprietary
single-client study.</span></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><strong><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>Contact Us</span></strong></p>

<p style='margin-top:0in;margin-right:0in;margin-bottom:15.0pt;margin-left:
0in'><span lang=EN-US style='font-size:10.0pt;font-family:"Calibri",sans-serif;
color:black'>iHealthcareAnalyst, Inc.<br>
2109, Mckelvey Hill Drive,<br>
Maryland Heights, MO 63043<br>
United States<br>
Email:&nbsp;sales@ihealthcareanalyst.com<u><br>
</u>Website: https://www.ihealthcareanalyst.com</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>

</div>

</body>

</html>
